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Coronaviruses in humans have been of concern since the emergence of 
SARS-CoV, MERS-CoV and SARS-CoV-2 over the past two decades. 
Coronavirus disease in humans can range from asymptomatic to mild or 
severe where symptomatic disease is associated with fever, cough, and 
respiratory symptoms. Next generation sequencing and phylogeny studies can 
provide insight into viral evolution due to the nucleotide polymorphisms which 
arise due to the inherent error rates. Nanopore sequencing can facilitate these 
studies rapidly and are therefore a useful public health tool for genome 
surveillance. MERS-CoV emerged in Saudi Arabia in 2012 and is associated 
with sporadic outbreaks. To facilitate rapid genomic surveillance of MERS-CoV 
in Saudi Arabia, a PCR amplification sequencing method compatible with 
Nanopore was designed. This approach is useful as data derived from this 
methodology can be used for phylogeny and variant analysis which supports 
investigation into transmission events and viral evolution. Upon the emergence 
of SARS-CoV-2 in late 2019, this approach was then repurposed and utilised 
on a subset of patients from the UK. Alternative viral genome sequencing 
approaches were then employed to assess the tissue tropism of SARS-CoV-2 
in fatal COVID-19 cases, where tropism was widespread, while inflammation 
was exclusive to pulmonary tissues. To complement the analysis conducted 
on the tissue of fatal COVID-19 patients, blood from patients at point of care 
were utilised for blood transcriptomics analysis. Both illumina and nanopore 
sequencing methodologies were employed to assess differences in transcript 
abundance in these patients. Transcriptomic profiles from COVID-19 patients 
were compared to profiles from Influenza patients and healthy controls, in 
addition to fatal and non-fatal COVID-19 cases. The key finding from this 
analysis was that immunoglobulin domains transcripts exhibited altered 
abundance when comparing COVID and Influenza patients, as well as 
between fatal and non-fatal COVID-19 cases. From this insight, it is 
hypothesised that an early adaptive immune response is associated with 
survival, or a delayed adaptive response is associated with fatality. As it is 
challenging to control variables from patient data, an hACE2 mice model was 
utilised to explore the host response against Influenza A virus and SARS-CoV-
 17 
2 as independent and sequential infections using lung tissue. Transcriptomic 
analysis revealed a sustained cytokine and interferon response in coinfected 
mice. Transcripts changing in abundance in both human blood and mice lungs 
were compared to generate a subset of transcripts that may be essential to the 
response to SARS-CoV-2 infection. In summary, the results described within 
this thesis provide insights into the novel coronavirus SARS-CoV-2 and 
COVID-19 disease in humans. Additionally, the outputs of this thesis provide 
a foundation for further investigation and development of Nanopore 




Figure 1.1: Coronaviruses are spherical and enveloped viruses with four structural proteins, S, N, M 
and E and an RNA genome. The RNA genome is associated with the nucleocapsid (N) protein 
forming a ribonucleoprotein core. .................................................................................... 33 
Figure 1.2: Epidemiological comparison between the three emerging coronaviruses SARS-CoV-2, 
SARS-CoV and MERS-CoV. Reproductive number, case fatality rate (CFR) and incubation time 
are estimates for SARS-CoV-2 as the pandemic is still ongoing. Laboratory confirmed infections 
and deaths for SARS-CoV-2 infections are values from the 4th of November 2020. ............... 38 
Figure 1.3: The genome structure of the emerging human coronaviruses SARS-CoV, MERS-CoV and 
SARS-CoV-2. The 5' end of the genome contains a leader sequence (L) and two overlapping 
open reading frames (ORFs) which occupy two-thirds of the genome. ORF1a and ORF1b are 
translated into two polyproteins (pp), pp1a and pp1ab which are further cleaved into 16 non-
structural proteins (Nsps). The 3’ end of the coronavirus genome encodes for the structural 
and accessory proteins, including Spike (S), Envelope (E), Membrane (M) and Nucleocapsid (N) 
proteins. .......................................................................................................................... 39 
Figure 1.4: Non-structural proteins derive from pp1a and pp1ab following cleavage and form the 
replication transcription complex. This figure is based upon known structures and protein 
interactions. These proteins form a complex on the negative strand during positive strand RNA 
synthesis. The model of the replicase shown contains the RdRp (nsp12), processivity factors 
(nsp7-8), and the ExoN complex (nsp14, nsp10). Ahead of the complex is nsp13 also known as 
the helicase, unwinding the dsRNA, where nsp9 as a dimer binds to the single stranded RNA 
as protection. Nsp16 is predicted to cap the 5’ end of the RNA.  Figure adapted in BioRender.
........................................................................................................................................ 42 
Figure 1.5: Coronaviruses transcribe subgenomic RNA via a process called discontinuous 
transcription. Transcription regulatory sequences are distributed throughout the genome (B) 
and upon transcription from these points, the RTC is able to template switch to the 
coronavirus leader sequence (L) located at the 5’ end of the viral genome. This facilitates the 
addition of the leader sequence onto the nascent subgenomic RNA strand. Negative sense 
sgRNA serves as a template for sg-mRNA. This occurs in a three-step model. 1. First a complex 
is formed where the leader sequence (in red) and core sequences (orange box) are brought 
into proximity to each other. 2. Base-paring scanning, the nascent negative strand RNA is 
shown in light blue and is complementary to the genomic RNA, the RTC is associated. 3. 
Template switch, as the newly synthesised strand has complementarity to the TRS of the 
leader, the template is switched to complete the copy of the leader sequence at the 5’ end of 
the sgmRNA. 4. Disontinuous transcription produces 5’ and 3’ co-terminal subgenomic 
mRNAs, the process is visualised linearly to represent the sgRNAs produced by this process. 
Adapted from (Hartenian et al., 2020, Sola et al., 2015). .................................................... 44 
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Chapter 1: Introduction 
 
Coronaviruses were once described as the backwater of virology and did not 
cause any significant disease in humans. The last two decades have seen the 
emergence of three major coronavirus threats. Severe acute respiratory 
syndrome coronavirus (SARS-CoV) arose in China in 2002, Middle East 
Respiratory Syndrome coronavirus (MERS-CoV) in Saudi Arabia in 2012 and 
now SARS-CoV-2 from China in 2019/2020. This latter virus has effectively 
caused a worldwide lockdown, sent shock waves through the world economy 
and is severely stretching healthcare infrastructures. These viruses cause 
severe respiratory illnesses and share similar genome architectures, 
replication strategies and common disease profiles. Whilst SARS-CoV was 
eradicated, both MERS-CoV and SARS-CoV-2 represent current ongoing 
health threats. This thesis focuses on the characterisation of MERS-CoV and 
SARS-CoV-2 using clinical samples, taken from patients with MERS and 
COVID-19, respectively. 
 




The International Committee on Taxonomy of Viruses classify coronaviruses 
as members of the subfamily Orthocoronavirinae of the family Coronaviridae 
in the Nidovirales order. Coronaviruses have single stranded positive sense 
RNA genomes,placing them in the realm of Riboviria and the Piscuvirocota 
branch of the Orthocoronavirinae kingdom (Koonin et al., 2020). Viruses within 
the subfamily Orthocoronavirinae are known for prevalent infections in both 
animals and humans. In humans they are associated with respiratory 
transmission and disease, whereas in animals disease presentation is varied, 
but is broadly respiratory and gastrointerstinal in nature. This subfamily 
consists of four genera based upon phylogenetic relationships and genomic 
organisation; the Alphacoronaviruses and Betacoronaviruses represent 
important human pathogens. These include the causative agents of the 
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common cold in humans such as HCoV-NL63 and HCoV-229E in the 
Alphacoronavirus genus and HCoV-OC43 and HCoV-HKU1 in the 
Betacoronavirus genus, all of which are endemic worldwide (Corman et al., 
2018). The more severe and emerging respiratory viruses such as SARS-CoV, 
MERS-CoV and SARS-CoV-2 belong to the Betacoronavirus genus. Gamma- 
and Deltacoronaviruses mainly infect avian species and impact the poultry 
industry globally (Cavanagh, 2005). 
 
Viruses within this family are pleiomorphic and enveloped with a diameter 
between 100-160 nm (McIntosh, 1974, Miller, 1986). Coronaviruses have the 
largest RNA genome of any RNA virus so far discovered, ranging between 27-
32kb in length (Gorbalenya et al., 2006). Within the genome, two-thirds of the 
5’ end encodes for the polyprotein (pp1ab), which is further processed into 16 
non-structural proteins (nsps) that are essential for coronavirus genome 
replication and transcription (Gorbalenya et al., 2006). Structural proteins are 
encoded nearer the 3’ end of the genome, including the envelope 
glycoproteins spike (S), which plays a role in host cell entry, envelope (E), 
membrane (M), and the nucleocapsid (N) (Figure 1.1). The M and E proteins 
are involved in inducing viral membrane topography and the N protein binds 
viral RNA to form a ribonucleoprotein structure. In that respect the virus 
resembles negative strand RNA viruses such as the mononegavirales – such 
as Ebola virus (EBOV). Additionally, there are accessory genes that vary 
between species and are unessential to genome replication (Cui et al., 2019) 
but involved in modulating the host response to infection (Masters, 2006, 






RNA viral genome 
Envelope (E) 
Nucleocapsid (N) 
Human Coronavirus Structure 
Figure 1.1: Coronaviruses are spherical and enveloped viruses with four structural proteins, S, 
N, M and E and an RNA genome. The RNA genome is associated with the nucleocapsid (N) 
protein forming a ribonucleoprotein core.  
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1.1.2 Discovery and epidemiology 
 
Human coronaviruses were first characterised in the 1960s, starting with 
Tyrrell and Bynoe who obtained virus culture from an adult infected with the 
common cold and subsequently inoculated volunteers intranasally, resulting in 
the production of cold symptoms (Tyrrell and Bynoe, 1966), thereby 
reproducing Koch’s postulates about an infectious agent. They termed this 
virus B814. The same year, Hamre and Procknow successfully grew virus 
isolates in tissue culture obtained from medical students with colds, and 
named the virus 229E (Hamre and Procknow, 1966). McIntosh et al termed 
viruses recovered from the human respiratory tract with “OC” to highlight that 
they were grown in organ cultures (McIntosh et al., 1967b). Virus from organ 
cultures when observed by electron microscopy were found to share 
resemblance with infectious bronchitis virus (IBV) cultures from chickens, and 
Hamre and Procknow’s 229E virus (Almeida and Tyrrell, 1967). This 
morphological resemblance was shared with mouse hepatitis virus (MHV) and 
transmissible gastroenteritis virus (TGEV) of swine establishing the new 
genus, coronavirus (Tyrrell et al., 1975, Witte et al., 1968, McIntosh et al., 
1967a). The etymology for coronavirus derives from the crown-like structure 
observed through the electron microscope.  
 
Through the development of serological techniques for human coronaviruses, 
it was discovered that infections were in fact seasonal, associated with more 
infections in winter as opposed to spring, where 15% of adult colds were 
estimated to be caused by coronavirus infections (McIntosh et al., 1970). More 
recent studies suggest 3-11% of all respiratory infections are caused by 
coronaviruses. However, this is dependent on the study population and the 
strains that are being queried (Geller et al., 2012, Gerna et al., 2006, Gerna et 
al., 2007, Chiu et al., 2005, Vabret et al., 2008). Beyond serology, Gaunt et al, 
designed a pan-coronavirus multiplex assay to assist in the study and 
diagnosis of coronaviruses whilst overcoming the seasonal variation of HCoV-
OC43, HCoV-NL63, HCoV-229E and HCoV-HKU1 and found the prevalence 
to be between 0.3 – 0.85%. This revealed that, within Edinburgh over a 3-year 
time frame, coronaviruses were seasonal between the months of December 
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and April, with the exception of HCoV-229E which was detected sporadically 
throughout the year as well as between December and April. HCoV-OC43 
dominated the first and third season with biennial peaks, whereas HCoV-HKU1 
dominated the second season (Gaunt et al., 2010). 
 
The seasonal human coronaviruses OC43 and 229E were found to cause 
epidemics every 2-3 years, where reinfection was found to be possible due to 
declining antibody titres following initial infections with 229E (Monto, 1974, 
Callow et al., 1990). Although, the severity of disease was often mild, they 
were found to occasionally be associated with pneumonia in young adults and 
children and exacerbated asthma in children and bronchitis in adults and the 
elderly population (Hamre and Procknow, 1966, McIntosh et al., 1970, Falsey 
et al., 1997, Falsey et al., 2002). Today it is known that human coronaviruses 
do not exclusively cause the common cold, but also more severe disease 
phenotypes such as bronchitis, viral pneumonia or croup (Riski and Hovi, 
1980, Woo et al., 2005, Talbot et al., 2009, Sung et al., 2010).  
 
SARS-CoV was the first pandemic threat from all three of the emerging 
coronaviruses in 2002, however, despite being considered highly lethal, the 
outbreak faded out due to public health interventions (WHO, 2003). The 
SARS-CoV pandemic ceased by June 2003, the case fatality rate associated 
with this virus was 9.7%, with 8098 reported cases and 774 deaths, where 
most cases were nosocomial acquired infections. In contrast, MERS-CoV does 
not currently present as a pandemic threat, however, this virus is associated 
with a much higher fatality rate of 34.4% with a total of 2494 reported cases 
and 858 deaths (Alfaraj et al., 2019). SARS-CoV-2, is less deadly than SARS-
CoV and MERS-CoV with an estimated CFR between 2.9 and 3.0%, but the 
transmissibility is far more with 173,989,093 cases and 3,756,947 deaths as 
of the 10th of June 2021 according to the WHO Coronavirus dashboard 
(https://covid19.who.int/) (Ghayda et al., 2020, WHO, 2020a). 
 
In Guangdong province, China, 2002; Severe Acute Respiratory Syndrome 
(SARS) was identified as a new clinical entity, and was associated with a dry 
cough, fever, dyspnoea and hypoxemia with rapid progression to pneumonia 
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(Zhong et al., 2003). The aetiological agent for the atypical pneumonia was 
isolated and sequenced, revealing that a novel coronavirus was responsible 
for the disease (Drosten et al., 2003, Peiris et al., 2003, Poutanen et al., 2003, 
Ksiazek et al., 2003). A physician from mainland China visited Hong Kong and 
subsequently infected 17 others through poor sewage works, this is thought to 
have been a super spreading event leading up to the pandemic as this 
eventually resulted in the spread of the virus to other countries, including; 
Toronto, Singapore and Hanoi (Hung, 2003, Zhong and Wong, 2004). By the 
end of the SARS 2002-2004 outbreak, there were over 8000 cases with 916 
deaths (Zhong and Wong, 2004). 
 
HCoV-NL63 was first described in 2004, however, it was soon clear that this 
was not an emerging virus with the same pandemic potential as SARS-CoV 
as initially this virus showed resemblance to infections with OC43 and 229E. 
The incidence of croup, however, is typical of infections with NL63 (van der 
Hoek et al., 2004, Chiu et al., 2005). The following year HCoV-HKU1 was 
isolated from a patient with pneumonia (Woo et al., 2005). In 2012 another 
novel coronavirus emerged following a case of renal and respiratory failure in 
a 60-year-old man in Jeddah, Saudi Arabia (Zaki et al., 2012). Following virus 
isolation and viral genome sequencing, the sixth human coronavirus was 
identified and named as Middle East Respiratory syndrome coronavirus 
(Group, 2013, de Groot et al., 2013, Zaki et al., 2012). MERS-CoV has the 
highest known fatality rate out of the human coronaviruses at 30% 
hospitalisation - and would be higher if not for this supportive care.  
 
Eight years on from the emergence of MERS in Saudi Arabia, a novel 
coronavirus now threatens the global population once again (Zhou et al., 
2020b). On the 31st of December 2019, pneumonia of an unknown cause was 
officially reported to the WHO (WHO, 2020b). This disease emerged in 
November 2019 in Wuhan City within the Hubei Province of China where 
human exposure to wildlife at the Huanan seafood wholesale market is thought 
to have been the epicentre of the pandemic – although there is currently no 
direct evidence of this. The causative agent of the disease, termed coronavirus 
disease 2019 (COVID-19), was identified to be caused by a novel human 
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coronavirus temporally named 2019-nCoV in January 2020 (WHO, 2020b). 
Three days later, cases of the novel coronavirus were confirmed in Thailand, 
and by January 30th 2020, the WHO declared a Public Health Emergency of 
International Concern (PHEIC). The International Committee on Taxonomy of 
Viruses (ICTV) later renamed 2019-nCoV to SARS-CoV-2 (Gorbalenya et al., 
2020). On March 11th 2020, the WHO declared the SARS-CoV-2 outbreak a 
pandemic (WHO, 2020b). 
 
The basic reproductive rate (R0) is a metric that is used to describe the spread 
of an infectious disease. R0 is a value that represents the average number of 
secondary cases that occur from one infectious case (Heffernan et al., 2005). 
An R0 value that is more than 1 is indicative of an infection that may persist or 
grow within a population, however, an R0 less than 1 is indicative of an infection 
that will decrease within the population (Heffernan et al., 2005). MERS-CoV 
has the lowest R0 value out of the emerging coronaviruses, although outbreaks 
have occurred, the scale has not reached a global pandemic and the pandemic 
potential of MERS-CoV is thought to be low (Breban et al., 2013). In 
comparison, SARS-CoV-2 and SARS-CoV have a higher R0 value and are 
both causative agents of global pandemics, with SARS-CoV-2 thought to have 


























Figure 1.2: Epidemiological comparison between the three emerging 
coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV. Reproductive 
number, case fatality rate (CFR) and incubation time are estimates for SARS-
CoV-2 as the pandemic is still ongoing. Laboratory confirmed infections and 
deaths for SARS-CoV-2 infections are values from the 4th of November 2020.  
 
1.2 Coronavirus genome organisation and proteins 
 
The focus of this study was to detect viral genomes in clinical samples 
(Chapter 2) and the host response to infection (Chapter 3 & 4) and therefore 
will be focused upon during this section. 
 
1.2.1 Coronavirus genome organisation 
 
Coronaviruses have the largest RNA genomes out of the known RNA viruses 
ranging from 25-32kb in the positive sense orientation. The viral genome of 
coronavirus contains 7-10 open reading frames (ORFs) and many proteolytic 
cleavage products (Payne, 2017). The viral genome of coronaviruses has a 5’ 
cap and a poly(A) tail, therefore the genomic RNA serves as a template. The 
two-overlapping ORFS, ORF1a and ORF1b, are directly translated into the 
polyprotein 1a and 1ab (pp1a/pp1ab) which is then cleaved into nsps which in 
turn form the replication-transcription complex (RTC) in a double membrane 
vesicle (DMV) (Chen, 2020). Typically, coronaviruses have at least 6 ORFs, 
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where the first ORF accounts for approximately two thirds of the entire 
coronavirus genome, this accounts for the 16 nsps. The frameshift mutation 
within ORF1 forms pp1a and pp1ab through ribosomal slippage, which in turn 
are processed by viral encoded proteases, such as chymotrypsin-like protease 
(3CLPRO) or main protease (Galani et al.) in addition to one or two papain-like 
proteases to generate 16 nsps (Masters, 2006; Ziebuhr, 2000). The ORFs 
towards the 3’ end of the genome encodes for at least 4 structural proteins, 
including S, M, E and N (Figure 1.3) (Hussain, 2008). Different species of 
coronavirus encode different accessory proteins and sometimes an additional 
structural protein such as (HE). 
 
 
Figure 1.3: The genome structure of the emerging human coronaviruses 
SARS-CoV, MERS-CoV and SARS-CoV-2. The 5' end of the genome contains 
a leader sequence (L) and two overlapping open reading frames (ORFs) which 
occupy two-thirds of the genome. ORF1a and ORF1b are translated into two 
polyproteins (pp), pp1a and pp1ab which are further cleaved into 16 non-
structural proteins (Nsps). The 3’ end of the coronavirus genome encodes for 
the structural and accessory proteins, including Spike (S), Envelope (E), 
Membrane (M) and Nucleocapsid (N) proteins.  
The MERS-CoV genome is 30,119 in length whereas SARS-CoV-2 is 29,903. 
An overview of the genes within their genomes and the proteins which they 
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produce is provided in Table 1.1. Both coronaviruses possess ORF1ab and 
the four structural proteins S, E, M and N, however, the genes that encode for 
the accessory proteins differ as well as their positions within the genome 





Table 1.1: Gene name and the associated location within the viral genome and 






















orf1a 266 - 13,483 
ORF1a 
polyprotein 
orf1a 279 – 13,433 
ORF1a 
polyprotein 
S 21,563 - 25,384 Spike protein  S 21,456 – 25,517 Spike protein 
orf3a 25,393 – 26,220 ORF3a protein orf3 25,532 – 25,843 ORF3 protein 
E 26,245 – 26,472 
Envelope 
protein  
orf4a 25,852 – 26,181 ORF4a protein 
M 26,523 – 27,191 
Membrane 
protein 
orf4b 26,093 – 26,833 ORF4b protein 
orf6 27,202 – 27,387 ORF6 protein orf5 26,840 – 27,514 ORF5 protein 
orf7a 27,394 – 27,758 ORF7a protein E 27,590 – 27,838 
Envelope 
protein 
orf7b 27,756 – 27,887 ORF7b protein M 27,853 - 28,512 
Membrane 
protein 
orf8 27,894 – 28,259 ORF8 protein  N 28,566 - 29,807 
Nucleocapsid 
protein 
N 28,274 – 29,553 
Nucleocapsid 
Phosphoprotein 
orf8b 28,762 - 29,100 ORF8b protein 
orf10 29,558 – 29,674 ORF10 protein     
 
 
1.2.2 Transcription and replication of the viral genome 
Coronavirus genomes are positive sense, which means they are able to be 
translated in the cytoplasm. The replication-transcription complex (Figure 1.4) 
facilitates the generation of negative strand RNA intermediates, where the 
synthesis of subgenomic mRNAs (sgmRNAs) involves a discontinuous step 




Figure 1.4: Non-structural proteins derive from pp1a and pp1ab following 
cleavage and form the replication transcription complex. This figure is based 
upon known structures and protein interactions. These proteins form a 
complex on the negative strand during positive strand RNA synthesis. The 
model of the replicase shown contains the RdRp (nsp12), processivity factors 
(nsp7-8), and the ExoN complex (nsp14, nsp10). Ahead of the complex is 
nsp13 also known as the helicase, unwinding the dsRNA, where nsp9 as a 
dimer binds to the single stranded RNA as protection. Nsp16 is predicted to 
cap the 5’ end of the RNA.  Figure adapted in BioRender.  
Mutation rates in RNA viruses are higher than in DNA viruses and their 
genomes tend to be shorter (Peck et al., 2018). Coronaviruses, however, 
exhibit the longest RNA genomes which are thought to be maintained by 
unique features of the RTC. Within the RTC are several RNA processing 
enzymes, of note is the 3’ – 5’ exoribonuclease of nsp14 which is unique to all 
RNA viruses and is thought to provide proof-reading ability (Eckerle 2010; 
Ogando, 2019; Smith, 2013). Genome surveillance through the SARS-CoV-2 
pandemic has revealed a nucleotide substitution rate of ~1 x 10-3 which is 
comparable to the rate observed for Ebola virus during the 2013-2016 Ebola 
Virus outbreak (Duchene et al., 2020, Carroll et al., 2015). Although, single 
nucleotide polymorphisms (SNPs) are not the only form of genetic variation 
observed in coronavirus genomes.  
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Transcription of coronaviruses is discontinuous, a process unique within the 
Nidovirales order (Sola et al., 2015).  The synthesis of coronavirus subgenomic 
mRNA (sgmRNA) includes a template switch to add the leader sequence 
(Figure 1.5) (Sawicki et al., 2007, Sola et al., 2015). Therefore, the sgmRNAs 
contains common 5’ and 3’ ends with the genome sequence, including the 
leader sequence at the 5’ end, where the fusion of the leader sequence occurs 
during negative strand synthesis at 6-7 nucleotide core sequences known as 
transcription regulatory sequences (TRS) (Hiscox et al., 1995b, van Marle et 
al., 1995). TRS’s are present at the 3’ end of the leader sequence as well as 
proceeding each ORF within the genome and are responsible for transcription 
termination and the acquisition of leader sequence RNA (Sawick, 2007; 
Perlman, 2009).  
 
Due to the discontinuous nature of coronavirus transcription, the genome is at 
risk of recombination events which appear as insertion or deletion events 
(Peacock et al., 2021). Recombination can give rise to viable genomes as well 
as defective interfering RNAs. Interestingly, recombination between different 
coronaviruses is thought to have given rise to the receptor binding domain of 
SARS-CoV-2 spike (Li et al., 2020e, Lam et al., 2020) as well as the S1/S2 
furin cleavage site (Zhou et al., 2020a). Analysis of MERS-CoV genomes 
derived from different host species has also revealed recombination events, 
and that these events can play a role in viral evolution and adaptation (Zhang 




Figure 1.5: Coronaviruses transcribe subgenomic RNA via a process called 
discontinuous transcription. Transcription regulatory sequences are distributed 
throughout the genome (B) and upon transcription from these points, the RTC 
is able to template switch to the coronavirus leader sequence (L) located at 
the 5’ end of the viral genome. This facilitates the addition of the leader 
sequence onto the nascent subgenomic RNA strand. Negative sense sgRNA 
serves as a template for sg-mRNA. This occurs in a three-step model. 1. First 
a complex is formed where the leader sequence (in red) and core sequences 
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(orange box) are brought into proximity to each other. 2. Base-paring scanning, 
the nascent negative strand RNA is shown in light blue and is complementary 
to the genomic RNA, the RTC is associated. 3. Template switch, as the newly 
synthesised strand has complementarity to the TRS of the leader, the template 
is switched to complete the copy of the leader sequence at the 5’ end of the 
sgmRNA. 4. Disontinuous transcription produces 5’ and 3’ co-terminal 
subgenomic mRNAs, the process is visualised linearly to represent the 
sgRNAs produced by this process. Adapted from (Hartenian et al., 2020, Sola 







1.3  MERS-CoV and SARS-CoV-2 proteins and functions 
 
The genomes of SARS-CoV-2 and MERS-CoV encode the structural proteins 
S, E, M and N and the polyproteins pp1ab and pp1a which are cleaved into 16 
nsps. Coronavirus nsp’s are highly conserved, highlighting the importance of 
their enzymatic activities and functional domains in viral replication (Snijder et 
al., 2003, Thiel et al., 2003). The accessory proteins are specific to each 
species of coronavirus, and are thought to drive host tropism, and 














S Spike protein is involved in host cell 
receptor binding and facilitates viral 
entry.  
(Beniac et al., 2006) 
E Envelope protein is involved in viral 
assembly and release. Can 
oligomerise and form an ion channel. 
(Venkatagopalan et al., 
2015, Verdiá-Báguena et 
al., 2012) 
M Membrane protein facilitates 
membrane curvature and provides the 
virion’s shape and is integral to virion 
assembly. M from SARS-CoV has 
been shown to induce apoptosis. M 
interacts with N to facilitate the 
encapsidation of genomic RNA. 
(Neuman et al., 2011, Tsoi 
et al., 2014, Siu et al., 2008) 
N Nucleocapsid protein binds to the RNA 
genome and allows for genome 
tethering to the replication-
transcription complex (RTC).  
(McBride et al., 2014) 
Nonstructural proteins  
NSP1 Induces host mRNA degradation and 
inhibits translation, resulting in 
blocking of innate immune response. 
(Huang et al., 2011a) 
NSP2 Binding to prohibitin proteins. (Cornillez-Ty et al., 2009) 
NSP3 Release of NSP1-3 (Papain like 
proteinase). 
(Lei et al., 2018) 
NSP4 Transmembrane scaffold protein, 
important for structure of DMVs. 
(Sakai et al., 2017) 
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NSP5 Cleaves at 11 sites of (3C-like 
proteinase) NSP polyprotein. 
(Stobart et al., 2013) 
NSP6 Generates autophagosomes. (Cottam et al., 2014) 
NSP7 Dimerises with NSP8, may act as a 
processivity clamp for RNA 
polymerase (NSP12). 
(te Velthuis et al., 2012) 
NSP8 Stimulates NSP12, may act as a 
primase. 
(te Velthuis et al., 2012) 
NSP9 Binds to helicase, RNA binding 
phosphate. 
(Zeng et al., 2018) 
NSP10 Co-factor for NSP16 and NSP14, can 
form heterodimers resulting in ExoN 
and 2-O-MT activity.  
(Smith et al., 2015) 
NSP11 Not yet determined. (Yan and Wu, 2021) 
NSP12 Copies viral RNA (RNA polymerase) 
methylation (guanine). 
(Subissi et al., 2014) 
NSP13 Unwinds duplex RNA (Helicase). (Jia et al., 2019) 
NSP14 3’ to 5’ exoribonuclease; ExoN, 
guanine N7-methyltransferase, N7-
MTase adds 5’ cap to viral RNA, and 
ExoN activity provides proofreading of 
viral genomes. 
(Subissi et al., 2014) 
NSP15 Degrade RNA to (endoribonuclease) 
evade host defence. 
(Deng and Baker, 2018) 
NSP16 2-‘O-MT; shields viral RNA from 
MDA5. 
(Decroly et al., 2011) 
 
1.3.1 Accessory proteins  
The accessory proteins encoded within coronavirus genomes vary in number, 
location, and size dependent on different species. The accessory proteins are 
thought to provide additional functions that are not directly associated with 
replication and transcription but are instead involved in the pathogenicity of the 
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natural host through virus host interactions (Liu et al., 2014, Schaecher and 
Pekosz, 2010). The term accessory proteins originates from before the use of 
animal models to study pathogenesis, as they were not required for replication 
of the viruses in cell culture based on deletion studies performed using reverse 
genetic approaches (Niemeyer et al., 2013, Michel et al., 2020, Schaecher and 
Pekosz, 2010, Thornbrough et al., 2016). Interestingly there is no nucleotide 
sequence homology between MERS-CoV and SARS-CoV accessory ORFs, a 
potential explanation for the differences in immune modulation between 
viruses from the same family (Menachery et al., 2017). MERS-CoV has five 
accessory proteins: protein 3 [p3], p4a, p4b, p5 and p8b. An overview of the 
MERS-CoV accessory protein functions is highlighted in Table 1.3. In vitro 
experiments where MERS-CoV accessory genes are not present 
demonstrated major impacts on viral replication and pathogenesis (Menachery 
et al., 2017). 
 
Table 1.3: Features of MERS-CoV accessory proteins 
Accessory 
protein name 
Function  Reference 
3 Single transmembrane domain with a 
N-glycosylation site, predicted to be 
involved in the secretory pathway.   
(Niemeyer et al., 
2013) 
4a dsRNA binding domain and type I 
interferon antagonist. 
(Niemeyer et al., 
2013) 
4b Inhibits OAS-RNase L pathways 
reducing antiviral activity.  
(Thornbrough et 
al., 2016) 




8b Inhibition of IRF3-mediated IFN- 
expression through interaction with 
HSP70. 




SARS-CoV-2 has 6 accessory proteins which play a role in host pathogenesis, 
and these are summarised in Table 1.4, some functions are deduced through 
high similarity to the SARS-CoV genome. 
Table 1.4: Features of SARS-CoV-2 accessory proteins 
Accessory 
protein name 
Function  Reference 
3a Interaction with TRAF3 resulting in the 
activation of caspase 1 and the 
maturation of IL-1 
(Siu et al., 2019) 
6 Interacts with NSP8 and is thought to 
promote polymerase activity. 




7a Type 1 transmembrane protein. Lysine 
residues subject to ubiquitination which 
drives inhibition of type-I interferon 
signalling via the phosphorylation of 
STAT2 . 
(Nelson et al., 
2005, Cao et al., 
2021) 
7b Derived from ribosomal slippage, has 
been shown to be incorporated into 
SARS-CoV virions, elucidating to 
structural properties.  
(Schaecher et al., 
2007) 
8 Inhibits IFN- and NF- pathways and 
interferon stimulated genes (ISGs). 
Suppression of innate immune 
responses. Patients with deletions in 
ORF8 were associated with milder 
disease.  
(Li et al., 2020a, 
Young et al., 
2020a) 
10 Unique to SARS-CoV-2, function is 
under investigation. Some have 
speculated it is not essential in vitro or 
in vivo. 




1.3.2 Infectious cycle 
The infectious cycle is initiated upon spike binding to the host receptor, which 
results in the release of viral RNA into the cytoplasm. The genome is 
translated, transcribed, and replicated which facilitates the assembly and 
release of the virion (Figure 1.6).  
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1.3.3 Binding and Entry 
Spike protein is a class I viral fusion protein that facilitates virus entry into the 
host cell and is the primary determinant of host tropism (Bosch et al., 2003). 
Upon binding, the spike protein undergoes proteolytic processing via host 
proteases which in turn result in receptor-mediated endocytosis (Hulswit et al., 
2016) (Figure 1.7). Following the binding of the host receptor and proteolytic 
processing of the receptor binding domain (RBD) of S, the viral envelope fuses 
with the cell membrane allowing the release of the nucleocapsid and viral 
genome into the cell. The MERS-CoV spike glycoprotein binds to its functional 
receptor, DPP4, via the N-terminal of S1 (Raj et al., 2013). Post attachment 
uses the C-terminal of S or S2, where interactions with proteases such as furin, 
TMPRSS2 and cathepsins occur, resulting in conformational changes that 
facilitates fusion with the host cellular membrane and thus release of 
nucleocapsid and viral RNA into the cytoplasm (Fehr and Perlman, 2015). 
Tetraspanin CD9 holds TMPRSS2 and DPP4 in a complex on the cell surface 
(Earnest et al., 2017). TMPRSS2 plays a role in SARS-CoV-2 infection by the 
same mechanism, however, angiotensin converting enzyme II (ACE2) is the 
functional receptor for virus entry (Ou et al., 2020, Hoffmann et al., 2020b). 
Shortly after the SARS-CoV pandemic from 2002-2003, ACE2 was identified 
as the receptor that facilitate infection (Li et al., 2003). Due to sequence and 
Figure 1.6: Coronavirus infectious life cycle: 1. Coronaviruses enter the host cell 
through receptor-mediated endocytosis, for SARS-CoV-2 the receptor is ACE2 with 
TMPRSS2, for MERS-CoV the receptor is DPP4. 2. Upon entry, and the release of 
genomic RNA, the genome is immediately translated due to the polyA tail to synthesise 
the polyproteins pp1a and pp1ab. 3. Individual nsps are a result of further processing 
to form the RTC.  4. The RTC replicates the viral genome within double membrane 
vesicles (DMVs) within the cytoplasm. 5. In addition to genome replication, sgmRNAs 
are produced by discontinuous transcription. 6. sgmRNAs are translated by the hosts 
ribosomes and are translocated into the endoplasmic reticulum (ER) through the ER-
to-Golgi intermediate compartment (ERGIC). 7. N protein encapsidates genomic RNA 
which results in the budding into the lumen of secretory vesicles.  Mature virions are 
released from the cell via exocytosis. Figure adapted in BioRender. 
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structural homology between SARS-CoV and SARS-CoV-2 spike proteins, 
ACE2 was quickly identified as the receptor for SARS-CoV-2 (Zhou et al., 
2020b, Hoffmann et al., 2020b). SARS-CoV-2 possess a furin cleavage site in 
the spike protein, and upon furin cleavage, a conserved C-terminal motif is 
exposed (Cantuti-Castelvetri et al., 2020). Such C-terminal motif’s are 
consistent with what has been previously descirbed as the C-end rule (CendR) 
and such peptides are able to bind to neuropillin-1 (NRP-1) (Teesalu et al., 
2009). NRP-1 has been shown to bind with the cleaved terminus of S1 and 
enhances viral entry and thus infectivity (Daly et al., 2020, Cantuti-Castelvetri 






Figure 1.7: SARS-CoV-2 enters the host cell by binding to ACE2, and MERS-
CoV enters by binding to DPP4. TMPRSS2 cleaves the spike protein causing 
conformational change and therefore activation of the S2 domain, allowing 
fusion of the enveloped bilayer to fuse with the host plasma membrane. Figure 
adapted in BioRender.  
1.3.4 Assembly and budding 
Following translation, the structural proteins, S, E and M are translocated to 
the ER. Coronavirus viral genomic RNA becomes associated with N protein, 
this facilitates the budding into the ER lumen and subsequently the ER-Golgi 
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2005, Perrier et al., 2019). This results in the formation of viral particles 
enveloped with host membranes with the addition of the coronavirus structural 
proteins M, E and S which are hypothesised to leave the cell via exocytosis 
(Stertz et al., 2007, de Haan and Rottier, 2005, Klein et al., 2020). Although 
with the emergence of SARS-CoV-2, there is now evidence egress can occur 
through the lysosomal trafficking pathway (Ghosh et al., 2020). As opposed to 
the biosynthetic secretory pathway, after reaching the Golgi apparatus/trans-
Golgi network, coronaviruses can be trafficked to lysosomes and use exocytic 
lysosomes (Ghosh et al., 2020). Interestingly, Ghosh et al (2020) noted 
deacidification and a reduction in lysosomal enzyme activity, which may 
interfere with other cellular processes including antigen presentation. 
 
1.3.5 The effects of virus infection at a cellular level and immune 
evasion strategies 
Although the host can process an antiviral defence response to coronaviruses, 
they utilise their proteins to antagonise the host innate response. This can be 
through targeting viral sensors or inhibiting downstream antiviral signalling 
molecules. Endemic coronaviruses that cause the common cold and are 
associated with mild symptoms, provoke a strong type I IFN response (Mesel-
Lemoine et al., 2012). In contrast, the emerging coronaviruses have been 
shown to hamper the hosts antiviral response, therefore, efficient immune 
evasion is associated with pathogenicity (Hu et al., 2021, Kasuga et al., 2021). 
 
Interferons (IFNs) were discovered in the late 50s as a substance that 
protected cells from viral infection (Isaacs and Lindenmann, 1957). There are 
three classes of IFNS; type I, type II and type III IFNs and all contribute to the 
response to viral infections and regulating the immune system (Pestka et al., 
2004, Mesev et al., 2019). The class of IFN is determined by the distinct 
heterodimeric receptor in which the IFN signals through (Mesev et al., 2019). 
Type I IFNs consist of , , ,  and  IFNs which bind to heterodimeric 
IFNAR1/IFNAR2 complexes (Schoggins, 2019). Type II IFNs only consist of 
IFN and binds to IFNGR1/IFNGR2 (Mesev et al., 2019). In 2003, 3 type III 
IFNs were discovered (IFN1, IFN2, IFN3), followed by IFN4 in 2014 and 
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were found to resemble interleukin-10 (IL-10) structurally (Kotenko et al., 2003, 
Sheppard et al., 2003, O'Brien et al., 2014). Upon interaction between IFNs 
and their corresponding receptors, intracellular kinases such as JAK1, JAK2 
and TYK2 are activated which in turn results in the phosphorylation of 
transcription factors STAT1 and STAT2 (Schoggins, 2019). Activated 
transcription factors translocate to the nucleus and bind to interferon-
stimulated response element (ISRE) or gamma-activated sequence (GAS) to 
induce the transcription of interferon stimulated genes (ISGs).  
  
Coronaviruses consistently show a limited induction of IFN and other type I 
IFNs in tissue culture, animal models and patient samples (Law et al., 2005, 
Funk et al., 2012, Blanco-Melo et al., 2020, Spiegel et al., 2005). In the 
presence of IFNs there is a reduction in viral RNA in tissue culture and animal 
models, reinforcing the sensitivity coronaviruses have to IFNs (Haagmans et 
al., 2004, Cinatl et al., 2003). During RNA replication, pattern recognition 
receptors (PRRs) such as RIG-1 and MDA5 can recognise dsRNA. However, 
multiple coronavirus proteins can antagonise different components of the cell 
signalling pathways responsible for the control and regulation of the innate 
immune response. For example, N can inhibit the ubiquitination of TRIM25, 
resulting in limited activation of RIG-1 and thus reduced detection of replicating 
RNAs which traditionally activate interferon regulatory factors through IRF3 
(Hu et al., 2017). Nsp8 can bind directly to MDA5 and block its ubiquitination 
supressing the production of IFNs (Yang et al., 2020b). Phosphorylation of 
IRF3 and IRF7 results in translocation into the nucleus, activating the 
transcription of IFNs, however, coronavirus proteins such as nsp3 can inhibit 
this phosphorylation, thus preventing entry into the nucleus and activation of 
IFN genes (Clementz et al., 2010, Wathelet et al., 2007, Devaraj et al., 2007, 
Kopecky-Bromberg et al., 2007, Zhou et al., 2012).  
 
Coronavirus infection can modulate host translation through the activity of 
nsp1 (Narayanan et al., 2008). Nsp1 inhibits the translation of host mRNA and 
triggers their degradation by binding with the 40S ribosomal subunit, ultimately 
supressing the function of STAT1 signalling (Kamitani et al., 2009, Wathelet et 
al., 2007). S proteins are also able to modulate translation processes through 
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interactions with translation factor elF3f (Xiao et al., 2008). N has also been 
identified as an interacting partner with eukaryotic translation factor 1 alpha 
(eEF1), and the expression of N in cells results in the inhibition of host protein 
expression (Zhou et al., 2008). The SARS-CoV accessory protein 7a has also 
been found to inhibit host protein expression through the induction of apoptosis 
(Kopecky-Bromberg et al., 2006), and is able to arrest the cell cycle at the 
G0/G1 phase (Yuan et al., 2006). 
 
RNA-modifying enzymes are encoded within the coronavirus genome, these 
can alter the properties of both host and viral RNAs. Nsp13 plays a role in 
facilitating immune evasion by removing 5’-triphosphate from viral RNAs, 
which is a recognised by RIG-I (Ivanov et al., 2004, Ivanov and Ziebuhr, 2004, 
Shu et al., 2020). Nsp14 then plays a role in 5’ capping the viral mRNA via the 
guanine-N7-methyltransferase (Chen et al., 2009, Ma et al., 2015). 
Additionally, nsp16 regulates the 2’-O-methylation of the viral RNA, which is 
also essential for the capping of viral RNA, furthering the evasion of antiviral 
sensors such as MDA5 and IFITS (Chen et al., 2011, Krafcikova et al., 2020, 
Züst et al., 2011). 
 
As structural proteins are translocated to the ER, it is expected that during viral 
infection that ER homeostasis is interrupted resulting in ER stress (Schröder 
and Kaufman, 2005, Zhang and Wang, 2012). Coronavirus genome replication 
has been shown to trigger an unfolded protein response (UPR) which is 
thought to regulate antiviral responses (Nakagawa et al., 2016). S proteins 
could be a driver of this response due to their large molecular weight and 
extensive glycosylation but also due to the dependence of ER chaperones to 
correctly fold the protein (Versteeg et al., 2007). In addition to the expression 
of viral proteins, the formation of DMVs and lipid depletion in the ER may 
contribute to ER stress, ultimately impacting cellular mRNA expression 
(Nakagawa et al., 2016). Coronaviruses hijack the ER to form the DMV where 
the virus can evade cytosolic PRR sensing (Hartenian et al., 2020, Hagemeijer 
et al., 2014). Nsp3, nsp4 and nsp6 facilitate this via membrane rearrangement 
of the ER (Hagemeijer et al., 2014). Stress granule (SGs) and processing body 
(P-bodies) formation has been shown to increase during active replication of 
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coronaviruses (Raaben et al., 2007, Sola et al., 2011). This increase was 
observed in parallel to an increase of elF2, therefore it was hypothesised that 
the translation of host mRNAs was shut off by triggering an integrated stress 
response (Raaben et al., 2007). 
 
 
1.4 Disease pathogenesis and the host response 
1.4.1 MERS-CoV 
Severe MERS-CoV infection in humans is associated with a highly lethal 
pneumonia, where renal dysfunction or failure is common (Arabi et al., 2014, 
Al-Abdallat et al., 2014, Guery et al., 2013). The incubation time for MERS-
CoV ranges between 2-14 days, with an average of 5 days, during which 
patients are asymptomatic (Choudhry et al., 2019). Clinical symptoms range 
from mild to severe, where in mild symptoms often present as a cough, fever 
and myalgia and severe symptoms include pneumonitis and respiratory failure. 
In addition, patients with MERS-CoV infections may experience abdominal 
pain, loss of appetite, and gastrointestinal symptoms such as diarrhoea and 
vomiting.  Risk of severe disease is increased by chronic diseases such as 
heart disease, kidney disease, hypertension, and diabetes (Drosten et al., 
2013). 
 
MERS-CoV induces pro-inflammatory cytokines, however, in comparison to 
SARS-CoV, lacks the stimulation of innate antiviral cytokines. This suggests 
that MERS-CoV delays this pro-inflammatory response thereby attenuating 
innate immunity (Lau et al., 2013). MERS-CoV establishes infection through 
the respiratory tract, however, DPP4 the receptor facilitating virus entry, is 
expressed on the epithelial surface of multiple organs, including the lungs, 
kidneys, bone marrow, thymus and intestines (Boonacker and Van Noorden, 
2003). Therefore MERS-CoV is able to disseminate throughout multiple 
tissues. Within the respiratory tract, DPP4 is predominantly expressed on type 
I and II pneumocytes, endothelial cells, non-ciliated bronchial epithelial cells, 
and a selection of hematopoietic cells (Raj et al., 2013, Meyerholz et al., 2016). 
DPP4 is expressed at a higher abundance in the lower respiratory tract than 
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in the upper respiratory tract and the nasal cavity (Widagdo et al., 2016). This 
expression is enhanced by chronic pulmonary diseases and thus may increase 
the chance of contracting the disease (Meyerholz et al., 2016). 
 
Interestingly, our understanding of MERS-CoV has been predominantly 
formed by in vitro studies due to the lack of availability of post-mortem studies 
(Choudhry et al., 2019). Animal models have been used in addition to accounts 
from a single post-mortem investigation (Ng et al., 2016). Antigens for MERS-
CoV were identified on pneumocytes, endothelial cells and epithelial cells of 
the airways and macrophages (Ng et al., 2016). This was consistent with 
analysis conducted on lung explants from infected humans (Chan et al., 2013, 
Hocke et al., 2013). 
 
Macrophages remove pathogenic material from the body and present the 
pathogen’s antigen to T-cells. Cytokines and chemokines released from 
macrophages aid in the removal of pathogens, regulating the immune system 
and the homeostasis of tissues (Choudhry et al., 2019, Murray and Wynn, 
2011). Macrophages contribute to the development of disease in MERS-CoV. 
Following infection of human epithelial cells, pro-inflammatory chemokines 
and cytokines are released from macrophages. This process is thought to 
contribute to inflammatory changes and tissue damage through the infiltration 
of immune cells in the lower respiratory tract (Zhou et al., 2014). Large 
numbers of macrophages and neutrophils have been identified in fluids derived 
from the lungs of MERS-CoV patients (Zaki et al., 2012, Guery et al., 2013). 
Furthermore, MERS-CoV has been shown to replicate in macrophages, 
demonstrating the virus’s ability to overcome the host immune response (Zhou 




Like MERS-CoV, SARS-CoV-2 can cause severe symptoms including acute 
respiratory distress (ARDS), pneumonia and renal failure (Wang et al., 2020b, 
Chan et al., 2020). Fever, cough and dyspnoea account for the most common 
symptoms in COVID-19 (Docherty et al., 2020). The incubation time for SARS-
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CoV-2 is approximately 5-6 days (Chan et al., 2020, Li et al., 2020b). COVID-
19 initially presents with early flu-like symptoms, however, progresses rapidly 
into systemic inflammation and multiorgan dysfunction. The ACE2 receptor 
that facilitates viral entry into the cell is expressed on multiple tissues (Figure 
1.8). Upon entry into the respiratory tract, SARS-CoV-2 initially enters the 
epithelial cells of the airway and alveoli, vascular endothelial cells, and alveolar 
macrophages (Harrison et al., 2020, Ziegler et al., 2020). Although ACE2 
mRNA has been demonstrated to be less abundant in lung tissue in 
comparison to extrapulmonary sites (Sun et al., 2021). However, previous 
studies have shown viral entry is dependent on TMPRSS2 even with a 
negligible ACE2 expression (Shulla et al., 2011). The addition of the furin 
cleavage site in the Spike protein provides an alternative cleavage opportunity 
that doesn’t depend on TMPRSS2 or cathepsin L for viral entry (Hoffmann et 
al., 2020a). This feature is thought to extend the tropism of SARS-CoV-2, 
especially as proteolytically active furin is expressed in human bronchial 
epithelial cells (Follis et al., 2006, Lukassen et al., 2020). In comparison to 
SARS-CoV, SARS-CoV-2 exhibits an enhanced ability to infect components 
of the upper respiratory tract. This is thought to be because of the higher affinity 
which SARS-CoV-2 displays for ACE2, which is expressed in nasal and oral 




Figure 1.8: ACE2 expression within the human body contributes to the 
multiorgan pathogenesis of SARS-CoV-2, DPP4, the receptor for MERS-CoV 
is highly expressed in the kidney and is thought to be associated with renal 
dysfunction or failure (Lambeir et al., 2003). Figure adapted from BioRender. 
Old age is a risk factor for severe COVID-19 (Docherty et al., 2020). 
Lymphocytopenia, neutrophilia, inflammation and coagulation markers have 
also been identified in patients over 65 in comparison to younger patients 
(Wang et al., 2020b, Liu et al., 2020b). A compromised adaptive immune 
response attributable to a reduced capacity of CD4+ and CD8+ T-cells to 
release IFN- and IL-2, as well as insufficient T-cell activation by dendritic cells, 
is also associated with older age (>55 years) (Zhou et al., 2020c).  
 
Patients with severe COVID-19 disease have been shown to have a higher 
proportion of macrophages and neutrophils within bronchoalveolar lavage fluid 
(BALF) in comparison to those with mild disease (Liao et al., 2020). Likewise, 
IL-6, IL-8 and CCL2 are elevated in severe disease (Liao et al., 2020, Qin et 
al., 2020, Blanco-Melo et al., 2020). Proinflammatory signals can contribute to 
disease of the lungs through elevation of C-reactive protein derived from the 
liver through STAT3-IL-6 signalling (Marnell et al., 2005). Neutrophil 
extracellular traps (NETS) may also be a potentiator of COVID-19 
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pathogenesis as these have been identified in the micro-vessels of patients 
with severe disease in comparison to mild (Zuo et al., 2020). Endothelial cell 
dysfunction may be the driver of the recruitment of activated neutrophils and 
monocytes (Varga et al., 2020). 
 
One common symptom of COVID-19 is anosmia and ageusia, the loss of smell 
and taste which can occur in the absence of other clinical symptoms (Lechner 
et al., 2020, Ellul et al., 2020). This has been used as a diagnostic marker due 
to the prevalence of this symptom (Lüers et al., 2020). The presence of 
anosmia may give clues into viral entry into the brain, as the olfactory bulb is 
not protected by dura (Ellul et al., 2020). This entry route is also used by other 
viruses such as herpes simplex virus which is able to cause viral encephalitis 
(Solomon, 2009). OC43 is also able to enter the central nervous system (CNS) 
via this olfactory route (Netland et al., 2008). Brain vascular endothelium and 
smooth muscle express ACE2, where in vitro studies have confirmed SARS-
CoV-2 replication in neuronal cells (Hamming et al., 2004, Chu et al., 2020). 
Post-mortem analysis of fatal COVID-19 patients identified SARS-CoV-2 in 
brain tissue in some of the study participants, however, there was no evidence 
of viral encephalitis or vasculitis or perivascular lymphocytic infiltration 
(Remmelink et al., 2020). As the pandemic progresses, more case reports are 
describing neurological manifestations caused by a SARS-CoV-2 infection 
(Ellul et al., 2020). 
 
1.5 Virus evolution 
The predominant drivers of genetic variation within coronaviruses are single 
nucleotide polymorphisms (SNPs) through polymerase driven errors, potential 
host factor driven RNA modifications, and insertion/deletions (indels) resulting 
from the discontinuous nature of viral RNA synthesis. While many mutations 
represent a neutral ‘genetic drift’ or have quickly died out, a subset may be 
affecting viral traits such as transmissibility, pathogenicity, host range, and 




Due to immense genomic surveillance efforts during the SARS-CoV-2 
pandemic, variants have been monitored in real time, allowing the research 
and public health communities to respond accordingly. Throughout the 
pandemic, variants have been termed variants of concern (VOC) or variants 
under investigation (VUI) and have been researched rapidly and extensively 
to determine the impact of evolution on public health countermeasures such 
as vaccines. Variants referred to are highlighted in Figure 1.9. To provide 
nomenclature for the expanding phylogeny of the SARS-CoV-2 genome during 
the pandemic, Rambaut et al (2020) proposed a system built upon a 
phylogenetic framework to identify lineages that contribute most to active 
spread (Rambaut et al., 2020). At the root of the SARS-CoV-2 phylogeny are 
two lineages, denoted as A and B, where A is the earliest linage of SARS-CoV-
2 viruses. Viruses that are descended from these are then assigned a 
numerical value, for example, B.1. This can then proceed to three sublevels, 
for example B.1.1.1, descendants beyond this would start a new parent 
lineage, for example C.1 (Rambaut et al., 2020). Although the variants 
discussed from here onwards may not have been relevant at the time of the 
study presented in Chapter 2, they are discussed to highlight the importance 
of genomic surveillance of coronaviruses.  
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Figure 1.9: An overview of mutations observed in the SARS-CoV-2 genome a 
year into the global pandemic. Figure made in BioRender. 
1.5.2 Mutations within SARS-CoV-2 spike 
One of the most characterised variants is D614G, a mutation in the spike 
glycoprotein. Viruses with this mutation were identified in February 2020, and 
by May 2020 it was detected in 80% of available sequences (Korber et al., 
2020, Yang et al., 2020a, Zhang et al., 2020). This variant was thought to 
rapidly replace the previous circulating virus due to an increased 
transmissibility, however, the D614G variant expanded exponentially across 
Europe and the Americas perhaps highlighting a founder effect (Korber et al., 
2020, van Dorp et al., 2020). The D614G variant was also found to have 
genetically linked mutations, including a P to L amino acid change in nsp12, 
hypothesised to contribute a fitness advantage to the virus (Volz et al., 2021a). 
Through in vitro studies utilising pseudoviruses, D614G has been shown to 
enhance entry into ACE2 expressing cells (Korber et al., 2020, Zhang et al., 
2020, Li et al., 2020c, Daniloski et al., 2021, Ozono et al., 2021). Viruses 
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without the D614G mutation are almost non-existent, with the exception of a 
lineage in Uganda which instead contains an alternative mutation in spike 
Q613H (Bugembe et al., 2021). This is thought to provide the same advantage 
as D614G and facilitates the co-circulation of the virus in this region (Bugembe 
et al., 2021). 
 
In the middle of 2020, it was discovered that mink were susceptible to reverse-
zoonotic SARS-CoV-2 infection (Enserink, 2020, Rabalski et al., 2020). It was 
discovered that several spike mutations repeatedly arose in these hosts both 
in the field and under laboratory conditions, of interest, the Y453F and N501T 
mutations (Richard et al., 2020, Oude Munnink et al., 2021). These mutations 
have shown an increased binding capacity to the human ACE2 receptor 
(Conceicao et al., 2020, Welkers et al., 2021). This variant has also been 
shown to partially escape neutralisation when challenged with convalescent 
sera (Hoffmann et al., 2021, Garcia-Beltran et al., 2021). 
 
In vitro  studies revealed early in the pandemic that serial passage in Vero E6 
cells resulted in the deletion of the furin cleavage site within the S protein (Pohl 
et al., 2021, Davidson et al., 2020, Lau et al., 2020). This has also been 
observed at a very low frequency in clinical and autopsy samples (Liu et al., 
2020c, Peacock et al., 2020, Wong et al., 2020b). The deletion enhances 
replication in cells lacking TMPRSS2 yet attenuates infection in cells 
expressing TMPRSS2 (Nguyen et al., 2020, Peacock et al., 2020, Sasaki et 
al., 2021). Likewise, this deletion is associated with a mild disease phenotype 
in animal models (Lau et al., 2020, Peacock et al., 2020, Wong et al., 2020b). 
This reinforces that cell entry is TMPRSS2-dependent at the cell surface or the 
early endosome allowing the virus to evade highly restrictive IFITM proteins 
(Peacock et al., 2021). 
 
The N501Y mutation is associated with the B.1.1.7 lineage and was first 
detected in Southeast England towards the end of 2020 (Volz et al., 2021b). 
The B.1.1.7 lineage contains 23 mutations, but of interest within the spike 
protein lies N501Y, 69-70, 144 and P681H (Peacock et al., 2021). N501Y 
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has been shown to increase binding to human ACE2, but also facilitates 
binding to mouse ACE2 (Starr et al., 2020, Choi et al., 2020, Gu et al., 2020, 
Zahradník et al., 2021). Also within the B.1.1.7 lineage are viruses harbouring 
the P681H mutants which lies adjacent to the S1/S2 furin cleavage site; this 
has been shown to enhance furin cleavage (Brown et al., 2021). 
 
The variant E484K has emerged in multiple lineages throughout the pandemic, 
including the South African Variant B.1.351, and twice independently in Brazil; 
P.1, P.2 (Tegally et al., 2021). Some clusters of the B.1.1.7 lineage also 
harbour the E484K variant (Collier et al., 2021). Particular concern was raised 
in regard to this variant due to studies demonstrating escape from 
convalescent anti-sera (Wang et al., 2021, Andreano et al., 2020, Greaney et 
al., 2021). It has been theorised that high seroprevalence within Brazil and 
South Africa may have driven the emergence of these variants (Buss et al., 
2021, Shinde et al., 2021). This variant, in combination with N501Y, has been 
shown to further enhance the binding to ACE2 (Zahradník et al., 2021, Starr 
et al., 2020). 
 
N439K lies directly within the RBD/ACE2 binding interface. Studies have 
shown this to increase ACE2 binding and is associated with lower Ct values in 
clinical samples (Thomson et al., 2021). Investigation into this variant revealed 
a decreased binding and neutralising effect from monoclonal antibodies, 
however, it was deemed unlikely to impact vaccine effectiveness (Li et al., 
2020c, Thomson et al., 2021). Similar interpretations were made with the 
L452R variant which was first detected in California and is now widespread 
across the USA (Zhang et al., 2021b, Greaney et al., 2021, Liu et al., 2021b). 
 
1.5.3 Mutations and deletions outside of SARS-CoV-2 Spike 
Most of the focus on variants for SARS-CoV-2 lies within the spike 
glycoprotein, however, other mutants and deletions have emerged within the 
SARS-CoV-2 genome throughout the course of the pandemic.  
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The ORF8 gene encodes a viral accessory protein that is proposed to interfere 
with the innate response of cells to infection. Viruses harbouring a deletion of 
this gene have been reported in patients from Singapore and were associated 
with milder infection (Young et al., 2020b), but the virus lineage carrying this 
deletion appears to have been outcompeted. Deletions in this gene and others 
involved encoding proteins that antagonise the innate immune response have 
been identified at a minor variant level within patients but are presumably not 
positively selected. 
 
Deletions within immunogenic regions may facilitate immune evasion. 
McCarthy, et al (2020), identified recurrent deletion regions (RDRs), within the 
N-terminal domain of the S glycoprotein which can be as small as 3 
nucleotides and are thought to play a role in antigenic diversity and evasion of 
recognition by neutralising antibodies (McCarthy et al., 2020). Viral genomes 
with deletions within RDRs of S have also found to be transmissible. Persistent 
infections are arguably subjected to selection pressures that are not present 
in typical COVID-19 infections which resolve within weeks (Choi et al., 2020, 
McCarthy et al., 2020, Kemp et al., 2021). Deletions in spike have been 
observed in immune-suppressed patients with a long-term infection, 
supporting intra-host evolution (McCarthy et al., 2020). 
 
From the analysis of 17,928 genome sequences, a 9-nucleotide deletion was 
identified in NSP1 which was found throughout several different geographical 
locations (Benedetti et al., 2020). NSP1 is a component of the coronavirus 
replication-transcription complex and has been shown to be involved in 
hampering the immune response (Kamitani et al., 2009). This deletion is 
postulated to affect the structure of the C-terminal domain which may impact 
viral replication and elicit a less pathogenic phenotype (Benedetti et al., 2020). 
 
Viral genomes harbouring deletions have been found alongside wildtype 
genomes within single patients. A 12-nucleotide deletion was identified in the 
E gene in a clinical isolate; however, the mutant was rare in clinical samples 
and emerged through cellular passaging of the virus (Sun et al., 2020). The 
mutant and wildtype viruses were both able to infect Vero cells and produced 
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comparable viral titres, however, the mutant viral culture had higher S protein 
content (Sun et al., 2020). As the mutant was not identified in clinical 
samples, it is possible that the deletion event is a result of passage. Frame 
shift mutations of 81 nucleotides have been observed within the Orf7a of 
SARS-CoV-2 viruses sequenced in Arizona, which result in the deletion of 
27-amino-acids. Orf7a is host restriction factor that plays a role in apoptosis 
although functional implications of this deletion have not been characterised 
(Holland et al., 2020).  
 
Analysis of recombination at the minor variant level in a cohort of patients from 
the UK showed evidence of deletion events throughout the viral genome. Of 
particular note of are those affecting Orf3a and Orf7a, genes that are involved 
in interferon responses and may act as defective genomes (Moore et al., 
2020). Such deletion variants may contribute to the transient emergence of 
SARS-CoV-2 isolates that are associated with milder disease (Young et al, 
2020). Deletion events may be associated with milder disease; however, they 
also aid immune system evasion. These findings reinforce the importance of 
deletions as a genetic change mechanism due to the implications on vaccine 
efficacy and development. 
 
1.5.4 MERS-CoV 
MERS-CoV genomic surveillance and genotype-to-phenotype assessment 
has not been conducted to the same extent and detail as for SARS-CoV-2. 
MERS-CoV evolutionary history and host range has been studied previously 
(Dudas et al., 2018, Zhang et al., 2016, Cotten et al., 2013). The major zoonotic 
reservoir for MERS-CoV is the camel and multiple introduction events from 
camels to humans have been documented between 2012 and 2019 (Zhang et 
al., 2021a, Dudas et al., 2018). The MERS-CoV spike glycoprotein is also 
subjected to selective to pressure, which is thought to facilitate cross-species 
transmission by changing MERS-CoV’s binding ability to host receptors 
(Zhang et al., 2016). Assessment of MERS-CoV genomes collected from 
patients has revealed the emergence of a lineage with a potential cleavage 
site for furin or trypsin-like proteases (Cotten et al., 2013). Although MERS-
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CoV remains a low pandemic threat, ongoing surveillance of variants is 
important. 
 
1.5.5 The roles of host-mediated RNA-editing in coronavirus evolution 
 
Mutations in virus genomes are usually considered to be a result of error-prone 
viral polymerases; however, host factors can also play a role in the editing of 
the viral genome.  The two main host candidates for endogenous mutagenesis 
are the RNA-editing enzymes of the Apolipoprotein B mRNA Editing Enzyme, 
Catalytic Polypeptide-like (APOBEC) and Adenosine Deaminase Acting On 
RNA (ADAR) families (Mourier et al., 2021). APOBEC proteins are interferon-
stimulated and responsible for the deamination of cytosine to uracil after 
replication and before packaging of virus particles (Salter et al., 2016, Salter 
and Smith, 2018, Di Giorgio et al., 2020), whereas ADAR proteins are 
responsible for the deamination of adenine to inosine driving A -> G changes 
during replication (Placido et al., 2007). APOBEC enzymes have been shown 
to interact with the nucleoprotein and impact replication in HCoV-NL63 in cell 
culture models (Milewska et al., 2018). For influenza virus, it has been 
previously shown that apparent RNA editing can result in the rapid emergence 
of antigenic variants with multiple concurrent amino acid changes (Peacock et 
al., 2017).  
 
Studies have shown a bias in C -> U mutations within the SARS-CoV-2 
genome, suggesting editing by APOBEC (Wang et al., 2020d, Simmonds, 
2020, Di Giorgio et al., 2020, Mourier et al., 2021, Graudenzi et al., 2021, 
Kosuge et al., 2020, Klimczak et al., 2020). RNA editing is enriched in putative 
RNA loop regions, presumably due to these being more exposed than other 
parts of the genome (Klimczak et al., 2020). Due to the observation of 
APOBEC-mediated SARS-CoV-2 genome hyper-editing, it has been 
suggested that cytidine rich regions should be avoided during the design of 
diagnostic tests (Wang et al., 2020c). 
 
Furthermore, virus-derived RNA sequences enriched for Uracil correlate with 
enhanced production of pro-inflammatory cytokines when comparing to the 
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sequence of a reference virus. Based upon previous studies which show that 
U-rich ssRNAs stimulate the innate immune response through TLR7 signalling 
(Takeda and Akira, 2005, Heil et al., 2004), Kosuge et al (2020), investigated 
the impact of C -> U point mutations on the host response, showing an 
increase in TNF-α and IL-6 production in immune cell lines (Kosuge et al., 
2020). 
 
1.6 Treatment and prevention 
 
Currently, there are no specific or targeted medical countermeasures for 
human coronaviruses. Disease is typically symptomatically managed where 
nonspecific therapeutics are used (Chafekar and Fielding, 2018). Although, 
during the SARS-CoV-2 pandemic, vaccines have been rapidly generated for 
emergency use. Therapeutics under investigation for coronavirus disease prior 
to the SARS-CoV-2 pandemic consisted of monoclonal antibodies (mAbs), 
direct-acting antivirals (DAAs) that inhibit proteases, helicases and 
polymerases and the use of interferons and steroids to modulate the immune 
response (Pruijssers and Denison, 2019). When designing treatments for 
coronaviruses, the inherent genetic diversity must be taken into consideration 
in order to avoid the emergence of drug resistant lineages. 
 
Nucleoside and nucleotide analogues such as ribavirin, molnupiravir and 
remdesivir can interfere with the viral polymerase of RNA viruses. Ribavirin is 
an approved broad spectrum anti-viral nucleoside drug used to treat 
Respiratory Syncytial Virus (RSV), hepatitis C (HCV), Lassa fever (LASV), 
Crimean-Congo haemorrhagic fever (CCHFV) and Hantavirus (Cameron and 
Castro, 2001). Ribavirin has been shown to be more beneficial to patient 
outcome with early administration in the context of MERS-CoV (Habib et al., 
2019). When combined with nitazoxanide and hexachloropene, ribavirin has 
shown antiviral activity against MERS-CoV. Furthermore, when ribavirin was 
combined with alisporivir enhanced antiviral activity was demonstrated (Cao 
et al., 2015, de Wilde et al., 2017). In addition, ribavirin when paired with IFN-
2a and lopinavir/ritonavir show encouraging results in a case study of MERS-
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CoV (Kim et al., 2016b, Sheahan et al., 2020). Evidence for SARS-CoV-2 is 
fairly limited at this time as clinical trials are ongoing (Khalili et al., 2020).  
 
Remdesivir is a nucleoside analogue that is able to inhibit the viral polymerase 
and thus stop viral replication. Although many viral polymerases exhibit 
proofreading capabilities, remdesivir is thought to evade this mechanism 
(Gordon et al., 2020, Agostini et al., 2018). Based on data produced by clinical 
trials, remdesivir has been authorised for emergency use by the FDA to treat 
patients with suspected or confirmed SARS-CoV-2 (Beigel et al., 2020, 
Eastman et al., 2020, Ferner and Aronson, 2020, Sheahan et al., 2020, 
Williamson et al., 2020, Grein et al., 2020). Clinical trials demonstrated that 
remdesivir treatment reduced the recovery time in hospitalised COVID-19 
patients and clinical improvements were seen in the majority of patients (Grein 
et al., 2020, Beigel et al., 2020). Molnupiravir is another nucleoside analogue 
being investigated as a therapuetic against SARS-CoV-2 and has been shown 
to promote mutagenesis (Gordon et al., 2021).  
 
Through successful clinical trials, therapeutics such as dexamethasone have 
significantly improved outcome for COVID-19 patients (Horby et al., 2020, 
Sterne et al., 2020). The success of dexamethasone in reducing mortality in 
COVID-19 patients reinforces the involvement of immunopathology in disease 
pathogenesis, however, this therapeutic is only useful in a severe disease 
situation and can delay the elimination of the virus and thus increase the risk 
of secondary infection due to the immunosuppression (Villar et al., 2020). 
 
Prevention for SARS-CoV-2 are stringent public health measures such as 
hand washing, social distancing and local or national lockdowns to reduce 
virus transmission and now vaccinations. Prior to the SARS-CoV-2 pandemic, 
SARS-CoV and MERS-CoV was identified as being difficult to vaccinate 
against due to the viruses sophisticated immune evasion mechanisms. Not 
only does coronavirus immunity wane rapidly, those who are most vulnerable 
include the elderly and there is also risk those vaccines may exacerbate lung 
immunopathology as opposed to preventing it (Honda-Okubo et al., 2015, 
Enjuanes et al., 2008). This lung pathology was associated with eosinophils in 
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response to inactivated whole SARS-CoV vaccines with alum adjuvants in 
mice (Bolles et al., 2011, See et al., 2006, Yasui et al., 2008, Tseng et al., 
2012). In an African green monkey study, similar immune pathology was 
observed after SARS-CoV rechallenge (Clay et al., 2012).  
 
Vaccines based on the spike glycoprotein of MERS-CoV were being explored 
with the use of viral vectors such as Chimpanzee Adenovirus, Oxford 
University 1 (ChAdOx1) (Dicks et al., 2012) and modified Vaccinia virus 
Ankara (MVA) (Gilbert, 2013, Gómez et al., 2013) in animal models (Alharbi et 
al., 2017). ChAdOx1 was found to induce a higher cellular and humoral 
immunogenicity than two doses of the MVA alternative in murine models 
(Alharbi et al., 2017, Munster et al., 2017). Previous studies have shown the 
viral vector was safe and immunogenic in humans (Antrobus et al., 2014). 
ChAdOx1 can also be used to vaccinate camels and therefore prevent 
potential transmission events, thus, ChAdOx1 presented an attractive vaccine 
candidate for rapid use against MERS-CoV (Warimwe et al., 2016, Alharbi et 
al., 2019).   
 
As the SARS-CoV-2 pandemic progressed, many SARS-CoV-2 vaccines 
became available for emergency use including Pfizer/BioNTech, Moderna and 
the AstraZeneca vaccine platforms (Thanh Le T Fau - Andreadakis et al., 
2020). The AstraZeneca vaccine utilised the SARS-CoV-2 spike sequence in 
the ChAdOx1 vector that was being investigated for MERS-CoV  (Li et al., 
2020f). Early studies showed that IgG antibodies against spike peaked on day 
28 and were maintained until day 56 (Folegatti et al., 2020). The neutralising 
IFN response peaked at day 14 and antibodies were induced after a booster 
at 28 days (Folegatti et al., 2020). Pfizer/BioNTech and Moderna utilise mRNA 
technology and showed to be effective at protecting from severe disease 
(García-Montero et al., 2021). These technologies also utilised the spike 
sequence and the mRNA molecules are delivered in lipid nanoparticles 
(Buschmann et al., 2021). Preliminary data from the mRNA vaccine trials 
revealed that antibodies were detectable 15 days after the 1st vaccination with 
neutralising activity after a 2nd dose (Jackson et al., 2020, Mulligan et al., 
2020). 
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1.7 Influenza viruses 
 
Although this thesis focuses on coronaviruses, chapter 3 and 4 uses influenza 
A virus as a comparator due to similarities in diseases and as influenza viruses 
are well characterised. In contrast to coronaviruses, influenza A (IAV) viruses 
belong to the Orthomyxoviridae family and Alphainfluenzavirus genus and 
have eight segmented single-stranded negative sense RNA molecules 
spanning a total of 13.5kb (Ghedin et al., 2005). Segments range from 890 to 
2341 nucleotides in length and code for a total of 12 proteins, these are 
highlighted in Table 1.5 (Ghedin et al., 2005). Influenza viruses can be divided 
into four types, A, B, C and D based upon differences in genetic and antigenic 
properties (Pleschka, 2013). Influenza A and B viruses are responsible for 
seasonal disease epidemics where IAV are known to cause pandemics due to 
the diversity and host range (Taubenberger and Morens, 2013). Influenza C 
viruses can cause mild respiratory disease in humans  whereas influenza D 
viruses mainly affect cattle and the public health threat to humans is 
considered low (Su et al., 2017). 
 
Table 1.5: Influenza virions contain 8 segments which encode for 11 proteins. 
The length of the segments, the proteins they encode, and their functions are 
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IAV virions have a lipid envelope with the surface glycoproteins, hemagglutinin 
(HA) and neuraminidase (NA) (Figure 1.10). Orthomyxoviridae viruses are 
approximately 80-120nm in diameter (ICTV, 2020). IAVs can be classified into 
further subtypes based upon the HA and NA proteins, there are 18 known HA 
(H1-H18) and 11 NA (N1-N11) antigens (Tong et al., 2013).   
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Figure 1.10: Influenza A viruses are roughly spherical or filamentous and 
enveloped with a lipid membrane. Inserted into the membrane are two 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). M2 is also 
embedded in the lipid membrane. The M1 matrix protein lies beneath the lipid 
membrane and provides rigidity to the lipid envelope by forming a shell. There 
are 8 segmented viral RNAs which are associated with NP and the RNA 
polymerase components, PB1, PB2 and PA. Nuclear export factor (NEP) is 
also present within the virion.  
HA is a homotrimer that facilitates viral entry into host cells by binding to sialic 
acids on glycoproteins or glycolipids (Matsuoka et al., 2013, Yao et al., 2008, 
Huang et al., 2003). Upon binding, IAV enters the cell through receptor-
mediated endocytosis (Muramoto et al., 2006). The reduced pH within the 
endosome that IAV uses to enter the cell, facilitates fusion with the endosomal 
membrane by conformational change of HA (Luo, 2012). The fusion between 
viral and endosomal membranes allow the M2 ion to open, forming a proton-
selective ion channel, resulting in acidification of the viral core (Holsinger and 
Lamb, 1991, To and Torres, 2019). Upon acidification, viral RNAs and their 
associated proteins are released from M1 to the cytoplasm of the cell (Pinto 
and Lamb, 2006, To and Torres, 2019). NP, PA, PB1 and PB2 have nuclear 
Neuraminidase (NA) 
Hemagglutinin (HA) 
M2 proton channel 




PB1, PB2, PA 
(RNA polymerase) 
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localisation signals (NLSs) that can bind to importin- and importin- (Pumroy 
et al., 2015, Nakada et al., 2015). 
 
Influenza replication and transcription occurs in the nucleus of the cell 
(Jackson et al., 1982, Amorim and Digard, 2006). IAV RNAs possess poly(A) 
tails, however, lack 5’ caps, therefore, to avoid recognition by host machinery, 
the virus undergoes a process known as ‘cap-snatching’ during transcription 
(De Vlugt et al., 2018, Clohisey et al., 2020). This is facilitated by PB1, PB2 
and PA by binding to the methylated 5’ cap of cellular mRNAs and 
endonuclease activity from PB2 (Li et al., 2001). Polyadenylation of viral 
mRNAs is achieved via a process known as stuttering where the RNA 
polymerase complex moves back and forth over uracil residues at the 5’ end 
of viral RNA templates (Zheng et al., 1999). 
 
Mutations can be introduced into the viral genome during replication by the 
RNA polymerase (Chen and Holmes, 2006). As discussed in coronaviruses, 
mutations in the virus can drive adaptations suitable for new hosts. For 
example, mutations in an avian strain IAV, H5N1, has been shown to drive 
transmission into mammals (Zhang et al., 2013). In addition to mutations, or 
antigenic drift, influenza viruses can undergo evolutionally change by a 
process termed reassortment and in very rare cases recombination (Shao et 
al., 2017, Mehle et al., 2012). As influenza viruses have segmented genomes, 
segments can be exchanged between influenza strains during virion assembly 
giving rise to new strains or subtypes depending on the combination of 
segments within the virus (Reid and Taubenberger, 2003). This reassortment 
can generate novel viruses achieving a new antigenic pattern known as 
antigenic shift (Shao et al., 2017). This mechanism of evolution is thought to 
drive the emergence of pandemic strains (Dawood et al., 2009). Influenza 
viruses can also undergo recombination, although this is rare in comparison to 
reassortment and mutation events (Shao et al., 2017). Recombination is more 
likely to be non-homologous than homologous in influenza viruses (Orlich et 
al., 1994, Suarez et al., 2004, Chare et al., 2003). 
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Negative sense viral RNAs and associated proteins leave the nuclease 
through the chromosome region maintenance 1 (CRM1) dependent manner, 
whereas the positive sense complexes through other mechanisms (Gao et al., 
2014, Chaimayo et al., 2017). NEP and M1 plays a crucial role in nuclear 
export by forming a complex with the viral ribonucleoproteins and interacting 
with CRM1 (Shimizu et al., 2011). M1 preferentially interacts with negative 
sense viral RNA complexes selecting them for export from the nucleus 
(Chaimayo et al., 2017). Viral proteins are synthesised in the cell’s cytoplasm 
where components of the IAV virion can be assembled ready for budding 
(Rossman and Lamb, 2011). Virions bud from the apical side of cells that are 
polarised and therefore HA, NA and M2 are transported to the apical 
membrane (Nayak et al., 2009, Samji, 2009). M1 is essential in closing off and 
budding the viral particle as it sits underneath the lipid bilayer (Burleigh et al., 
2005, Nayak et al., 2009). Viral packaging is thought to occur through either 
the random packaging model (Enami et al., 1991, Bancroft and Parslow, 2002) 
or the specific packaging model (Smith and Hay, 1982).Evidence leans 
towards the latter model as packaging signals have been observed in the 5’ 
and 3’ non-coding and coding regions of viral segments (Fujii et al., 2003, Fujii 
et al., 2005, Bancroft and Parslow, 2002, Smith and Hay, 1982). To complete 
virion egress, sialic acid residues are cleaved from glycoprotein and glycolipids 
by NA, without this, egress would not occur (Palese et al., 1974). 
 
Influenza infections in humans cause high fever, body ache and fatigue 
(Fukuyama and Kawaoka, 2011). In comparison to coronaviruses, incubation 
period is slightly shorter with a range between one and four days (Lessler et 
al., 2009). Although symptoms can vary between IAV strains, they typically 
improve within days (Fukuyama and Kawaoka, 2011). Strains such as the 
2009 pandemic H1N1 virus and H5N1 viruses have higher pathogenicity than 
seasonal influenza viruses. These highly pathogenic strains can result in 
severe pneumonia and require hospitalisation. The 1918 influenza pandemic 
was estimated to be responsible for 50 million deaths worldwide (Fukuyama 
and Kawaoka, 2011). Like with coronaviruses, this variability in pathology 
between strains and between people are determined by the host’s immune 
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responses and viral factors (Fukuyama and Kawaoka, 2011, Lessler et al., 
2009, Godlee et al., 2011).  
 
IAV infect epithelial cells within the respiratory tract and alveoli, thus giving rise 
to injury of alveolar that drives the failure in gas exchange and in some cases 
lead to ARDS and death (Herold et al., 2015). Following cell entry, IAV PAMPs 
are recognised by PRRs such as TLR3, TLR7 and TLR8 in cytoplasmic 
endosomes, where TLR3 recognises dsRNA (Goubau et al., 2014, Chen et al., 
2018). Through these innate immune mechanisms, an interferon signalling 
pathway is activated. Like all viruses, IAV has mechanisms to evade the hosts 
immune response. For example, NS1 interferes with the RIG-I signalling 
pathway by inhibiting TRIM25 preventing essential ubiquitination of RIG-I 
(Fukuyama and Kawaoka, 2011). Adequate suppression of IFN-regulated 
genes is thought to be the driver of pathogenesis in 1918 pandemic influenza 
(Fukuyama and Kawaoka, 2011, Geiss et al., 2002).  
 
1.8 Outbreak preparedness 
Research plays an essential role in the response against the emergence of a 
novel disease, however, the concept of research preparedness itself requires 
research. Through an evaluation and comparison to the response to SARS-
CoV and SARS-CoV-2, the global response has been able to develop 
diagnostic tests, sequence the viral genome, isolate the virus, and begin 
vaccine trials in a much shorter timescale (Kinsella et al., 2020). This rapid 
response is dependent on consortium driven research that allows for timely, 
high-quality investigation to take place, that relies on collaboration and the 
sharing of knowledge, expertise, and facilities. 
 
1.8.1 Consortium driven research 
Work included in this thesis has been in collaboration with 3 main consortia 
involved in the SARS-CoV-2 pandemic response in the UK.  
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1.8.2 International Severe Acute Respiratory Infection Consortium 
(ISARIC) 
The ISARIC World Health Organisation (WHO) Clinical Characterisation 
Protocol (CCP) allows for the gathering of clinical data and samples 
(https://isaric.org/). This protocol encourages data analysis and processing to 
be done in a globally harmonised manner. This protocol has been curated by 
multidisciplinary experts across the world (Dunning et al., 2014), and employed 
in response to outbreaks such as MERS-CoV in 2012 (Zaki et al., 2012), 
Influenza A virus (H7N9) in 2013 (Gao et al., 2013), Ebola virus in 2014 (Baize 
et al., 2014), Monkeypox (Vaughan et al., 2018) and MERS-CoV in 2018, 
SARS-CoV-2 in 2020 (Wang et al., 2020a). 
The ISARIC WHO CCP has played a crucial role in the research response to 
pandemic and has allowed standardisation of sample collection and data 
analysis for the COVID-19 outbreak. Ultimately, this has allowed clinical 
investigation to progress as quickly as possible. 
1.8.3 ICECAP 
Inflammation in COVID-19-Exploration of Critical Aspects of Pathogenesis  
(ICECAP, https://www.ed.ac.uk/inflammation-research/research/icecap) was 
established as a rapid response to the COVID-19 pandemic out of the 
University of Edinburgh. ICECAP collect and analyse tissue samples to 
understand COVID-19 and other fatal diseases, with the aim to contribute to 
developing diagnostic tests and therapeutics for these conditions. 
 
1.8.4 COG 
In March 2020, the COVID-19 Genomics UK Consortium (COG-UK) was 
launched (COG-UK, 2020) (https://www.cogconsortium.uk/). This was a £20 
million supported investment from the UK Research and Innovation (UKRI), 





1.9  Research objectives 
 
1.9.1 Research project 
This research project utilises sequencing methodologies that allow rapid 
turnaround in data and analysis to further understand coronavirus diseases. 
Two main sequencing methods compatible with the Oxford Nanopore 
sequencer are employed including: an amplicon-based virus detection and a 
transcriptomic approach is used to understand the host response to SARS-
CoV-2 and IAV in a mice model and compared to transcriptomic signatures 
observed in humans (Figure 1.11). Chapter 3 utilises both nanopore and 
illumina sequencing to assess the host response at point of care.  
 
Figure 1.11: This thesis utilises samples from patients such as nasopharyngeal 
swabs and blood, in addition to tissue samples from post-mortem samples 
from fatal COVID-19 patients and mice models. RNA is extracted and 
processed for sequencing on nanopore devices or illumina. Data is then 
interrogated to study the viral genomes derived from these samples or to look 
at the host response in patients or a mice model.  
Chapter 2: Amplicon-based detection and sequencing of MERS-CoV and 
SARS-CoV-2 in nasopharyngeal swabs 
Rapid detection of viral genomes is important for disease surveillance, 
especially in an epidemic or pandemic. This chapter was exclusively for 
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MERS-CoV and considering the pandemic, the approach was reappropriated 
to support work required for the COVID-19 response.  
• To design an amplicon approach for viral genome detection in 
nasopharyngeal clinical samples of MERS-CoV and SARS-CoV-2 to 
assess mutations. 
 
Chapter 3: Elucidating the host transcriptomic response to SARS-CoV-2 in 
patients at point of care in comparison to IAV infection 
• To contrast and compare the blood transcriptome of patients at point of 
care with COVID-19 or Influenza to identify unique transcripts involved 
in COVID-19 disease.  
• To compare the transcriptome of patients with fatal and non-fatal 
COVID-19 disease to determine markers of fatality. 
• To compare nanopore and illumine sequencing methodologies for 
investigating the host response to a novel disease.  
 
Chapter 4: Transcriptomic sequencing to understand the host response to 
sequential IAV and SARS-CoV-2 infections in mice, and singular infections in 
humans. 
• To use a transcriptomic approach compatible with nanopore 
sequencing for rapid investigation of the host response in mice 
sequentially infected with IAV and SARS-CoV-2 to understand the 
impact of Influenza season on the pandemic and to compare this with 
singular infections in mice and to parallel with the blood transcriptome 





Chapter 2: Amplicon sequencing approaches to 
study MERS-CoV and SARS-CoV-2 genomes and 
RNA synthesis in clinical samples. 
 
2.1 Introduction 
Coronaviruses have been a causative agent for severe emerging human 
diseases since 2002 with the discovery of SARS-CoV. Viral genome 
sequencing is now an essential tool in an outbreak response and real time 
rapid sequencing has been used in several outbreaks of high consequence 
infections. For example, the EBOV epidemic in West Africa and the 2018 
Lassa fever outbreak in Nigeria. In West Africa this was achieved via amplicon 
generation and rapid sequencing in the field on the Oxford Nanopore MinION 
portable sequencer (Carroll et al., 2015, Quick et al., 2016b). The approach 
was also used to identify a transmission event from a man who had a persistent 
infection to his sexual partner in Guinea. This not only provided molecular 
epidemiology, but also gave insight into EBOV and its persistent properties 
(Diallo et al., 2016). The use of the MinION in the 2018 Lassa fever outbreak 
allowed the rapid identification of rodent-to-human transmission events as 
opposed to human-to-human, which informed outbreak containment 
(Kafetzopoulou et al., 2019). 
 
MERS-CoV is a prioritised disease and on the WHO list for research and 
development in emergency settings (Mehand et al., 2018). This study originally 
aimed to design and evaluate an amplicon approach for MERS-CoV to aid 
contact-tracing capabilities in Saudi Arabia. Sporadic infections still occur 
within Saudi Arabia, and there is a need to understand transmission dynamics 
by following the patterns of nucleotide changes in the viral genome. The 
geographical range of MERS-CoV, at least in camels, is also expanding into 
the Horn of Africa and areas surrounding Saudi Arabia (Zhou et al., 2021). 
Identifying transmission events is of particular importance as there is currently 
no licenced vaccine or specific treatment for MERS-CoV and shutting down 
transmission chains is essential in controlling outbreaks as seen with SARS-
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CoV in Singapore (Liu et al., 2005, Ruan et al., 2003, Ooi et al., 2005). During 
this project, the SARS-CoV-2 pandemic occurred. Therefore, the amplicon-
based approach was also re-tasked to study SARS-CoV-2 – the novel -
coronavirus.  
 
For coronaviruses, an amplicon-based sequencing approach would be used 
to identify products of viral RNA synthesis. The unique discontinuous 
transcription mechanism means that there are unique sequencing markers to 
elucidate between active transcription and replication and the viral genome 
through the identification of leader/gene junction sequence. The implication of 
the discontinuous transcription during negative strand synthesis is that 
coronavirus RNA will include insertions/deletions and recombination.  
 
Coronavirus RTCs have proof-reading ability due to activity from nsp14, 
therefore mutation rates are considered moderate for coronavirus genomes in 
comparison to other virus families in the Ribovira realm (Subissi et al., 2014, 
Smith et al., 2015). Recombination drives genetic change in coronavirus 
genomes, manifesting as insertions and deletions, which have been observed 
in cell culture and in vivo for animal coronaviruses such as infectious bronchitis 
virus, MERS-CoV and now SARS-CoV-2 (Kottier et al., 1995, Davidson et al., 
2020, Sabir et al., 2016, Kim et al., 2016a, Young et al., 2020a). Deletions in 
coronavirus genomes can be associated with a mild clinical disease (Young et 
al., 2020a). Therefore, as part of this chapter, bioinformatic tools were utilised 
to identify deletions in coronavirus genomes from patients. Genome with 
deletions may also act as defective interfering RNAs. 
 
Although mutational frequencies are considered low in coronaviruses due to 
the function of nsp14, SNPs and minor variants of coronaviruses are 
contributors to genetic change and viral evolution. Viral genomes as they 
undergo replication through the viral replicase creating hundreds to thousands 
of progenies, that will differ at one genome position. This contributes to the 
idea of quasispecies or minor variants, and the distribution of mutants within a 
viral population. The abundance of variants may change due to natural 
selection pressures. In fact, due to ongoing global efforts to sequence SARS-
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CoV-2 genomes from patients, the scientific community has been able to 
identify key SNPs that may influence viral transmissibility, virulence, 
antigenicity, and pathogenies. Of note, an A to G nucleotide mutation at the 
position 23,403 resulting in a glycine (G) in place of aspartate (D) or D614G in 
the SARS-CoV-2 spike glycoprotein (Korber et al., 2020). This mutation was 
identified in February 2020, and by May, was identified in approximately 80% 
of sequences and is associated with other genetically linked mutations 
(Korber, 2020, Yang, 2020). This infectious titre of this variant had a 2.6 - 9.3-
fold increase in comparison to previous strains in vitro, thus, highlighting the 
importance of studying variants in combination with their infectivity, 
pathogenicity, and immunogenicity as they emerge (Korber et al., 2020). As 
expected, variants have emerged throughout the course of the pandemic. The 
samples utilised in this chapter were collected between March and April 2020, 
therefore predate the emergence of current VOCs and VUIs.  
 
Although the viral polymerase may be the main source of sequence diversity 
within an RNA viral genome, there are host factors to also consider during the 
analysis throughout this chapter. APOBEC activity has been found to play a 
role in virus replication and is associated with C to U changes in dsRNA 
(Milewska et al., 2018).  ADAR is a host RNA binding protein which catalyse 
the deamination of adenosine to inosine in dsRNA (Polson et al., 1991). This 
adenosine to inosine editing causes instability of the base and encourages the 
binding to cytosine. Most sequencing technologies and bioinformatic pipelines 
pick up ADAR editing from A to G (Cao et al., 2018). ADAR and APOBEC 
enzymes can both be stimulated by IFN and are thought to play a role in the 
intrinsic viral response (Sedger, 2013). The global proportion of base changes 
observed through amplicon sequencing of MERS-CoV genomes were 
visualised in this study. Despite error rates being high and potentially 
problematic with MinION sequencing, with sufficient read depth in a sample, 
an overview of the minor variant frequency/population may emerge. It is worth 
noting that although consensus genomes are returned by many genome 
sequencing pipelines, the virus population exists as a pool of minor variants 
with an infected individual. 
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In addition to the assessment of coronavirus genomes from respiratory 
samples from patients with MERS-CoV or SARS-CoV-2 in this Chapter, RNA 
from tissues of fatal COVID-19 cases were extracted and sequenced to 
determine tissue tropism for SARS-CoV-2. At the time of this study, little was 
known about the tissue tropism of the virus, apart from speculation due to the 
wide expression of ACE2 and lessons learnt from SARS-CoV in 2002 which 
included evidence of gastrointestinal detection and transmission (Hung, 2003). 
Moreover, corticosteroids show evidence of reducing fatality, implying the 
immune response may influence outcome, although it was unknown whether 
inflammation was a direct response to the presence of virus or an independent 
immunopathologic process. This analysis allowed for the organotropism 
mapping of SARS-CoV-2 and, through collaboration, was collated with cellular 
staining of the spike protein, histological evidence of inflammation from 37 
anatomical sites and multiplexed immunofluorescence the pulmonary immune 
response. The network ARTIC sequencing protocol was chosen for these 
samples in order to overcome the fragmented RNA which resulted during the 
tissue homogenisation process, and due to the addition of the leader primer 
that allowed for subgenomic RNA enrichment. Identification of a subgenomic 
RNA was interpreted as a proxy measurement for active transcription of the 
virus. 
 
This chapter describes an amplicon-based sequencing approach that can be 
used for MERS-CoV and SARS-CoV-2 whole genome sequencing using 30 
primer pairs. The approach was first tested on RNA from infected cells for 
validation, then RNA from nasopharyngeal aspirates or respiratory swabs from 
MERS-CoV or SARS-CoV-2 patients. The thought behind longer amplicons 
was to identify potential deletion and recombination events that may be missed 
during the generation of shorter amplicons. Data obtained from patients with 
either MERS-CoV or SARS-CoV-2 were interrogated for deletions and 
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2.2.1 Sample collection of MERS samples  
Ethical approval was obtained from the Institutional Review Board no 18-102, 
King Fahad Medical City. Nasopharyngeal aspirates (NPA) were collected 
from MERS-CoV positive patients admitted to different hospitals within Saudi 
Arabia. MERS-CoV diagnosis was confirmed by quantitative polymerase chain 
reaction (qPCR) (Biomerieux diagnostics).  For this study, there was no 
identifying information associated with the NPAs with a confirmed MERS-
CoV diagnosis. The NPA sampling was carried out as per the hospital’s 
guidelines. Briefly, a catheter was inserted into the nose, directed posteriorly 
and towards the opening of the external ear, to reach the posterior pharynx. 
Suction was applied and the catheter was slowly withdrawn using a rotating 
movement, remaining less than 10 seconds in the nasopharynx. The catheter 
was then rinsed with a small volume of sterile 0.9% saline solution to ensure 
adequate specimen volume. Samples were stored at −80◦C until use. Nucleic 
acids from the NPA were extracted using EZ1 Virus Mini Kit v2 (Qiagen 
[955134]). Only two samples were evaluated in this chapter due to limited 
access due to the COVID-19 pandemic. 
 
2.2.2 Sample collection and RNA extraction of SARS-CoV-2 samples 
Patients were recruited under the International Severe Acute Respiratory and 
emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol 
CCP (https://isaric.net/ccp) by giving informed consent. ISARIC CCP was 
reviewed and approved by the national research ethics service, Oxford 
(13/SC/0149). Samples from clinical specimens were processed at CL3 at the 
University of Liverpool as part of the study described in this chapter. 
Nasopharyngeal swabs were collected in viral transport media. Swabs were 
left to defrost in a Tripass I cabinet in CL3. The swab was removed from the 
tube and dipped in virkon before disposal to reduce dripping and aerosol 
generation.250l of viral transport media was removed from the swab sample 
and added to 750l of Trizol LS (Invitrogen (10296028) and mixed well. 




2.2.3 Sample collection and RNA extraction of post-mortem samples 
from patients with COVID-19. 
Ethical approval was granted by the East of Scotland Research Ethics 
Service (16/ES/0084). Twelve patients were recruited onto the study either 
by the consent of the patient themselves or through permission from relatives 
once the patient had died of COVID-19. For each patient, 37 tissue sites 
were sampled for histology and virology including 23 targeted specifically to 
the respiratory tract. Samples were added to 1ml TRIzol reagent (Fisher) per 
0.3-0.5cm2 of tissue and stored at -80°C. This was conducted by 
collaborators at the University of Edinburgh. Samples were sent to Liverpool 
where they were transferred to 1.5ml Precellys tubes filled with ceramic 
beads in the Tripass Class I cabinet. The tubes were added to the 
Fisherbrand bead mill 24 homogeniser, within the cabinet, and homogenized 
at full speed for 4 minutes. When the sample was completely homogenized, 
the sample was centrifuged at 12,000g for 5 minutes to pellet non-
homogenised tissue and beads. Sample was transferred to a fresh tube and 
extraction was continued at CL2 conditions.  
 
2.2.4 RNA extraction at CL2 
Phasemaker tubes (Invitrogen (A33248)) were centrifuged at 12,000g for 30 
seconds before transferring the Trizol/sample mix into the tube and incubating 
for 5 minutes at room temperature. 200l of chloroform (Sigma (496189)) is 
added to 1ml of Trizol and mixed vigorously for 15 seconds and then incubated 
at room temperature for 5-10 minutes. Samples are then centrifuged for 15 
minutes at 12,000g at 4C. The upper aqueous layer was transferred to a fresh 
tube. 500l of isopropanol supplemented with 50ng/l GlycoBlue Coprecipitant 
(Invitrogen (AM9515)) was added to the sample and shaked well before 
incubating for 10 minutes at room temperature. The sample was centrifuged 
at 12,000g at 4C for 10 minutes and the supernatant was discarded leaving 
the RNA precipitate undisturbed. The pellet was resuspended in 1ml of 75% 
ethanol, vortexed and centrifuged at 7,500g at 4C for 5 minutes. Ethanol was 
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removed and pellet was allowed to dry before resuspending in 50l of RNase-
free water. RNA was then DNase treated with the TURBO-free Kit (Invitrogen 
(AM1907)) by adding 0.1 volume of 10X TURBO DNase Buffer and 1l of 
TURBO DNase enzyme to the RNA and mixing gently. The reaction was 
incubated at 37C for 30 minutes. The DNase enzyme was inactivated by 
adding 0.1 volume of the DNase Inactivation Reagent and incubating for 5 
minutes at room temperature. Finally, the reaction was centrifuged at 10,000g 
for 1.5 minutes and supernatant was transferred to a fresh tube, where RNA 
was stored at -80C until further use.  
 
2.2.5 Primer design for amplification of MERS-CoV and SARS-CoV-2 
RNA. 
Twenty MERS-CoV genome sequences were aligned with MAFFT against a 
reference sequence (NC_019843.3 – the ‘Erasmus Medical Centre 
(EMC)’ sequence) in Ugene (v.38). These sequences represent viruses 
collected in regions of Saudi Arabia and countries that reported cases, 
including South Korea. 30 primer binding sites were chosen from conserved 
regions after alignment, so that a minimum of roughly 1000 bp sequential 
amplicons would be generated with an approximately 200 bp overlapping 
region at each terminus. The viral genome was amplified using 30, 15 and 8 
primer pairs to determine the limit for amplicon length for sequencing. For 
SARS-CoV-2, alignments based on the NCBI reference (NC_045512.2) and 
16 sequences published on GISAID in January 2020 were used to identify 
conserved regions for primer design. Primers for the generation of overlapping 
amplicons were designed using the Primer3Plus platform and validated with 
Primer Blast (NCBI) to avoid the selection of primers with high self-
complementary scores. Primers were synthesised by Eurofins Genomics. The 
stock concentrations were 100M, and primers were diluted in DNase/RNase 







Figure 2.1: Location of conserved primer pairs (Table 2.1) on the MERS-CoV 
genome and position compared to the MERS-CoV genes. Primer pairs can be 
used to generate amplicons of varying lengths including 30 (A), 15 (B) and 8 
amplicons (C) as shown. Primers for SARS-CoV-2 were generated using the 
same approach, the locations of the 30 primer pairs described in Table 2.2 are 











Table 2.1: Details of primers sequence specific to MERS-CoV used in this 
study. The expected product size is given for the 30-amplicon approach (see 
Figure 2.1).  































































































































































































Table 2.2: Details of primers sequence specific to SARS-CoV-2 used in this 
study. The expected product size is given for the 30-amplicon approach 
Primer 
name 
Sequence 5’-3’ Location Size 
(bp) 
Multiplex 
















































































































































































































































































































2.2.6 cDNA synthesis and PCR 
Superscript IV reverse transcriptase (Thermofisher [18090010]) and random 
hexamers (2.5uM) were used to generate cDNA templates from RNA by 
annealing template RNA to primers at 65°C for 5 minutes and then placing on 
ice. Annealed template RNA is then reverse transcribed with superscript IV 
reverse transcriptase (Invitrogen) in the presence of SSIV Buffer, 100mM DTT 
and RNaseOUT RNase Inhibitor (Invitrogen) at 23°C for 10 minutes then 55°C 
for 10 minutes and finally 80°C for 10 minutes. cDNA was diluted 1:5 before 
amplification.  cDNA was amplified using Q5-high fidelity DNA polymerase 





Table 2.3: PCR condition for 30, 15, and 8 amplicon approach MERS-CoV and 
SARS-CoV-2. 
 
Step  Temperature  Time  Note  








10 sec  
30 sec  
50*, 90**, or 180*** 
sec  
For 30*, 15**, or 8*** 
amplicon approach  
Final extension  72C°  2 min    
 
 
PCR products were ran on a 1% agarose gel in TAE buffer to confirm the 
presence of amplicons.  
 
2.2.7 Network ARTIC 
Template RNA (11l) was incubated with 50M random hexamers and 10mM dNTPs mix at 65°C for 5 
minutes before placing on ice. Annealed template RNA was then reverse transcribed with superscript IV 
reverse transcriptase (Invitrogen) in the presence of SSIV Buffer, 100mM DTT and RNaseOUT RNase 
Inhibitor (Invitrogen) at 42°C for 50 minutes and 70°C for 10 minutes. V3 artic primers 
(https://github.com/artic-network/artic-ncov2019/tree/master/primer_schemes/nCoV-2019/V3) were 
pooled and diluted into two pools for multiplexed PCR. Q5 2X Mastermix (NEB), 3.6 l of primer pool 1 
or 2, nuclease free water and 2.5 l of cDNA in a 25 l reaction. Reactions were incubated using the 
conditions stated in  
 





Table 2.4: PCR condition for network artic PCR amplification step.  
Step  Temperature  Time  
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Initial denaturation  98C°  30 sec  
Denaturation  




15 sec  




2.2.8 Library preparation for MinION sequencing 
Amplicons per patient were pooled and cleaned with AMPure XP Beads 
(Beckman Coulter [A63882]) at a 1:1 ratio. PCR products were incubated with 
the beads at room temperature for 10 minutes before pelleting on a magnetic 
rack and washing twice with 70% ethanol. PCR products were resuspended in 
15 l of nuclease free water and 1 l was quantified on the qubit fluorometer. 
Samples were normalised to 200 fmol, i.e. 50ng for network artic derived 
amplicons, and 160ng for RSLA derived amplicons, in a 12.5 l volume. Ultra 
II End-prep reaction buffer and enzyme mix (NEB) were added to the reaction 
and incubated at 20°C for 5 minutes then 65°C for 5 minutes. When 
multiplexing, unique native barcodes were ligated to end-prepped DNA per 
patient sample by Blunt/TA Ligase (NEB) in a thermocycler for 20 minutes at 
20°C and 10 minutes at 65°C. Up to 24 samples were then pooled. AMPure XP 
beads were added to the reaction mixture and incubated for 5 minutes at room 
temperature before pelleting on a magnetic rack and washing twice with 70% 
ethanol. The pellet was resuspended in 35ul of nuclease water and incubated 
at room temperature for 2 minutes before transferring to a fresh tube and 
quantifying with qubit. Nanopore adapters, AMII, were ligated onto the 
barcoded DNA with NEBNext Quick Ligation Reaction Buffer and Quick T4 
Ligase (NEB) by gently mixing and incubating at room temperature for 20 
minutes. The reaction mixture was purified with the use of AMPure XP beads 
by incubating on a hula mixer for 10 minutes, spinning down and pelleting on 
a magnet. The bead pellet was then washed and resuspended in Short 
Fragment Buffer (SFB) and returned to the magnetic rack, twice before 
resuspending in 15 l of elution buffer. The library was quantified and 50-100 
fmols was loaded onto the flow cell and sequenced on the MinION, MinIT or 





Fast5 files were base called using Guppy (v.3.6.0). Fastqs were initially 
mapped to the NCBI MERS reference NC_019843.3 or SARS-CoV-2 
reference NC_045512.2 using minimap2 (v.2.17) with the -ax map-ont 
parameters.  Samtools (v.1.10) was used to sort and index the alignment files, 
picard (v.2.23.4) was used to remove amplification duplicates then a custom 
perl script kindly provided by Dr David Matthews, University of Bristol, was 
used to study minor variants. Data was visualised using R studio. A read depth 
at a single nucleotide of <20 was not taken forward into analysis to mitigate for 
random errors.  
 
The nCoV-2019 novel coronavirus bioinformatics (https://github.com/artic-
network/fieldbioinformatics) protocol was also used to map, polish and call 
consensus on viral genomes using medaka. Reads were filtered based upon 
expected amplicon size (400-700 bp for artic and 850-1700 for RSLA) using 
Nanofilt (De Coster et al., 2018) to mitigate for chimeric reads. Medaka was 
then used to call consensus and variants.  SVIM (v.1.4.2) took the raw 
alignment files (BAM) and interrogated them for deletions at the minor variant 
level (Heller and Vingron, 2019). Deletion candidates with more than 5 
supporting reads were carried forwards for further consideration.  
 
2.2.10 Phylogeny 
A multiple sequence alignment of consensus sequences from MERS-CoV 
patients and 20 other MERS-CoV sequences downloaded from Genbank 
(Table 2.5) was conducted using MUSCLE with 8 iterations in the Geneious 
software package v.2020.2.4 (Edgar, 2004). To determine an appropriate 
substitution model for phylogenetic analysis of consensus sequences, multiple 
alignments in nexus format, were uploaded to JModel2 
(https://github.com/ddarriba/jmodeltest2) to calculate likelihood and BIC 
values, before producing a tree with MrBayes within the Geneious software 
suite (Darriba et al., 2012). The GTR model was employed with 4 gamma 
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categories and an MCMC chain length of 1,100,000 with 4 heated chains. A 
MERS-CoV isolate from a P.kuhlii bat (MG596803.1) was included as an 
outgroup. Consensus trees were generated using 10% burn-in and a support 
threshold of 50% and visualised using FigTree (version 1.4.4). The tree was 
exported as a nexus file and imported into R studio using the ape package to 
drop the outgroup tip to allow for clear resolution of the relationships between 
the more closely related MERS-CoV sequences.  
 
Table 2.5: Viral genome sequences used to determine phylogenetic 
relationships of consensus sequences generated by the amplicon sequencing 
approach for MERS-CoV.  











Middle East respiratory 




Hu/Riyadh/2013 KJ156944.1 GenBank 
Middle East respiratory 




Hu/England/2013 KM015348.1 GenBank 
Middle East respiratory 




Hu/UAE/2014 KP209313.1 GenBank 
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Middle East respiratory 




Hu/Seoul/2015.1 KU308549.1 GenBank 
Middle East respiratory 
syndrome coronavirus isolate 
MERS-CoV/KOR/Seoul/050-1-
2015, complete genome 
 
Hu/Seoul/2015.2 KX034094.1 GenBank 





Camel/UAE/2014 KY581700.1 GenBank 





Hu/Oman/2015 KY673148.1 GenBank 





Camel/Oman/2015 KY673149.1 GenBank 
Middle East respiratory 
syndrome-related coronavirus 
strain Hu/Riyadh-KSA-
7413/2017, complete genome 
 
Hu/Riyadh/2017 MG366483.1 GenBank 
Middle East respiratory 
syndrome-related coronavirus 
isolate Bat-
Bat/Italy/2011 MG596803.1 GenBank 
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CoV/P.khulii/Italy/206645-
63/2011, complete genome 
 
















Camel/Kenya/2018 MH734114.1 GenBank 















Hu/Jordan/2014 MK039553.1 GenBank 














FAO-1/2018, complete genome 
 
Camel/Eygpt/2018 MK967708.1 GenBank 






Hu/Jeddah/2017 MN723543.1 GenBank 






Hu/Riyadh/2018 MN723544.1 GenBank 
Middle East respiratory 






Middle East respiratory 








For SARS-CoV-2 consensus sequences, where sequencing experiments 
obtained more that 50% of a consensus sequence, Pangolin version 2.0.8 
(https://github.com/cov-lineages/pangolin) was used to determine the SARS-
CoV-2 lineage information in comparison to all published sequences on 
GISAID as of the 19th of October 2020.To generate phylogenetic trees and 
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genome SNP maps, Llama version 0.1 (https://github.com/cov-lineages/llama) 
was used to determine where consensus sequences compared to others 
published throughout the ongoing outbreak. 
 
2.2.11 Identification of subgenomic transcripts from viral genome 
sequence data 
The reads of each sample were aligned to the corresponding NCBI SARS-
CoV-2 (MW041156.1) reference genome using minimap (v.2.17) (Li, 2018) 
with the ‘-ax splice --secondary=no’ options. The sam files produced by 
minimap were then converted into bam files for identification of leader gene 
fusion sites that occur through discontinuous transcription in these samples 
with portcullis (v1.12) (Mapleson et al., 2018). The splicing sites spanning 
leader (1 to 80 nts) at the 5’UTR and the beginning of each known transcript 
were thought as the signal of subgenomic mRNAs. A ratio of sub-genomic 
reads was determined in comparison to the total number of reads and 












2.3.1 Validation of primers and generation of amplicons using total RNA 
purified from MERS-CoV and SARS-CoV-2 infected cells  
 
To evaluate the utility of the selected primers for the amplification of viral 
RNA under controlled conditions, RNA was purified from MRC-5 cells that had 
been infected with the EMC strain of MERS-CoV at a MOI of 5. Infection was 
carried out under CL3+ conditions at the University of Bristol, and total RNA 
purified from infected MRC5-cells at 16 hrs post-infection. Vero cells were 
infected with SARS-CoV-2 at Public Health England, Porton Down at 
CL3. This RNA was used as a template to prime cDNA synthesis using random 
hexamers. This resulted in amplification conditions (Table 2.3) such that the 
MERS-CoV genome was amplified using either 30 amplicons (Figure 2.2A), 
15 amplicons (Figure 2.2B) or 8 amplicons (Figure 2.2C) where the annealing 
temperature was the same for each primer set. The rationale being that using 
the same amplification conditions across all primer pairs would be more 
efficient if large scale sample analysis were required and in the case of SARS-
CoV-2 allowed for the option to multiplex reactions. The data indicated that for 
the 30 amplicon approach PCR products were observed that spanned 
the MERS-CoV genome. For the 15 and 8 amplicon approach products 
were also observed that spanned the MERS-CoV genome. However, 
amplification of these products varied in efficiency.  Therefore, in the design 
for the SARS-CoV-2 approach, the 30-amplicon approach was used and a 
multiplex PCR was devised to allow for higher throughput.  
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Figure 2.2: Validation of primers designed for MERS-CoV sequencing. RNA 
extracted from MERS-CoV infected cells were reverse transcribed with 
random hexamers and cDNA was then used as a template for PCR using 30, 
15 and 8 primer pairs. Agarose gel electrophoresis of amplicons generated 
using 30 (A), 15 (B) and 8 (C) primer pairs were ran against a 1kb ladder to 





Figure 2.3: Validation of primers designed for SARS-CoV-2 sequencing. (A) 
Schematic diagram of the SARS-CoV-2 genome showing the position of major open 
reading frames and the position of the amplicons along the genome. (B). Agarose 
gel electrophoresis analysis of the amplicon products resulting from RT-PCR using 
the designated forward and reverse primers to amplify the SARS-CoV-2 genome 
from RNA purified from Vero cells infected with the virus. (C). The amplicon 
products were purified and sequenced on a single flow cell using an Oxford 
Nanopore MinION. Shown are the number of reads that map (y-axis) to each 




Figure 2.4: Validation of primers designed for MERS-CoV sequencing using 
clinical samples. Agarose gel electrophoresis of amplicons generated using 30 
(A) and 15 (B) combinations of primers pairs. These primer pairs were used to 
generate amplicons in combination with RT of RNA extracted from nasal 




2.3.2 Generation of amplicons from patients infected with MERS-CoV and 
SARS-CoV-2 and derivation of consensus genome sequence  
  
Data indicated that the 30 and 15 approaches could be used to 
generate fragments from clinical samples, although coverage was more even 
in the 30-amplicon approach (Figure 2.4A and Figure 2.4B, respectively). The 
8-amplicon approach was not sufficient for obtaining coverage across the 
MERS-CoV from a clinical sample (data not shown).  
  
The PCR products generated in the 30 and 15 amplicon approaches from 
MERS-CoV patients (from separate patients) were sequenced on separate 
flow cells for each patient. Sequencing reads generated by the MinION were 
aligned to a reference sequence using minimap2. Fastq files were trimmed 
based on expected amplicon size with Nanofilt (De Coster et al., 2018), and 
primer sequences were trimmed as part of the Network ARTIC bioinformatics 
pipeline that utilised medaka for consensus sequence determination. In 
addition, a custom script written in perl was used to count the number of each 
nucleotide against the reference sequence (NC_019843.3) in SAM 
format, that had a mapping quality score of 10 or more, providing information 
about the minor variation within each patient. The analysis showed that 
complete genome sequence could be obtained from the 30 amplicon (Figure 
2.5A) and 15 amplicon approaches (Figure 2.5B). Consensus sequences 
were compared to each other and 20 MERS-CoV sequences available on 
GenBank to relatedness to other published isolates (Figure 2.6). Patient 10 is 






Figure 2.5: Full genome coverage of MERS-CoV is achieved with 30 primer 
pairs and 15 primer pairs from clinical samples. Read depth analysis of 30 as 
determined by custom perl script (A) and 15 (B) amplicons sequenced on 
single flow cell. Coverage of each position on the MERS-CoV genome is 

























Figure 2.6: The two patient consensus sequences were compared with 
multiple alignment with MERS complete genome sequences available on 
GenBank using the MUSCLE algorithm with 8 iterations. JModel2 was used to 
determine the most appropriate substitution model before producing a tree with 
MrBayes within the Geneious software suite. The GTR model was employed 
with 4 gamma categories and an MCMC chain length of 1,100,000 with 4 
heated chains. A MERS-CoV isolate from a P.kuhlii bat (MG596803.1) was 
included as an outgroup. Consensus trees were generated using 10% burn-in 
and a support threshold of 50% and visualised using FigTree (version 1.4.4). 
Outgroup was dropped for visualisation. Patient 10 and Patient 115 are 






























2.3.3 Analysis of the minor variant population within patients  
 
The nucleotide substitution rate can drive the selection of genotypic and 
phenotypic variants of MERS-CoV. Whilst variation and potential functional 
changes in consensus genomes have been compared between patients, 
the ability to monitor minor variants and their frequency and how these 
contribute to the overall viral phenotype within a patient is unknown. Therefore, 
methodologies were developed that could be used to assess the minor variant 
frequency within a sample from a patient. The custom perl script used to call 
the consensus also revealed the nucleotide depth and the counts of each 
nucleotide at each position (Figure 2.5). The depth was used to normalise the 
mutation frequency into a proportion instead of a raw count, allowing 
comparison for samples of different read depth. Nucleotides that had a count 
less than 20 were removed from analysis. As proof of principle, this approach 
was applied to the sequencing data obtained from patients 10 and 115. 
Patient 10 appeared to have more base changes in comparison to patient 
115 (Figure 2.7). Transitions (A>G, G>A, C>U, T>C) were more frequently 
observed as expected. Where C>U seemed more prominent than other 
mutations, suggestive of involvement of host enzyme APOBEC.  
 
2.3.4 Identification and analysis of deletions in the MERS-CoV viral genome 
in samples from patients  
 
MERS-CoV alignment files from the 2 individual patients were assessed with 
SVIM for the presence of deletions, deletions with more than 5 supporting 
reads were considered for further consideration. Deletions were identified in 
both patients (Table 2.6), patient 115 was sequenced with the 15-amplicon 
approach and therefore generated amplicons over 2kb in length. A deletion of 
77 bases that spans the orf4b and orf5 gene was identified in this patient. 





Figure 2.7: The sequencing reads were mapped to the patient consensus viral 
genome sequence. The custom script counted the number of each base at 
each genome position with a quality score >10. Positions with a depth <20 
were removed from the analysis.  This figure shows the proportion of base 
changes observed in comparison to the patient’s dominant consensus 
reference genome. Overall, transitions were observed more frequently than 
transversions, where C>U is the most observed base-change. We hypothesise 
that although transitions are more common, that APOBEC may have an 
influence on the MERS-CoV genome. Patient 10; dark grey, Patient 115; light 



































G > A G > C G > U
Base Change
 
Table 2.6: Analysis of deletions present in the MERS-CoV genome from patients 115 and 10. Columns from left to right; Patient 
number, deletion start position (bp), deletion end position (bp), the number of supporting reads for this deletion, the quality score 
(which takes into consideration the mapping quality scores, where a value greater than 10 has higher confidence), standard deviation 
(SD) of the deletion span (bp) and SD of the position of the deletion from the supporting reads. Coordinates are given for the affected 
gene, and in the case of overlap, the second gene is provided.  






























115 26820 26897 97 99 1.96 1.83 26093 26833 Orf4b 13 26840 27514 Orf5 57 
10 
1315 2149 6 7 0.41 0.2 279 21514 Orf1ab 834     
3576 4551 10 12 3.46 57.21 279 21514 Orf1ab 975     
7611 8507 31 38 0.62 0.23 279 21514 Orf1ab 896     
8818 9056 22 27 2.63 3.02 279 21514 Orf1ab 238     
9407 10044 14 17 0.27 0.4 279 21514 Orf1ab 637         
 28514 29110 40 49 56.94 15.59 28566 29807 N 544     
 
 
Figure 2.8: Validation of SARS-CoV-2 primers on clinical samples (A) 
Agarose gel electrophoresis analysis of amplicons generated by RT-
PCR from RNA isolated from a nasopharyngeal swab taken from 
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patient REMRQ0001, who had coronavirus disease 2019 (COVID-19) 
and diagnosed positive for SARS-CoV-2 by a laboratory-based test. 
Primer pairs are indicated above each amplicon. (B) The amplicon 
products were purified and sequenced on a single flow cell using an 
Oxford Nanopore MinION. Shown are the number of reads that map 
(y-axis) to each amplicon across the SARS-CoV-2 genome from 5′ to 
3′ (x-axis). (C) Agarose gel electrophoresis analysis of amplicons 
generated by RT-PCR from RNA isolated from a nasopharyngeal 
swab taken from patient REMRQ0001, who had COVID-19, and 
subsequently found negative for SARS-CoV-2 by a laboratory-based 
test. Note that the brightness of the image has been adjusted post-
image capture to show amplicon products more clearly. 
2.3.5 Using the amplicon approach to sequence SARS-CoV-2 from the 
first COVID-19 patients in Liverpool 
Following validation of SARS-CoV-2 primers on cell culture RNA 
(Figure 2.3), the approach was then assessed opportunistically on 
clinical samples from the first patients at the Liverpool Royal Hospital 
in early 2020. These patients tended to be in hospital for isolation 
purposes rather than treatment. Patient 1 (REMRQ0001) was 
asymptomatic, however, acquired a positive test result and was 
isolated. Patient 2 (REMRQ0002) was admitted to hospital 5 days after 
symptom onset.  
The viral genome detectable on day 1 of sampling from patient 1 and 
segments that were still amplifiable on day 3 of sampling despite a 
negative diagnostic test (Figure 2.8). Products that were observed on 
the agarose gel represented sequence from the viral polymerase 
(orf1ab) and the membrane (M) region, a less intense band was 
observed in the orf8/nucleoprotein gene sequence.  
Samples from patient 2 became available; this was another 
opportunity to assess the amplicon system, and therefore RNA from a 
nasopharyngeal swab was extraction and 30 segments of the SARS-
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CoV-2 genome were amplified with PCR and sequenced on the 
MinION to confirm the presence of viral RNA (Figure 2.9). Some 
regions of the genome had lower sequence read depth.  
 
Figure 2.9: (A,B) Agarose gel electrophoresis analysis of amplicons 
generated by RT-PCR from RNA isolated from a nasopharyngeal 
swab taken from patient REMRQ0002, who had COVID-19, and 
diagnosed positive for SARS-CoV-2 by a laboratory-based test. Primer 
pairs are indicated above each amplicon. Note that the image in (B) is 
the same image as (A) but the brightness has been enhanced post-
image capture in order to more clearly show amplicon products. (C) 
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The amplicon products were purified and sequenced on a single flow 
cell using an Oxford Nanopore MinION. Shown are the number of 
reads that map (y-axis) to each amplicon across the SARS-CoV-2 
genome from 5′ to 3′ (x-axis). 
 
2.3.6 Development of a multiplex PCR for high throughput of clinical 
samples 
 
To increase capacity and throughput, each primer set was pooled into six 
groups (Table 2.2), ensuring that adjacent amplicons were in separate pools. 
Using RNA from SARS-CoV-2 infected cells as a positive control, the multiplex 
was tested on RNA from nasopharyngeal swabs from patients. The agarose 
gel for each multiplex pool for 2 patients, including a positive and negative 
control shows amplification of DNA (Figure 2.10). The multiplexed reactions 
were pooled for each patient and prepared for sequencing on the MinION. 
Figure 2.10B-C shows the viral coverage obtained from the patients using this 
method, although, the amplicon between 26kb and 27kb has not amplified to 
the same efficiency as the others. 
 
2.3.7 Assessing deletion events in SARS-CoV-2 from patients with 
COVID-19 
As recombination is a driver of genetic change and diversity in coronaviruses, 
the data obtained using the RSLA approach was interrogated for deletions at 
the minor variant level using SVIM in 24 patients. Several deletion events were 
identified (Table 2.7) and were present in genes associated with interferon 
antagonism, such as orf3a and orf7a.  
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Figure 2.10: (A) Agarose gel electrophoresis analysis of amplicons generated 
by multiplex RT-PCR from RNA isolated from a nasopharyngeal swab taken 
from patients who had COVID-19 and diagnosed positive for SARS-CoV-2 by 
a laboratory-based test. Primer pairs are indicated above each amplicon and 
exemplar data from two patients (numbers 36 and 37) are shown. Note that 
amplicons from multiplex pool 1, for patient 36, is shown to the left as these 
were run on a separate gel. Also shown are negative controls and a positive 
control using RNA isolated from SARS-CoV-2 infected cells. (B,C). The 
amplicon products were purified, barcoded and sequenced on a single flow 
cell using an Oxford Nanopore MinION. Shown are the number of reads that 
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map (y-axis) to each amplicon across the SARS-CoV-2 genome from 5′ to 3′ 
(x-axis). 
Table 2.7: Analysis of deletions in the SARS-CoV-2 genome in patients with COVID-19. The columns from left to right are as 
follows: patient number, deletion start position (bp), deletion end position (bp), number of reads supporting this deletion, 
quality score (similar to number of reads supporting, but also takes into account read mapping quality scores with a score 
greater than 10 having higher confidence), standard deviation (SD) of deletion span (bp) from supporting reads, SD of deletion 
position (bp) from supporting reads. If the deletion interrupts a gene, these are the coordinates of the gene, the gene name, 
and the bp overlap with the deletion. In cases where the deletion overlaps >1 gene, the information of the second gene is 
provided. 
 



































Day 1  
19325 19380 9 10 4.42 
58.4
2 
266 21555 Orf1ab 55 − − − − 
 20294 20429 8 10 0 0 266 21555 Orf1ab 135 − − − − 
 25417 25796 10 12 0.79 0.86 25393 26220 Orf3a 379 − − − − 
 27578 27624 16 19 2.49 2.45 27394 27759 Orf7a 46 − − − − 









2143 2198 5 5 4.36 
73.6
9 
266 21555 Orf1ab 55 − − − − 
 
2375 2421 8 8 5.54 
82.8
5 
266 21555 Orf1ab 46 − − − − 
 
2589 2642 6 6 3.2 
41.7
8 
266 21555 Orf1ab 53 − − − − 
 
2654 2741 5 5 8.73 
51.8
8 
266 21555 Orf1ab 87 − − − − 
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2859 2904 9 10 2.42 
88.4
8 
266 21555 Orf1ab 45 − − − − 
 
RAL01006  
Day 1  
20274 20383 7 8 6.2 7.5 266 21555 Orf1ab 109 − − − − 
 20279 20340 10 12 3.83 2.57 266 21555 Orf1ab 61 − − − − 
 
27594 27640 10 11 2.37 
31.7
7 
27394 27759 Orf7a 46 − − − − 
 RAL01007 
Day 1  
27386 27699 91 99 0.86 1.66 27394 27759 Orf7a 305 27202 27387 ORF6 1 




27020 27073 11 13 0.6 0.3 26523 27191 M 53 − − − − 
 27522 27761 24 29 1.09 2.04 27394 27759 Orf7a 237 − − − − 







2025 2088 5 5 7.16 
80.9
4 
266 21555 Orf1ab 63 
 
25508 25568 6 6 8.31 
61.4
5 
25393 26220 Orf3a 60 
 
27884 27934 6 6 7.19 
27.4
3 
27894 28259 Orf8 40 
 
RAL01005 
Day 1  
27546 27650 7 8 
14.6
1 
64.8 27394 27759 Orf7a 104 
 












25398 25776 12 14 1.56 
69.8
7 
25393 26220 Orf3a 378 
 27555 27625 31 38 1.94 5.71 27394 27759 Orf7a 70 
 
8676 8723 11 12 1.79 
38.6
1 
266 21555 Orf1ab 47 
 RAL01011 28444 28775 62 77 1.29 1.31 28274 29533 N 331 
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25480 25551 97 99 1.62 2.04 25393 26220 Orf3a 71 
 REMRQ015 
Day 1 







25429 25641 11 13 17 7.89 25393 26220 Orf3a 212 
 
25432 25808 10 12 5.24 
44.6
2 
25393 26220 Orf3a 376 
 





































27690 27732 6 6 2.25 
49.8
5 
27394 27759 Orf7a 42 
 
28011 28062 13 14 5.36 
77.8
2 
27894 28259 Orf8 51 
 
28196 28238 5 5 2 
96.7
3 
27894 28259 Orf8 42 
 
28481 28536 5 5 3 
64.7
3 
28274 29533 N 55 
 
28601 28718 5 5 4.82 
43.7
6 
28274 29533 N 117 
2.3.8 Identification of SNPs in respiratory swabs 
To demonstrate the sequences generated with the SARS-CoV-2 sequence 
approach described in this chapter belonged to SARS-CoV-2, consensus 
genomes from patients were analysed with Pangolin and Llama. Consensus 
sequences with more than 50% identity were taken forward (Table 2.8) and 
compared with the sequences that were similar from the GISAID sequence 
database. Clinical isolates from cell culture consistently generated consensus 
sequences above 99%. The performance of clinical samples varied, where day 
1 samples were more likely to provide more sequence information. Through 
this 1145 SNPs were identified (6.58 SD+/-2.42 per sequence) in 174 
sequences that were included in the analysis, in comparison to the reference 
sequence. The C > U nucleotide change was observed the most in this cohort 
of patients (Figure 2.11Figure 2.11: The number of SNPs against the SARS-
CoV-2 reference were counted per consensus genome (n=174). GraphPad 
Prism v.8.4.3 was used to plot the occurrences of each SNP as an average 
and error bars representing the standard deviation. C >U changes were the 
most observed. No U > A or U > G changes were observed in this dataset 
sequences.). Supplying further evidence for the involvement of APOBEC in 
genetic changes of coronaviruses. Well characterised SNPs were identified in 
this dataset, such as A23403G responsible for the D614G amino acid change 
in the S protein, C14408T responsible for the P323L mutation in Orf1a.  
 
Table 2.8. Consensus sequences derived from patients were called with the medaka pipeline within the ARTIC nCoV19 bioinformatics 
pipeline. Llama was used to identify SNPs in comparison to the SARS-CoV-2 RefSeq and Pangolin was used to determine the lineage 
of the consensus. Sequence name identifies patient number, day of sampling and month of sampling, if known (all samples were 
processed by April 2020). N prop; the proportion of Ns in the consensus sequence due to insufficient sequencing coverage, No. 
SNPS; the number of SNPs identified in the available sequence, and SNPS identified; the position of the SNP is stated followed by 
the nucleotide change.  
 







Isolate/SCV2-004  B 0.04 7 6948 8782 11083
GT 
21005 25452 28144 28253           
AC TC CT CT CT CT 
Isolate SCV2-005  B 0.04 7 6948 8782 11083
GT 
21005 25452 28144 28253 
     
AC TC CT CT CT CT 
Isolate SCV2-006  B 0.04 6 6948 8782 11083
GT 
21005 28144 28253             
AC TC CT CT CT 
Isolate SCV2-007  B.1 0.04 6 3037 8782 14408 23403
AG 
25350 28144 
      
CT TC CT CT CT 










    
CT TC CT CT CT 
Isolate SCV2-009  B.1 0.04 7 3037 8782 10138 14408 23403
AG 
25350 28144 
     
CT TC CT CT CT CT 
RAL01001.1 Day1 
March20 
- 0.33 4 1059 8782 23403
AG 
28144                 




- 0.34 2 8782 28144 
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CT CT TC CT 
RAL01002.2 Day1 
Feb20 
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AG 
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TC CT CT 
RAL01003.2 Day1 
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CT TC CT CT 
RAL01004.2 Day1 
Feb20 










   
CT TC CT CT 








        
Feb-20 CT TC CT CT 
RAL01005.1 Day3 
March20 
B.4 0.07 7 1397 8782 11083
GT 
12249 21658 28144 28688 
     
GA TC CT CT CT TC 
RAL01005.2 Day3 
March20 
B.4 0.07 6 1397 8782 11083
GT 
12249 28144 28688             
GA TC CT CT TC 
RAL01005 Day1  B.4 0.07 6 1397 8782 11083
GT 
12249 28144 28688 
      
Feb-20 GA TC CT CT TC 
RAL01006.1 Day1 
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CT TC CT CT CT CT 
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B 0.24 3 8782 11083
GT 
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CT TC CT CT 
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Mar-20   CT CA TC CT CT CT 
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GT 
14805 17247 20646 26144
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25572 28144 28887 
    
Mar-20   AG TC TC CT CT CT 
RX1CC0044 Day9 B 0.21 5 8782 11083
GT 
17247 28144 28887               
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RX1CC0045.1 Day1  B.23 0.07 7 431 3765 8782 11474
AG 
20270 28144 28737 
     
Mar-20   GA AG TC CT CT CA 
RX1CC0045.2 Day1 B.23 0.04 7 431 3765 8782 11474
AG 
20270 28144 28737           
Mar-20   GA AG TC CT CT CA 
RX1CC0045 Day3 B.23 0.09 6 3765 8782 11474
AG 
20270 28144 28737 
      
Mar-20   AG TC CT CT CA 
RX1CC0046.1 Day1  B.23 0.07 5 431 8782 11474
AG 
20270 28144               
Mar-20   GA TC CT CT 
RX1CC0046.2 Day1 B.23 0.09 5 431 8782 11474
AG 
20270 28144 
       
Mar-20   GA TC CT CT 
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Mar-20   AG TC CT CT TC CT 
RX1CC0049 Day1  B.1.153 0.24 4 3037 8782 28144                 
 132 
Mar-20   CT TC 23403
AG 
CT 
RX1CC0056 Day1  B.1.153 0.21 5 3037 8782 11798 23403
AG 
28144 
       
Mar-20 CT TC TC CT 
RX1RA0098 Day1 - 0.37 2 8782 28144                     
Apr-20 TC CT 










   




Figure 2.11: The number of SNPs against the SARS-CoV-2 reference were 
counted per consensus genome (n=174). GraphPad Prism v.8.4.3 was used 
to plot the occurrences of each SNP as an average and error bars representing 
the standard deviation. C >U changes were the most observed. No U > A or U 
> G changes were observed in this dataset sequences.  
 
2.3.9 SARS-COV-2 is detectable in multiple tissues in fatal covid-19 
patients  
 
To assess the tissue tropism of SARS-CoV-2 in fatal COVID-19, 37 distinct 
anatomical tissue sites were sampled during autopsy from 12 patients who 
died of severe COVID-19. Following RNA extraction, the amplicon approach 
by the Artic Network was used in order to mitigate the fragmentation of RNA 
resulting from tissue homogenisation. Amplicons generated from this 

















































































reference genome and the breadth of coverage above 20 per position was 
calculated. Viral RNA was detectable in all of the tissues sampled in fatal 
COVID-19 cases.  Higher viral coverage was obtained from lower respiratory 
tract tissue throughout the 12 patients that were assessed (Figure 2.12). There 
was no association between the time from illness onset to death and the 
number of PCR positive tissues (Figure 2.14). Viral subgenomic RNA was 
identified, most commonly from the N gene, indicative of active transcription in 
multiple sites.  
 
 
Figure 2.12: To assess tissue tropism of SARS-CoV-2, RNA was extracted 
from 37 anatomical sites from 12 patient’s post-mortem. The artic primers were 
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sequence on the MinION. Sequencing reads were aligned to the SARS-CoV-
2 reference genome and coverage at 20X was calculated and plotted. 
Anatomical sites are coloured by organ system. 
2.3.10 Presence of RNA in respiratory tissue is associated with 
inflammation 
 
Viral RNA was identified throughout post-mortem tissue samples, however, 
upon comparison with the inflammation data, there was minimal evidence of 
inflammation in non-pulmonary organs. The pulmonary tissue showed 
characteristics of acute respiratory distress syndrome (ARDS), thrombosis and 
bronchopneumonia. Pulmonary inflammation was identified without the 
detection of viral RNA, suggesting that virus independent immunopathology, 







Figure 2.13: Distribution of SARS-CoV-2 RNA for all patients was determined 
by PCR and was confirmed by sequencing (colour intensity represents the 
frequency of detectable RNA, dotted line on legend denotes maximal 
frequency within the patient cohort) (n=11). Extent of organ-specific 
inflammation was assessed semi-quantitatively (0-3; no inflammation (0) to 
severe inflammatory changes (3)) with aggregate scores visualised (n=11) in 
Dorward et al (2020). 
 
SARS-CoV-2 distribution was widespread (Figure 2.13) yet varied (Figure 
2.14). A discordance was observed between the presence of viral RNA and 
inflammation, both between and within tissues. Within this cohort, inflammation 
was seen in the presence of viral RNA predominately in the lungs, however, 
there were examples of inflammation within lung tissue in the absence of viral 
RNA, for example in patient H (Figure 2.14). Beyond the pulmonary and 
reticulo-endothelial organs, little inflammation was observed, despite the 
detection of viral RNA within the tissue.  
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To complement PCR and sequencing conducted as part of this thesis, the 
presence of the S protein was evaluated in randomly selected positive tissues 
through histopathological staining by other groups (Dorward et al., 2020). The 
S protein was identified in most PCR positive tissues, and rarely in PCR 
negative sites. Often, S protein was identified in the epithelia of the respiratory 
tract, gastrointestinal tract, liver and kidney, with limited presence in 
macrophages and endothelial cells within lung tissue. Cell-to-cell spread of 
SARS-CoV-2 is indicated by a ‘foci of infection’ observed in non-pulmonary 
tissues (Dorward et al., 2020). Detectable RNA in the kidney (n=4), liver (n=4) 
and the gastrointestinal tract (n=7) was not associated with inflammation in 













Figure 2.14: Visualisation of the presence of viral RNA as determined through PCR 
and sequencing as positive or negative, alongside the inflammation score for each 
patient recruited to the study. Time from illness onset to death in days is highlighted 
on the left. *; patient was ventilated. 
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2.3.11 Phylogeny and SNPS 
Unfortunately, very few sequences facilitated the generation of full consensus 
genomes, however, those with more than 50% of sequence available were 
analysed to determine the prevalence of SNPs. The consensus sequences 
were analysed by Pangolin and Llama to determine viral lineages and 
phylogenetic relationships to other published sequences on GISAID. Table 2.9 
shows the proportion of Ns within the consensus sequence generated and 
what SNPs were identified. Sequences with a relatively high N proportions 
were still able to provide SNP information, despite missing information. SNPs 
were visualised as a map to determine whether there was variation between 
tissues from the same patient (Figure 2.15) 
 140 
 
Figure 2.15:  Visualisation of the SNPs detected in viral genome sequences 
obtained from post-mortem tissues and the closest related sequences 
available on the GISAID database.  Sequence names are on the left, reference 
 141 
sequence is presented on the bottom axis, and genome position for the SNP 
is on the top axis. N represents missing sequencing data, and the nucleotide 
is unknown at that position. 
Table 2.9: Consensus sequences derived from post-mortem samples were called with the medaka pipeline within the ARTIC nCoV19 
bioinformatics pipeline. Llama was used to identify SNPs in comparison to the SARS-CoV-2 RefSeq and Pangolin was used to 
determine the lineage of the consensus. Sequence name identifies patient number and tissue,N prop; the proportion of Ns in the 
consensus sequence due to insufficient sequencing coverage, No. SNPS; the number of SNPs identified in the available sequence, 
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2.3.12  Sub-genomic RNA was mainly detectable in the lower respiratory 
tissue 
Portcullis was used identify coronavirus leader sequences fused to gene 
sequences as a proxy measurement of active transcription. Samples with no 
reads mapping to a leader sequence, were removed from the analysis. The 
total mapped reads were compared to the raw counts of leader sequences 
identified and then the proportion of subgenomic reads to determine 
correlation. Before normalisation, the Pearson’s rank coefficient was 
r=0.15(CI=0.05-0.25, df=350, p = 0.004), suggesting a very weak yet 
significant positive relationship, for example the more reads mapped results in 
more leader gene fusion detection is a weak positive relationship. Upon 
normalisation and the generation of a ratio, there was no significant 
relationship (r=-0.08(CI=-0.18-0.03), df=350, p=0.16) (Figure 2.16). The 
proportion of subgenomic mRNAs detected using this approach was on 
average 0.002 +/- 0.01SD, although ranged from 2x10-6 to 1.47x10-1. All of the 
subgenomic RNAs that were identified were plotted as a proportion to 
summarise the most abundant sgmRNA associated with each patient and 
each tissue (Figure 2.17).  As expected, N transcripts were detected the most 
often throughout tissues and patients.  Patient 5 and 10, had a higher 
proportion of ORF1AB leader sequences than other patients out of the 
available sequences. This could be indicative of viral genome detection as 
opposed to transcripts. Pulmonary tissues appear to have a more diverse 
range of detectable leader sequences, this may be due to a more consistent 
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Figure 2.16: Normalisation of the number of leader sequences identified against the total 
mapped reads. A weak positive linear relationship was observed before normalisation 
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Figure 2.17: Subgenomic mRNA derived from coronavirus discontinuous transcription, were 
counted using the tool Portcullis. A global analysis of the proportion of each leader type was 
plotted as per patient or tissue to gain insight into viral transcription in various tissues in severely 
ill patients.  
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2.4 Discussion 
Viral genome detection and analysis in real-time plays an essential role in viral 
disease outbreaks. While this concept itself is not novel and has been 
deployed previously in West Africa during the EBOV outbreak, Nigeria during 
the Lassa Fever Outbreak and for Dengue and Chikungunya surveillance, an 
approach for MERS-CoV did not exist at the beginning of this project. 
Therefore it was the aim of this study to design an amplicon based sequencing 
approach to aid and support MERS-CoV surveillance and transmission studies 
in Saudi Arabia (Quick et al., 2016b) (Kafetzopoulou et al., 2019, 
Kafetzopoulou et al., 2018). The work on MERS-CoV was mainly conducted 
at King Fahad Medical City, Riyadh in Saudi Arabia, as it was important to the 
researchers involved in this study to keep this work in-house and encourage 
sustainability of the project, this also means that elements of this project on 
MERS-CoV remain unfinished due to restrictions enforced by the ongoing 
SARS-CoV-2 pandemic. However, lessons learnt on the MERS-CoV project 
were reappropriated for the novel coronavirus, SARS-CoV-2.  
 
As coronavirus replication transcription complexes have proof-reading 
abilities, during virus replication recombination and the resulting potential 
deletions and insertions may account for the wide genomic diversity observed 
in some strains (Jackwood et al., 2010, Kottier et al., 1995, Kusters et al., 
1990). These recombination events drive coronavirus evolution and have the 
potential to affect vaccine strategies (Sohrab and Azhar, 2020). To identify 
these events using sequencing, the rapid long read length 
approaches offered by Oxford Nanopore were advantageous. Sample quality 
can also inform design of sequencing strategies and a RT-PCR approach was 
adopted to recover viral genome/transcript information, as opposed to direct 
RNA sequencing approaches. Therefore, rather than designing very short 
amplicons, as in the case of alternative methods such as Network ARTIC, 
longer amplicons were constructed through selection of appropriate primer 
pairs (Figure 2.1).  
 
First the primers pairs were assessed on purified RNA from MERS-CoV or 
SARS-CoV-2 infected cells before assessing the efficiency in clinical samples. 
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Both primer schemes were able to amplify the coronavirus genome, and this 
was confirmed by running PCR products on agarose gels (Figure 2.2). In the 
case of MERS-CoV, the amplicons were tested with 30, 15 or 8 primer pairs 
to test the boundaries for how long the amplicons could be. Full genomes were 
covered with both the 30 and 15 amplicon approaches, however, the 8-
amplicon approach, although working on cell culture, did not show the same 
results with clinical samples, this is likely to be due to the quality of the clinical 
samples. Although the 15-amplicon approach was able to provide full genome 
coverage above 20X, the efficiency of each primer pair differed, and the 
coverage was less even in comparison to the 30-amplicon approach.  
 
Intra-host sequence diversity of MERS-CoV was investigated using data 
obtained from a script written in perl which essentially counts the number of 
each nucleotide at each position in an alignment file. MinION sequencing is 
known for its high error rates, however, as this is entirely random, it was 
hypothesised that although the number of base-changes would be over-
reported in MinION sequencing data, the proportion of particular changes may 
still be of interest. Figure 2.7 shows the proportion of base changes observed 
against the dominant or consensus sequence of the patient. Transitions were 
more frequently observed in comparison to transversions. Although transitions 
occur more readily, as expected, there are certain host factors that can drive 
sequence diversity in viruses. Of particular interest for coronaviruses is the 
host protein APOBEC, this enzyme is responsible for deaminizing cytosine 
generating uracil and has been highlighted in the literature for other 
coronaviruses such as HCoV-NL63 and SARS-CoV-2 (Cao et al., 2018, Di 
Giorgio et al., 2020, Milewska et al., 2018, Wang and Wang, 2009).  
 
The proportion of base changes are less in patient 115 in comparison to patient 
10 (Figure 2.7). Patient 115 and patient 10 consensus information was derived 
by 2 amplicon approaches whereas patient 10 was sequenced using the 30-
amplicon approach and patient 115 was sequenced with longer amplicons, 
therefore the observed differences could be due to the approach as opposed 
to genuine mutations. 
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Although the number of samples from MERS-CoV patients were limited, 
sequencing, data was assessed for deletion events at the minor variant level. 
Through this analysis deletions were observed in ORF4a, ORF5, N and 
ORF1A. Deletions in this region may have implications on virus pathogenesis, 
ORF4A is able to inhibit early antiviral responses (IFN α/β) in the host (Yang 
et al., 2015), likewise ORF5 has been implicated in the reduction of the 
inflammatory response (Menachery et al., 2017). 
 
Primers for SARS-CoV-2 were designed in a similar fashion to the MERS-CoV 
primers and, following the results from the MERS-CoV the 30-amplicon 
approach, were used to improve throughput via multiplexing. Initial 
assessment of the SARS-CoV-2 primers were conducted on two patients at 
the beginning of pandemic in the UK, where segments of the viral genome 
were detected in an asymptomatic patient when a laboratory test deemed the 
patient negative. This highlighted the sensitivity of this approach. The multiplex 
reaction was able to generate full genome coverage in the case of cell-culture, 
however, when amplifying clinical samples, the amplification of the genome 
between 26kb and 27kb was not efficient. Therefore, this primer pair required 
further to go under more evaluation and testing. From the samples that were 
sequenced with this approach, deletion analysis was carried out using SVIM 
on 24 samples. This identified deletions in genes responsible for the interferon 
response at the minor variant level. These deletions may not be competitive or 
transmitted, however, it is known that deletions can attenuate disease (Young 
et al., 2020a). 
 
An amplicon-based sequencing approach was utilised to assess the 
distribution of SARS-CoV-2 within tissues from fatal COVID-19 patients to 
contribute to the understanding of severe disease. The work in this chapter 
contributed to a wider study where results were validated with S protein 
staining and inflammation scoring (Dorward et al., 2020). Overall, this study 
demonstrated that SARS-CoV-2 distribution is widespread and variable in 
patients with fatal COVID-19, with an unexpected inflammatory response 
discordance. If organ injury and damage is collateral to an inflammatory 
response against SARS-CoV-2, an association between virus presence and 
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inflammation would be expected. However, evidence from this study suggest 
that inflammation can occur within lung tissue without the detection of viral 
RNA. This provides two explanations, that either non-resolving inflammation 
can occur following viral clearance, or inflammation can occur in areas of the 
lung where viral replication had never occurred. Taking the sensitivity of PCR 
into consideration, the latter explanation is possible. This is further supported 
by the fact that both RNA and S protein were detectable, from the post-mortem 
studies, in tissues up to 42 days after onset of illness and not associated with 
an inflammatory response. In addition, there was no correlation between the 
onset of illness to death timescale and the number of PCR positive organs 
identified.  
 
Interestingly, in the post-mortem studies, viral RNA was in kidneys, liver and 
the intestine with no associated inflammation or organ damage. Through 
spatial resolution of the S protein in non-pulmonary tissue, cells containing the 
S protein did not have adjacent localised immune response, consistent with 
avian coronaviruses that can replicate in cells within the gut without giving rise 
to histological or macroscopic changes (Raj and Jones, 1997). 
 
Upon examination of lung tissue as discussed in Dorward et al (2020), SARS-
CoV-2 RNA presence in the lung was not linearly associated with the presence 
or nature of the lung inflammatory response, where bronchopneumonia and 
diffuse alveolar damage was identified with and without detectable viral RNA. 
Likewise, with the presence of inflammation. These immunopathologic 
observation reveal immune responses that involve the lung and the 
reticuloendothelial system, which are likely to be virus independent. This is 
likely to be an underlying mechanism for severe disease and is supported by 
the success observed with corticosteroid-based therapeutics (Sterne et al., 
2020). Further investigation into viral tolerance and the dysregulated immune 
response would aid better understanding of severe COVID-19 disease. 
 
Viral sequences obtained as part of this study were further analysed to 
generate consensus sequences and to investigate mutations present in the 
genome. Unfortunately, as it was not possible to amplify the whole coronavirus 
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genome in many samples, this limited the analysis. It is likely that the 
homogenisation of the tissues prior to extracting RNA resulted in the RNA’s 
fragmentation, thus hindering PCR amplification. Consensus sequences that 
had more than 50% of the sequence available were analysed through Llama 
to identify the sequences that were most closely related and to observe the 
SNP profile. Due to the inconsistency of sequence available for analysis, it was 
difficult to compare the SNP profile from different tissues within the same 
patient. To overcome this, the short-read illumina sequencing platform could 
be used to generate a larger read depth, this technology is also better 
equipped for fragmented RNA in comparison to the ARTIC pipeline which 
seeks to generate amplicons of 400bp.  
 
As the Network ARTIC method was used, including a primer complementary 
to the leaser sequence, the data was assessed to detect the presence of 
sgmRNA, despite incomplete sequencing coverage. Using Portcullis, sgmRNA 
was detected, although at a low ratio in comparison to mapped reads. The 
detection of sgmRNA implies that the viral replicase is actively undergoing the 
process of discontinuous transcription, to allow for the production of viral 
proteins. This type of data analysis is novel and opportunistic. The quality of 
this analysis would be improved with sequencing data that supplied full 
coverage, however, the simple detection of sgmRNA is still informative. The N 
gene was observed more often than other sgmRNAs, as expected (Hiscox et 
al., 1995a, Pyrc et al., 2004).  
 
Sequencing data from post-mortem samples could also be interrogated for 
deletion events. As mentioned previously, recombination is the primary driver 
of coronavirus evolution, more so than mutations due to the proofreading 
ability of NSP14. Current literature suggests that viral genomes in long-term or 
persisting infections can accumulate deletions in the S gene that encodes for 
the N-terminal of the S protein (McCarthy et al., 2020). Such deletions within 
this region have been termed RDRs and have been hypothesised to occur as 
part of a host evasion strategy (McCarthy et al., 2020). 
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Viral genome sequencing is an indispensable tool for the surveillance of viral 
evolution. This chapter describes the design of an amplicon sequencing 
method for MERS-CoV and SARS-CoV-2 and demonstrates that data 
produced from this approach can be utilised for phylogeny, SNP detection, 
minor variant analysis and that sgmRNAs are detectable with network ARTIC. 
Amplicon sequencing approaches such as ARTIC are now gold standard in 
the surveillance of SARS-CoV-2 in the ongoing pandemic. This in combination 
with evolving bioinformatic tools and automation allow monitoring of viral 
evolution in real time. Although deletions and minor variation analysis are often 
overlooked in these surveillance pipelines. This chapter provides rationale for 
further investigation into quasispecies and deletions and their role evolution 
and disease phenotypes. Minor variant frequencies have been shown to 






Chapter 3: Elucidating and comparing the host 
transcriptomic response to SARS-CoV-2 and IAV in 
patients at point of care 
 
3.1 Introduction 
As was shown in EBOV disease the host response can play an instrumental 
role in viral disease and outcome (Liu et al., 2017). Organ damage observed 
in lung tissue in post-mortem samples from patients who died of severe 
COVID-19 highlighted a virus independent immunopathologic response 
(Chapter 2). The post-mortem study illustrated the importance of a 
multidisciplinary approach in the case of the emergence of novel disease 
(Dorward et al., 2020). Respiratory viral infections are a leading cause of 
disease globally, and the impact on the health of both adults and children can 
be significant and pose a threat to health services, especially during peak 
seasonal infection rates (2019, Morbey et al., 2017, Dawood et al., 2012). How 
the host responds to infection can dictate disease progression and severity 
and understanding this response can provide insight on the clinical 
management of patients and the design of therapeutics. For example, in 
hospitalised cases with patients infected with SARS-CoV-2, dexamethasone 
is used to reduce mortality (Sterne et al., 2020, Horby et al., 2020). This 
compound is a glucocorticoid that is thought to decrease inflammation and the 
immune pathology associated with COVID-19. 
 
Throughout the pandemic, SARS-CoV-2 infections have been compared to 
influenza infections in the media, with claims that SARS-CoV-2 is no worse 
than influenza. Studies comparing Influenza and COVID-19 have revealed that 
although there are similarities between clinical observations reflective of 
systemic inflammation, such as C-reactive protein (CRP), white blood cell 
counts (WBCs) and neutrophil counts (Galani et al., 2021), COVID-19 patients 
were associated with a higher risk of developing respiratory distress, 
pulmonary embolism, septic shock and haemorrhagic strokes (Piroth et al., 
2021). Severe disease in patients with COVID-19 was associated with obesity, 
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diabetes, hypertension, and dyslipidaemia whereas patients with influenza 
severe disease was associated with heart failure, chronic respiratory disease, 
cirrhosis and deficiency anaemia (Piroth et al., 2021). Comparison of in-
hospital mortality between COVID and Influenza patients revealed that COVID 
patients were at a relatively higher risk of mortality at 16.9% compared to 
Influenza at 5.8% (Piroth et al., 2021). The immune response to influenza has 
been studied extensively and therefore presents a useful comparison with 
which to understand disease caused by SARS-CoV-2 (Kreijtz et al., 2011). 
However, it is important to consider the differences in pathogenesis between 
seasonal influenza viruses and emerging pandemic influenza viruses before 
such comparisons are made (Uiprasertkul et al., 2007, Uiprasertkul et al., 
2005, van Riel et al., 2007, van Riel et al., 2006). In brief, the body initiates 
defence through cells of the innate immune system such as macrophages, 
granulocytes, and dendritic cells (Chaplin, 2010, Marshall et al., 2018). These 
cells release proinflammatory cytokines and interferons resulting in the 
inhibition of viral replication and transcription and the recruitment of additional 
immune cells to stimulate an adaptive immune response (Chaplin, 2010, Wu 
and Metcalf, 2020). Virus-specific T-cells are ultimately responsible for the 
initiation of a humoral and cellular mediated immunity (Chaplin, 2010, 
Rosendahl Huber et al., 2014).  
 
Seasonal coronaviruses give rise to very mild disease, with severe disease 
predominantly associated with comorbidities (Cabeça et al., 2013), however, 
symptoms associated with emerging coronaviruses (SARS-CoV, MERS-CoV, 
and SARS-CoV-2), are more severe and clinical outcomes are more diverse. 
Unlike the seasonal coronaviruses, the emerging coronaviruses are more 
likely to infect the lower respiratory tract which can give rise to acute lung injury 
(ALI) or acute respiratory distress syndrome (ARDS), pneumonia, septic 
shock, and multi-organ failure (Chen et al., 2020). Host risk factors for severe 
COVID-19 include older age, male sex and underlying health conditions such 
as diabetes and cardiovascular disease (Cevik et al., 2020a), with the immune 
response substantially contributing to clinical outcomes (Cevik et al., 2020b).  
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Viruses rely on host mechanisms to facilitate the viral life cycles. In addition to 
utilising the host machinery to translate viral proteins, and the manipulation of 
cellular components to enable RNA synthesis, certain coronavirus proteins 
can modify the cell signalling profile which ultimately influence pathogenesis. 
This is reinforced by the observation of milder disease in combination with the 
deletion of ORF8 in patients (Young et al., 2020a), and the deletion of 
accessory genes in vitro (Thornbrough et al., 2016, Niemeyer et al., 2013). For 
respiratory viruses, the virus must first pass through a mucus layer protecting 
the airway epithelium to infect the host through engagement with a receptor 
where active replication and transcription of viral genomes can be initiated. In 
the case of SARS-CoV-2, the receptor binding domain of spike binds with 
ACE2 in the nasal cavity (Ou et al., 2020, Hoffmann et al., 2020b, Ziegler et 
al., 2020, Zhao et al., 2020, Lukassen et al., 2020, Xu et al., 2020), where an 
initial asymptomatic phase lasts between 1-2 days, where viral replication 
occurs in the upper respiratory tract. Symptoms emerge within 2-14 days from 
the first encounter, including fever, dry cough, pharyngitis, and shortness of 
breath. When the virus reaches the lower respiratory tract, a strong innate 
immune response is triggered, which results in an enhanced proinflammatory 
response responsible for the generation of ARDS and other respiratory 
complications (Shah et al., 2020). 
 
Once SARS-CoV-2 enters the cell, the immune system can recognise the virus 
or its surface epitopes, prompting the innate immune response. Pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) 3, 7 and 8, 
expressed on or within epithelial and innate immune cells can detect 
evolutionarily conserved molecular structures known as pathogen associated 
molecular patterns (PAMPs). TLRs are often the first to sense the virus and 
activate the production of interferon (IFN) within the cell. PRRs can also detect 
the effects of virus infection through damage-associated molecular patterns 
(DAMPs) which are endogenous molecules released by damaged or dying 
cells to inform the innate immune system of a potential threat. Although, 
coronavirus non-structural proteins can impact the function of the host’s 




This chapter aimed to identify distinct genes that are unique to SARS-CoV-2 
infections when comparing to the more characterised respiratory virus 
influenza virus, and thus provide distinction in respiratory infection and 
outcome. Long read length sequencing was trialled to provide rapid insight into 
the host response in humans with COVID-19 or influenza virus. One of the 
difficulties of studying SARS-CoV-2 in humans is access to deep tissues and 
the potential complications of co-infections, and hence the utility of post-
mortem samples in characterising severe disease.  
 
Publications in support of this Chapter are: 
Jelmer Legebeke, Jenny Lord, Rebekah Penrice-Randal, Andres F. Vallejo, 
Stephen Poole, Nathan J. Brendish, Xiaofeng Dong, Catherine Hartley, John 
W. Holloway, Jane S. Lucas, Anthony P. Williams, Gabrielle Wheway, Fabio 
Strazzeri, Aaron Gardner, James P.R. Schofield, Paul J. Skipp, Julian A. 
Hiscox, Marta E. Polak, Tristan W. Clark, Diana Baralle. Distinct immune 
responses in patients infected with influenza or SARS-CoV-2, and in COVID-
19 survivors, characterised by transcriptomic and cellular abundance 
differences in blood. medRxiv 2021.05.12.21257086; doi: 
https://doi.org/10.1101/2021.05.12.21257086  
 
For this publication I conducted the RNA extractions from whole blood 
collected in PAXgene tubes from patients recruited into the Flu-POC and COV-
POC studies in Containment Level 3. Extracted RNA was sent to the centre of 
genomic research (GCR) for Illumina sequencing and I sequenced a subset of 
samples were sequenced on the GridION. Data presented in this chapter is 
from independent analysis.  
 
Manuscript in preparation:  
Rebekah Penrice-Randal, Xiaofeng Dong, Aaron Gardner, Jelmer Legebeke, 
Jenny Lord, Andres Vallejo Pulido, Stephen Poole, Nathan J. Brendish, 
Catherine Hartley, John W. Holloway, Jane S. Lucas, Tony Williams, Gabrielle 
Wheway, Marta E. Polak, Fabio Strazzeri, James Schofield, Paul J. Skipp, 
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Julian A. Hiscox, Tristan W. Clark, and Diana Baralle. Prognosis of COVID-19 





3.2.1 Sample collection of COVID-19 and Influenza patient samples 
Human blood samples were obtained as part of the Influenza Point of Care 
study (Beard et al., 2019) and COV19-POC study (Brendish et al., 2020). 
COV-19POC was a non-randomised interventional trial designed to evaluate 
the clinical impact of molecular point-of-care testing for SARS-CoV-2 in adult 
patients presenting to hospital with suspected COVID-19. Collection of 
samples took place during the first wave of the pandemic in the UK, from 20th 
March to 29th April 2020. All patients were recruited from the Acute Medical 
Unit (AMU), Emergency Department (ED) or other acute areas of 
Southampton General Hospital. The study was approved by the South Central 
- Hampshire A Research Ethics Committee: REC reference 20/SC/0138, on 
the 16th March 2020. For full details, see the protocol, available at: 
https://eprints.soton.ac.uk/439309/2/CoV_19POC_Protocol_v2_0_eprints.pdf
. The FluPOC study was a multicentre randomised controlled trial designed to 
evaluate the clinical impact of molecular point-of-care testing for influenza in 
hospitalised adult patients with acute respiratory illness during influenza 
season, using the Biofire FilmArray platform (Beard, 2019 #272). The trial took 
place during influenza season over the winters of 2017/18 and 2018/19. All 
patients were recruited from the Acute Medical Unit (AMU) and Emergency 
Department (ED) of Southampton General Hospital and from Hampshire 
County Hospital. The study was approved by the South Central - Hampshire 
A Research Ethics Committee: REC reference 17/SC/0368, approved on the 
7th September 2017.  
 
Patients gave written informed consent or consultee assent was obtained 
where patients were unable to give their consent. Demographic and clinical 
data were collected at enrolment and outcome data collected retrospectively 
from case note and electronic systems. The data management systems 
ALEA and BC platforms were used for data capture and management. Blood 
samples including whole blood in RNA PAXgene tubes were collected from 
SARS-CoV-2 positive patients within 24 hours of enrolment follow-up samples 
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were obtained on day 14 (+/- 4) and days 28 (+/- 4) where patients remained 
alive and in hospital at these time points. The study was prospectively 
registered with the ISRCTN14966673 on the 18th March 2020. Blood samples 
including whole blood in RNA PAXgene tubes were collected from Influenza 
positive patients within 24 hours of enrolment. The study was prospectively 




All work was performed in accordance with risk assessments and standard 
operating procedures approved by the University of Liverpool Biohazards Sub-
Committee and by the UK Health and Safety Executive. Work with SARS-CoV-
2 was performed at Containment Level 3 until deactivated.  
 
3.2.3 Extraction of RNA from blood samples 
Blood samples were obtained into PAXgene Blood RNA tubes (BRT) 
(Preanalytix) from patients with either COVID-19 or influenza virus. Total RNA 
was extracted using the PAXgene Blood RNA Kit (PreAnalytix) at Containment 
Level 3 in a Tripass Class I hood. PAXgene BRT were incubated at room 
temperature for at least 2 hours before extraction was initiated. PAXgene BRT 
were centrifuged for 10 minutes at 5000g, supernatant was discarded and 4ml 
of RNase-free water was added to the pellet and vortexed until the pellet had 
dissolved. The tube was centrifuged for a further 10 minutes at 5000g and 
supernatant was discarded. 350l of Buffer BR1 was added to the pellet and 
vortexed until the pellet dissolved, before transferring to a 
1.5ml microcentrifuge tube, where 300l of Buffer BR2 and 40l of proteinase 
K was added. The reaction was vortexed and incubated for 10 minutes at 55C 
and 400rpm in a shaker incubator. The lysate was then transferred into a 
PAXgene Shredder Spin Column placed in a 2ml processing tube and 
centrifuged for 3 minutes at maximum speed. Flow through was transferred 
into a fresh 1.5 ml microcentrifuge tube before the addition of 350l of 
molecular grade ethanol. The sample was vortexed and briefly centrifuged. 
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700l of the sample was transferred into a PAXgene RNA spin column in a 
2ml processing tube and centrifuged for 1 minute at maximum speed. The spin 
column was then placed into a new processing tube and 350l of Buffer BR3 
was added before centrifuging for a minute at maximum speed, flow-through 
was discarded. The DNase mix was then prepared by adding 10l of DNase I 
stock solution to 70l Buffer RDD per sample, in a 1.5ml microcentrifuge tube. 
The DNase mixture was mixed gently and briefly centrifuged before adding 
80l directly to the spin column and incubating at room temperature for 15 
minutes. A further 350l of Buffer BR3 was added to the spin column and then 
centrifuged at maximum speed for 1 minute. The flow-through was discarded 
and 500l of Buffer BR4 was added to the spin column, and centrifuged for 1 
minute at maximum speed, flow-through was discarded and a further 500l 
was added to the spin column before centrifuging for 3 minutes at maximum 
speed. The spin column was transferred into a new processing tube and 
centrifuged for a minute at maximum speed. The spin column was then placed 
in a 1.5 ml microcentrifuge tube and 40l of Buffer BR5 was added to the 
membrane and centrifuged at maximum speed for a minute to elute the RNA. 
This elution step was repeated and extracted RNA was stored at -80C until 
further use. 
 
3.2.4 Library preparation for long read length sequencing 
 
cDNA sequencing libraries were prepared using the PCR-cDNA Barcoding 
sequencing kit (SQK-PCB109), starting with 50ng of total RNA which 
was accurately quantified using a Qubit 3.0 fluorometer (Thermofisher) 
and the Qubit RNA HS Assay Kit (Thermofisher). RNA was incubated with 10 
mM dNTPs, 2mM VN primers in a total volume of 11 ml for 5 minutes at 65°C 
and then snap cooled on a pre-chilled freezer block. Strand-switching Primers 
(SSP) at 10mM were added to the reaction with 5X Reverse Transcriptase 
Buffer and RNaseOUT (Invitrogen) and incubated at 42 °C for 2 minutes, 
before adding 1 l of Maxima H Minus Reverse Transcriptase (Invitrogen). The 
reaction was incubated at 42 °C for 90 minutes, followed by a heat inactivation 
step at 85 ºC for 5 minutes.  
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The samples were then multiplexed and amplified by adding 1.5 µl of Barcode 
Primers, 25 µl of 2X LongAmp Taq Master Mix (NEB), 18.5 µl nuclease-free 
water to 5 µl of reverse-transcribed RNA in quadruplicates, with the cycling 
conditions shown in Table 3.1. 
 
Table 3.1: Cycling conditions for the amplification of transcriptome sequencing 
libraries for Oxford Nanopore. 
 Temperature Time No. of cycles 
Initial 
denaturation 
95 ºC 30 secs 1 
Denaturation 95 ºC 15 secs 14 
Annealing 62 ºC 15 secs 14 
Extension 65 ºC 75 secs 14 
Final extension 65 ºC 6 mins 1 




Following amplification, 1 µl of exonuclease I (NEB) was added to each 
reaction and incubated at 37 ºC for 15 minutes, followed by 80 ºC for 15 
minutes. Quadruplicates were then pooled into a 1.5ml Eppendorf DNA LoBind 
tube and 0.8X the volume of AMPure XP beads (Beckman Coulter) were 
added. The mixture was incubated for 5 minutes on a hula mixer. Tubes were 
briefly centrifuged before pelleting on a DynaMag2 magnetic rack. 
Supernatant was discarded, and the pellet was washed with 200 µl of freshly 
prepared 70% ethanol twice before briefly centrifuging and allowing the pellet 
to dry on the magnet, ensuring all ethanol is removed. The pellet was 
resuspended in 12 µl of Elution Buffer (EB) and incubated on a hula mixer at 
room temperature for 10 minutes. The beads were pelleted on the magnetic 
rack and the eluate was transferred into a fresh tube, taking 1 µl for 
quantification on the qubit fluorometer for each barcoded library.  
 
 165 
Barcoded samples were pooled together ensuring that samples were 
equimolar and did not exceed 100fmol per flow cell. For adapter ligation, 1 µl 
of Rapid Adapters (RAP) were added to pooled sequencing libraries and 
incubated at room temperature for 5 minutes at room temperature.  
 
Flow cell priming buffer was prepared by adding 30 µl of flush tether buffer 
(FLT) to 1.5ml flush buffer (FB). The priming port of the flow cell was opened, 
and the small air bubble was removed with a 1000 µl by drawing approximately 
20 µl. Then, 800 µl of the priming buffer was added to the priming port and 
incubated for 5 minutes. In the meantime, 37.5 µl of Sequencing Buffer (SQB) 
and 25.5 µl of Loading Beads (LB) was added to 12 µl of adapter ligated DNA. 
Before loading the library to the flow cell, the SpotON sample port cover was 
removed, and a further 200 µl of the priming buffer was added into the priming 
port, and 75 µl of the library was added drop wise to the SpotON sample port. 
 
The MinKNOW GUI was used to initiate sequencing and was ran for up to 72 
hours. Fast5 files were base called using the high accuracy calling model. 
 
3.2.5 Illumina sequencing 
 
Following the manufactures protocols, total RNA was used as input material 
into the QIAseq FastSelect–rRNA HMR (Qiagen) protocol to remove 
cytoplasmic and mitochondrial rRNA with a fragmentation time of 7 or 15 
minutes. Subsequently the NEBNext® Ultra™ II Directional RNA Library Prep 
Kit for Illumina® (New England Biolabs) was used to generate the RNA 
libraries, followed by 11 or 13 cycles of amplification and purification 
using AMPure XP beads. Each library was quantified using Qubit and the size 
distribution assessed using the Agilent 2100 Bioanalyser and the final libraries 
were pooled in equimolar ratios. The raw fastq files (2 x 150 bp) generated by 
an Illumina® NovaSeq 6000 (Illumina®, San Diego, USA) were trimmed to 
remove Illumina adapter sequences using Cutadapt v1.2.1. The option “−O 3” 
was set, so the that 3’ end of any reads which matched the adapter sequence 
with greater than 3 bp was trimmed off. The reads were further trimmed to 
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remove low quality bases, using Sickle v1.200 with a minimum window quality 
score of 20. After trimming, reads shorter than 10 bp were removed.  
 
3.2.6 Data analysis  
 
3.2.6.1 Transcriptomics analysis and identification of 
differentially expressed genes 
Multiplexed sequencing reads were base called and demultiplexed by Guppy 
basecaller.  Minimap2 was used to index and map reads to the reference 
transcriptome Homo_sapiens.GRC.38.cdna.all) to generate alignment files 
using the –ax map-ont -N 100 -p 1.0 parameters (Li, 2018). Alignment files 
were sorted and indexed with samtools before counting reads using Salmon 
with the corresponding annotation file (Homo_sapiens.GRCh38.101.gtf) from 
Ensembl using –noErrorModel -l U parameters (Li, 2018, Patro et al., 2017). 
For illumina data, paired reads were inputted into Salmon. 
The edgeR package was used to normalise sequencing libraries and identify 
differentially expressed genes, defined as at least a 2-fold difference from 
the mock infected group (n=5) and a false discovery rate (FDR) less than 
0.05 (Robinson et al., 2010). 
Principle component Analysis (PCA), volcano plots, heatmaps and Venn 
diagrams were produced in R studio using the following packages: edgeR, 
ggplot2 and pheatmap.   
 
3.2.6.2 Gene ontology  
 
Differential gene expression data was used for gene ontology enrichment 
analysis of biological process terms in each group using 
the ClusterProfiler programme in R (Yu et al., 2012). The compareCluster 
function was used to compare increasing and decreasing DE genes in each 
group with a q-value cut-off of 0.05 was used with a Benjamini-Hochberg-FDR 
correction. GOSemSim was used to simplify and remove redundant GO terms 





3.2.6.3 In silico Immune profiling to determine relative 
abundance of immune cell types between patient 
groups 
To determine the relative abundance of 22 immune cell types from illumina 
and nanopore datasets, TMM normalised cpm values were deconvoluted 
using the reference gene signature matrix (LM22) on the CIBERSORTx 
website using 100 permutations (Newman et al., 2019). The relative 
abundance of the immune cell types determined by gene expression data was 
plotted with ggplot2 in RStudio. To determine significance, a one-way ANOVA 
and Tukey’s HSD post-hoc test was used.  
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3.3 Results 
Work described in Chapter 2 and the resulting collaborative publication led by 
pathologists at the University of Edinburgh (Dorward et al., 2020) gave an 
insight into severe COVID-19. This was only possible through post-mortem 
analysis of infected patients. However, COVID-19 has a spectrum of severity 
ranging from mild to severe symptoms (including fatal outcome). Such deep 
tissue sampling is not possible in living patients. Therefore, to investigate 
COVID-19 in mild/severe infections blood samples were taken from different 
cohorts of patients with COVID-19. Those who then went on to survive or die 
were compared and separately patients with influenza virus infection as 
another comparator from a respiratory infection where people ended up 
hospitalised. Blood samples have provided a useful sentinel for the host 
response is patients with Ebola virus disease and provide a window into the 
disease process with time if longitudinal samples can be obtained (Liu et al., 
2017). 
 
To investigate the host response to SARS-CoV-2 and influenza virus in living 
patients who then went on to survive or die of infection, blood samples were 
used as a basis for transcriptional profiling.  For the samples from humans two 
sequencing approaches were compared to assess and define the host 
response. The first was an Illumina RNAseq based approach on all 82 COVID-
19 and 88 Influenza samples from the human study. Five of the Influenza 
samples failed sequencing based due to acquiring less than 2 million reads, 
and four of the samples from the COVID-19 cohort were excluded. However, 
Illumina sequencing can take time, and therefore an alternative approach was 
assessed based on using long read length sequencing, to assess utility in an 
outbreak setting. In this case, 60 samples from the COVID-19 cohort including 
10 fatal cases and 20 from the Influenza cohort were selected randomly to be 
processed for MinION sequencing, to determine whether data obtained was 
comparable to data from the Illumina sequencing platform. An overview of the 
patient characteristics is provided in Table 3.2. Multiple time points of some 
patients within the COVID-19 cohort. Samples from healthy controls were used 
to determine which changes in transcript abundance were relevant to infection.  
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Table 3.2: Overview of the patient characteristics of the samples included in 
the Illumina sequencing study. For age, the median is stated with the 25th-75th 
percentile. 
 Healthy COVID-19 Flu 
Number of 
Patients 
5 83 83 
Age (years) 30 
(29-36) 
61 
(47.75 – 73.25) 
59  
(42 – 73) 
Sex F=1 
M=4 
F = 29 
M = 55 
F = 36 






Respiratory disease (21) 
Asthma (13) 
Chronic kidney disease (6) 
Chronic liver disease (3) 
Diabetes (19) 
Malignancies (7) 







Respiratory disease (44) 
Asthma (not recorded) 
Chronic kidney disease (4) 
Chronic liver disease (0) 
Diabetes (8) 
Malignancies (6) 
Dementia (not recorded)  
Immunosuppressed (5) 
 






3.3.1 Analysis of the host response in humans with COVID-19 compared 
to influenza virus. 
 
Sequencing reads obtained from Illumina sequencing were counted against 
the human transcriptome and normalised to cpm. Differential gene expression 
was conducted in EdgeR to determine the transcripts that were increasing and 
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decreasing in abundance when comparing to healthy controls or each disease 
state (Table 3.3). Overlapping transcriptional profiles from patients with 
COVID-19 (n=83) and influenza (n=83) at POC were observed, although both 
groups separated from healthy donors (n=5) (Figure 3.1). The transcripts that 
were identified as being different between COVID and influenza patients, with 
a logFC more than 2 and an FDR value less than 0.05, were plotted as box 
and violin plots to visualise the distribution and differences in expression within 
the groups (Figure 3.2).  
 
 
Table 3.3: Number of genes with an FDR less than 0.05 and a logFC less than 
-2 or more than 2 for COVID-19 and Influenza patients. 
 COVID Flu COVID vs Flu 
Increasing abundance 2761 2700 23 




Figure 3.1: Principal component analysis of 171 samples. Transcriptional profiles from 
COVID-19 patients (n=83) and Influenza patients (n=83) overlap, however, separate 
from healthy controls (n=5). The log2 cpm values following TMM normalisation and 
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 Figure 3.2: Transcripts that are differentially abundant between COVID and Influenza 
patients. To identify genes that were differentially expressed between COVID and 
Influenza patients, a contrast matrix was formed using (groupCOVID-groupHealthy)-
(groupFlu-groupHealthy). The log10 CPM values were plotted as boxplots with violin 
























































































































































































































































































































































































































































































































































































































3.3.2 Gene ontology reveals small difference between COVID-19 and 
influenza patients 
 
To determine the biological relevance of the transcripts that were identified as 
increased or decreased in abundance, ClusterProfiler was used to assess 
gene ontology terms for biological processes (BP), molecular functions (MF) 
and cellular components (CC) and the top 20 were presented in (Figure 3.3). 
The transcripts that were increasing and decreasing in abundance for COVID-
19 and influenza patients were then assigned to gene ontology (GO) terms for 
biological process (BP), molecular function (MF) and cellular component (CC). 
As transcriptional profiles were revealed to be overlapping in the PCA plot 
(Figure 3.1), both COVID-19 and influenza patients shared similar GO terms 
(Figure 3.3).  
 
The transcripts decreasing in abundance in COVID-19 patients and not 
influenza patients can be assigned to BP GO terms; the negative regulation of 
ubiquitin-dependent catabolic processes, regulation of leukocyte chemotaxis 
and negative regulation of ubiquitin-protein transferase. Whereas influenza 
patients and not COVID-19 patients transcripts decreasing in abundance were 
associated with; regulation of natural killer cell mediated cytotoxicity, positive 
regulation of signal transduction by p53 class mediator and the positive 
regulation of nitric oxide biosynthetic process. Anion transport and 
neurotransmitter transport were unique to COVID-19 and influenza patients 
respectively in the GO terms related to transcripts increasing in abundance.  
 
The top MF GO terms revealed mainly similarities, except for receptor 
regulator and receptor ligand activity GO terms associated with transcripts 
decreasing in abundance for influenza patients, as well as MHC class II 
binding and chemokine and cytokine activity. CC GO terms show transcripts 
decreasing in abundance in COVID-19 patients and not influenza patients are 
associated with the MHC class II protein complex and the organelle inner 





COVID Flu COVID Flu
neurotransmitter transport
positive regulation of nitr ic oxide biosynthetic process
regulation of natural killer cell mediated cytotoxicity
positive regulation of signal transduction by p53 class mediator
regulation of synapse organization
multicellular organismal signaling
visual system development
regulation of hormone levels
circulatory system process
anion transport
regulation of system process
regulation of membrane potential
adult behavior









homophilic cell adhesion via plasma membr ane adhesion molecules
detection of chemical stimulus
sensory perception of smell
detection of chemical stimulus involved in sensory perception of smell
natural killer cell mediated immunity
defense response to bacter ium
negative regulation of ubiquitin−protein tr ansferase activity
regulation of leukocyte chemotaxis




natural killer cell chemotaxis
ribonucleoprotein complex subunit organization
regulation of leukocyte mediated cytotoxicity






nuclear−transcribed mRNA catabolic process , nonsense−mediated decay
establishment of protein localization to endoplasmic reticulum
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cytokine activity
MHC class I protein binding
chemokine activity
ankyrin binding
secondary active transmembrane transporter activity
growth factor activity




drug transmembrane transporter activity
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receptor ligand activity
receptor regulator activity
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passive transmembrane transporter activity
channel activity
metal ion transmembrane transporter activity
inorganic molecular entity transmembrane transporter activity
G protein−coupled receptor activity
NADH dehydrogenase (quinone) activity
NADH dehydrogenase (ubiquinone) activity
NADH dehydrogenase activity
chemokine receptor binding
MHC protein complex binding
carbohydrate binding
ubiquitin−protein transferase regulator activity
mRNA 5'−UTR binding
rRNA binding
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Figure 3.3: clusterProfiler was used to compare up and down regulated transcripts as 
determine through differential gene expression. Dot plots were used to visualise the 
Gene Ontology terms for biological processes, Molecular Function and Cellular 
Components. The size of the dot refers to the gene ratio associated with that cluster 
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3.3.3 Comparing differentially expressed genes between fatal and non-
fatal COVID-19 patients 
 
In addition to comparing COVID and Influenza blood transcriptomes, profiles 
from fatal (n=16) and non-fatal (n=67) COVID-19 disease were compared. The 
number of genes increased and decreased in abundance with an FDR value 
less than 0.05 are shown in Table 3.4. More genes were downregulated in the 
Fatal group in comparison to the non-fatal group. Overlapping transcriptional 
profiles were revealed through PCA (Figure 3.4), and the top 24 genes were 
plotted to visualise important genes involved in fatality (Figure 3.5). Many 
transcripts associated with immunoglobulin’s were identified in these top 
genes, where higher transformed log2 cpm values were higher in non-fatal 
cases when compared to fatal and healthy groups (Figure 3.6). Irf7 was 
identified in higher abundance in fatal cases of COVID-19 
 
 
Table 3.4: Number of genes with an FDR less than 0.05 and a logFC less than 
-2 or more than 2 for fatal and non-fatal COVID-19. 
 Fatal Non-Fatal Fatal vs 
NonFatal 
Increased 2972 2696 18 





Figure 3.4: Principal component analysis of 88 samples. Transcriptional profiles from 
fatal COVID-19 patients (n=16) and non-fatal COVID-19 patients (n=67) overlap, 
however, separate from healthy controls (n=5). The log2 cpm values following TMM 


































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.5: The TMM normalised CPM values were plotted as violins with a boxplot to visualise 
transcripts that had been determined as significantly different between fatal and non-fatal 
COVID-19 by differential gene expression analysis in EdgeR. 12 of the transcripts presented 
are associated with immunoglobulin kappa chain (IGK) genes, where the fatal group is more 
comparable to healthy controls than the survivors.   
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3.3.4 Gene ontology reveals transcripts associated with the adaptive 
immune response are decreased in abundance in fatal COVID-19 
The top 20 BP, MF and CC GO terms are presented in Figure 3.6. Terms were 
shared between both fatal and non-fatal profiles, however, biological 
processes associated with the adaptive immune response, T-cell activation, 
lymphocyte and leukocyte activity were identified as GO terms that were 
decreased in Fatal COVID-19 and not in Non-fatal COVID-19. Molecular 
function analysis highlights decreased MHC class 1 protein binding in fatal 
COVID, and cellular component analysis suggests a decrease in T-cell 
receptor complexes.  
Down Up
Fatal NonFatal Fatal NonFatal
blood circulation
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regulation of membrane potential
potassium ion transport
sensory perception of smell
regulation of leukocyte chemotaxis
negative regulation of ubiquitin−dependent protein catabolic process
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Figure 3.6: Genes that were increased or decreased in abundance for Fatal 
and Non-Fatal COVID were assessed for Gene Ontology terms using 
ClusterProfiler. Terms were simplified to filter out redundant terms and the top 
20 terms were plotted for biological Process, molecular function and cellular 
component terms. 
 
3.3.5 Transcriptomic analysis from long reads 
Illumina sequencing is the gold standard sequencing technology for the 
assessment of transcriptomes from biological organisms, however, this 
platform can be logistically challenging due to long wait times. A subset of 
samples that were sent for illumina sequencing were also sequenced using 
the long-read cDNA-PCR approach for nanopore sequencing. An overview of 
the samples that were randomly selected for MinION sequencing and matched 
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with Illumina data are shown in Table 3.5. Samples that were removed from 
the analysis due to low read numbers are highlighted.   
3.3.5.1 Sequencing performance  
In general, Illumina sequencing resulted in 60 times more sequencing reads in 
comparison to the MinION experiments (Table 3.5), although sequencing 
reads from MinION were approximately 5 times as long as the expected 
illumina sequencing reads of ~150bp (Figure 3.7). The number of reads 
mapping to the host transcriptome according to Salmon was less than that of 
MinION (Table 3.5). 
 
 
Figure 3.7: Fastq files for all clinical samples sequenced were inputted into 
NanoPlot to determine the distribution of the sequencing read length. The 
average read length of for the MinION data was 705 and quality score of 11 




Table 3.5: Number of reads acquired per sample on each sequencing platform 
used for differential gene expression analysis. Number of MinION reads refer 
to sequencing reads with a quality score above 7. Number of reads, number 
of reads mapped and % reads mapped were determined with salmon and 
parsed with MultiQC. Samples highlighted in orange were removed from 
analysis due to low read number. * refers to fatal cases of COVID-19.  
 
Nanopore Illumina 
PhenoID M Reads % Aligned M Aligned M Reads % Aligned M Aligned 
CoV0005 2.5 94.70% 2.4 56.1 32.10% 18 
CoV0011 0.1 83.80% 0.1 58.5 35.70% 20.9 
CoV0033 0.4 79.20% 0.3 58.8 40.00% 23.5 
CoV0038 8.8 95.20% 8.4 62.9 34.20% 21.5 
CoV0041 0.2 88.80% 0.2 35.7 33.30% 11.9 
CoV0057 5.3 87.00% 4.6 56.2 37.00% 20.8 
CoV0073* 1.0 84.10% 0.8 82.6 31.70% 26.2 
CoV0126 4.2 91.50% 3.8 61.7 32.60% 20.1 
CoV0128 3.6 92.00% 3.3 76.6 33.30% 25.5 
CoV0132 1.9 92.40% 1.8 55.9 27.90% 15.6 
CoV0137* 3.0 92.30% 2.8 55.0 34.20% 18.8 
CoV0155 0.6 86.40% 0.5 45.7 29.10% 13.3 
CoV0160 3.7 96.90% 3.6 57.3 30.20% 17.3 
CoV0164 8.0 87.40% 7 71.1 34.90% 24.8 
CoV0166 8.9 93.60% 8.3 87.1 37.10% 32.3 
CoV0167 1.1 84.80% 0.9 84.5 28.40% 24 
Cov0174 3.2 89.90% 2.9 61.6 33.30% 20.5 
CoV0177 0.3 88.70% 0.3 56.9 33.90% 19.3 
CoV0190 5.5 95.50% 5.3 62.7 37.80% 23.7 
CoV0194 1.7 82.50% 1.4 61.8 35.30% 21.8 
CoV0201 0.7 82.30% 0.6 65.0 29.70% 19.3 
CoV0206 0.5 85.10% 0.4 69.6 34.90% 24.3 




PhenoID M Reads % Aligned M Aligned M Reads % Aligned M Aligned 
CoV0233 0.3 97.10% 0.3 52.6 32.50% 17.1 
CoV0244* 3.0 79.70% 2.4 59.2 31.40% 18.6 
CoV0250 3.2 88.30% 2.8 65.6 30.20% 19.8 
CoV0252 4.4 90.70% 4 67.3 33.00% 22.2 
CoV0261 0.1 78.00% 0.1 55.5 40.70% 22.6 
CoV0267* 3.2 83.90% 2.7 51.8 31.30% 16.2 
CoV0268 1.9 83.30% 1.6 62.8 33.90% 21.3 
CoV0270* 3.3 90.70% 3 57.1 30.80% 17.6 
CoV0271 5.1 86.90% 4.4 63.2 25.30% 16 
CoV0276* 2.6 85.90% 2.2 62.8 32.00% 20.1 
CoV0291* 5.0 78.20% 3.9 52.3 30.60% 16 
CoV0292 3.4 79.70% 2.7 43.9 31.90% 14 
CoV0303* 11.2 91.30% 10.2 56.2 34.00% 19.1 
CoV0306 6.5 95.90% 6.2 57.6 35.40% 20.4 
CoV0311 1.7 95.80% 1.6 53.8 31.80% 17.1 
CoV0312* 1.9 83.50% 1.6 53.2 38.00% 20.2 
CoV0332 1.1 89.20% 1 56.7 33.00% 18.7 
CoV0347 1.0 86.90% 0.9 61.0 29.00% 17.7 
CoV0356 1.5 93.10% 1.4 43.3 39.00% 16.9 
CoV0373 0.3 94.50% 0.3 59.1 34.20% 20.2 
CoV0460* 6.0 85.30% 5.1 53.3 31.90% 17 
Cov0466 1.4 90.30% 1.3 58.7 31.00% 18.2 
CoV0474 0.3 87.30% 0.3 72.0 32.80% 23.6 
CoV0499 0.4 93.80% 0.4 63.1 34.40% 21.7 
Flu092 12.3 88.60% 10.9 70.8 35.90% 25.4 
Flu148 1.4 80.60% 1.1 78.6 30.40% 23.9 
Flu183 6.7 86.70% 5.8 66.2 33.10% 21.9 
Flu190 2.2 87.40% 1.9 62.3 32.60% 20.3 




PhenoID M Reads % Aligned M Aligned M Reads % Aligned M Aligned 
Flu225 7.1 94.60% 6.7 61.5 36.90% 22.7 
Flu250 10.5 84.40% 8.9 64.1 30.40% 19.5 
Flu271 6.0 95.30% 5.7 53.7 44.30% 23.8 
Flu327 7.4 90.70% 6.7 57.8 34.10% 19.7 
Flu357 10.5 90.80% 9.5 59.0 35.60% 21 
Flu370 1.4 90.20% 1.3 54.1 32.70% 17.7 
Flu371 7.9 92.70% 7.3 52.9 34.20% 18.1 
Flu381 3.2 93.30% 3 59.8 35.60% 21.3 
Flu385 9.3 91.70% 8.5 65.6 30.50% 20 
Flu390 6.6 85.90% 5.7 46.4 32.10% 14.9 
Flu394 3.4 69.90% 2.4 51.9 28.90% 15 
Flu403 4.5 91.20% 4.1 58.8 31.30% 18.4 
Flu450 20.0 93.70% 18.7 53.8 34.60% 18.6 
Flu491 6.1 94.90% 5.8 58.7 37.80% 22.2 
Healthy1 6.2 71.30% 4.4 186.8 66.90% 125 
Healthy2 5.0 81.30% 4.1 168.4 64.30% 108.3 
Healthy3 4.3 78.50% 3.4 177.5 72.30% 128.3 
Healthy4 4.3 72.70% 3.1 176.2 63.10% 111.2 




3.3.5.2 Normalised CPM values are moderately correlated 
between Nanopore and Illumina sequencing reads 
Transcript count files from Salmon for Illumina and Nanopore datasets were 
imported into R and converted into TMM normalised CPM values using edgeR. 
To determine whether there was a relationship between the illumina and 
nanopore expression data, a data frame was generated with common genes 
identified in both sequencing datasets. Data points were then plotted as a 
hexbin scatter graph to illustrate any correlation between matched samples 
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sequenced on Illumina and Nanopore (Figure 3.8). Illumina and Nanopore 
expression values were found to be moderately correlated with Pearson 
(r=0.48 p= < 2.2e-16), although Figure 3.8 shows that data points were denser 
just below 101 for nanopore and Illumina expression values, indicating 




Figure 3.8: Nanopore and Illumina expression datasets were filtered so only 
transcripts present in both datasets were considered. Nanopore and Illumina 
CPM values were plotted as a hexbin scatterplot showing the distribution of 
log10 CPM. Each data point represents the normalised CPM for a transcript 
from matched samples. The blue line represents the correlation. 
 
3.3.5.3 Stronger correlation was observed when 
comparing Log2 fold change from common 
transcripts within the datasets 
 
To compare nanopore and Illumina datasets further, differential gene 










































final list of differentially expressed genes with the log2 fold change value were 
filtered to ensure the transcripts were present in both datasets before 
comparison. A stronger correlation was identified between illumina and 
nanopore datasets when considering log2 fold change over log10 CPM values. 
Differentially expressed genes identified in COVID vs Healthy in illumina and 
nanopore data were found to correlate strongly with Pearson (r = 0.70, p = < 




Figure 3.9: Log2 fold change of transcripts identified in both illumina and nanopore 
datasets were compared to determine the relationship between the data. Data points 
were coloured to highlight whether the transcript was significant in both Illumina and 
Nanopore, Illumina only, Nanopore only or not significant in both datasets. Log2 fold 
change comparison was plotted for both COVID and Flu. Pearson correlation for 
COVID (r=0.70, p= < 2.2e-16), Influenza (r=0.73, p = < 2.2e-16). 
 
3.3.6 Comparing Nanopore and Illumina sequencing methods to 
investigate the host response  
 
RNA was sequenced on both the MinION and Illumina platforms to allow for 
technology comparisons and to determine whether the same conclusions can 
be made through rapid sequencing technologies despite lower sequencing 
read depths. Sequencing reads from MinION and Illumina were counted 
against the human transcriptome (Homo_sapiens.GRCh38.101.cdna.all.fa) 
using Salmon. In brief, Salmon count files were imported into R and differential 
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gene expression analysis was conducted with EdgeR. Library sizes were 
observed, and raw counts were transformed into Log2 counts per million. 
Library sizes were more consistent within the Illumina dataset in comparison 
to the MinION dataset, however, following normalisation, the median log2 cpm 
was comparable. Both sequencing datasets reveal overlapping transcriptional 
signatures between COVID-19 and Influenza patients and clear separation 
from the healthy controls when analysed independently, suggesting that 
transcriptional signatures in both infection groups are non-specific anti-viral 
signalling pathways (Figure 3.10).  
 
When forming a contrast between Influenza and COVID blood transcriptomes 
derived from nanopore sequencing, a total of 9964 were identified and when 
using COVID only samples to compare fatal and non-fatal covid, a total of 8634 
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The number of up and down regulated genes were identified for each condition 
per sequencing technology, Illumina sequencing was able to identify nearly 6 
times as many upregulated transcripts, although comparable down regulated 
transcripts (Table 3.6). To further compare the differentially expressed genes 
derived from MinION sequencing and Illumina sequencing, Venn diagrams 
were produced in using iVenn (Heberle et al., 2015) (Figure 3.11). Illumina 
sequencing generated more reads and thus identified more differentially 
expressed genes. However, unique differentially expressed genes were 
identified in each condition. There were more upregulated genes shared 
between Influenza and COVID patients sequenced with illumina (2131), 
however, 306 were shared across all conditions.  
 
Table 3.6: The number of significant increasing and decreasing transcripts 
identified in each group of patients derived from MinION and Illumina 
sequencing. 
 COVID Flu 
MinION Illumina MinION Illumina 
Increasing 
abundance 
801 2761 787 2700 
Decreasing 
abundance 
286 261 414 370 
 
The number of transcripts identified as being expressed in different abundance 
in the nanopore data alone, for COVID and Influenza comparisons, as well as 
fatal and non-fatal comparisons are stated in Table 3.7.  
 
Figure 3.10: Transcriptional signatures between COVID-19 and Influenza patients 
overlap. A principal component analysis was performed to compare the log2 
transformed counts per million (cpm) values of patients with COVID-19 (n=35) and 
Influenza(n=19) against healthy controls (n=5) in a 2-dimensional plot.  (A) data 
acquired from MinION sequencing, (B) data acquired from illumina.  
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Table 3.7: The number of transcripts identified as increased or decreased in 
abundance in the nanopore data when making the stated contrasts.  
 COVIDvHealthy FluVHealthy COVIDvFlu 
Up 801 787 66 
Down 286 414 0 
 FatalVHealthy NonFatalVHealthy FatalVNonFatal 
Up 584 646 4 
Down 407 212 94 
 
 
3.3.6.1 Genes identified in both datasets reinforce 
biological importance of immunoglobulin 
domains in COVID-19 disease 
The aim of this data analysis was to determine which transcripts are unique 
and therefore important in disease caused by SARS-CoV-2. Using influenza 
as a comparison, 23 genes were found to be increasing in abundance in the 
illumina dataset, with 66 in the Nanopore dataset, only 10 transcripts were 
identified in both of these, most of which were immunoglobulin domains 
(Figure 3.12). There was no cross over between the sequencing methods and 
the decreasing transcripts for the COVID-19 and Influenza comparisons. GO 
term assessment of these transcripts revealed that all of these were all 
associated with the immunoglobulin complex and the majority were involved 
in the activation of the classical complement pathways (Table 3.8) 
 
In addition to characterising the differences between disease caused by 
SARS-CoV-2 and IAV, contrasts were made between fatal and non-fatal 
COVID-19. Illumina was able to identify 21 transcripts increasing in 
abundance, whereas nanopore was only able to identify 4, with only one 
transcript identified in both datasets, CD163. In general, more genes were 
identified as decreasing in abundance, when comparing fatal with non-fatal 
transcriptomic profiles, where illumina identified 75, and nanopore 94. With 40 
transcripts being common in both datasets. The majority of which are 
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immunoglobulin transcripts (Figure 3.13).  Assignment of GO terms these 40 
genes demonstrate that they are associated with the immunoglobulin complex 










Figure 3.11: Venn diagrams showing the number of differentially expressed genes 
shared between COVID and Influenza patients as well as differentially expressed genes 
identified between MinION and Illumina sequencing.  
Increased in abundance 





















Table 3.8: GO Terms assigned to the transcripts identified in both Nanopore 
and Illumina data sets when comparing COVID-19 and influenza patients 
differentially expressed genes. 
 
GO Category Description Count % Log10(P) Log10(q) 


















6 60.00 -10.63 -7.72 


















Figure 3.12: Venn diagrams illustrating the number of common and unique 
transcripts identified as increased in abundance when comparing transcriptional 
profiles of COVID-19 and Influenza patients with Illumina and Nanopore 
sequencing technologies. The intercept, or genes identified in both illumina and 
nanopore are listed. No genes were identified as decreasing in abundance between 
these conditions in either dataset.  


































































Increased in abundance 
Decreased in abundance 
Figure 3.13: Venn diagrams illustrating the number of common and unique transcripts 
identified as increased or decreased in abundance when comparing transcriptional 
profiles of fatal and non-fatal COVID-19 patients with Illumina and Nanopore 
sequencing technologies. The intercept, or genes identified in both illumina and 
nanopore are listed. 
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Table 3.9: GO Terms assigned to the transcripts identified in both Nanopore 
and Illumina data sets when comparing fatal to non-fatal COVID-19 
differentially expressed genes 
 
3.3.6.2 Using in silico immune profiling to determine 
relative abundance of immune cell types between 
COVID and Influenza patients at point of care  
CIBERSORTx was used to deconvolute transcript expression data into relative 
abundance of immune subtypes. Transcript expression data matched samples 
sequenced on illumina and nanopore were inputted into the CIBERSORTx 
website independently to determine whether outputs from the different 
technologies deliver the same biological information.  The relative abundance 
of each immune subtype derived from nanopore or illumina data was plotted 
as a scatter graph to determine whether the datasets were related. Through 
Pearson’s correlation, a strong relationship was observed between matched 
samples sequenced on Nanopore and Illumina platforms (Figure 3.14). 
 
 
GO Category Description Count % Log10(P) Log10(q) 












29 72.50 -58.71 -54.57 











21 52.50 -34.57 -31.58 




17 42.50 -28.36 -25.49 





4 10.00 -11.46 -8.78 
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21 immune subtypes are plotted comparing the relative abundance in COVID 
and Influenza patients with healthy controls (Figure 3.15). Table 3.10 provides 
a descriptive summary for each comparison and the adjusted p-values are 
presented in Table 3.12. The immune deconvolution showed subtle 
differences between COVID and Flu. According to Nanopore data, plasma 
cells were the only cell type with statistically significance when comparing the 
means of COVID and Influenza expression data (p=0.006), whereas no 
significance was observed within the illumina dataset. According to illumina 
data memory B-cells were significantly higher in relative abundance for 
Influenza patients (p=0.030) and Macrophages (M0) were significantly higher 
with COVID patients (p=0.005). In both datasets, CD8 T-cell expression from 
COVID and Influenza patients were significantly different to the healthy 
controls (p=<0.001), likewise with resting memory CD4 T-cells and neutrophils. 
Naïve CD4 T-cells from Influenza and COVID patients were only found to be 






0.00 0.25 0.50 0.75 1.00




























Figure 3.14: Relative abundance values for immune cell types derived from 
CIBERSORTx analysis for Nanopore and Illumina TMM normalised cpm. 
Through Peason correlation analysis, a strong correlation was observed 
(r=0.93, p = 2.2e-16). 
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3.3.6.3 In silico Immune profiling to determine relative 
abundance of immune cell types between fatal 
and non-fatal patients at point of care 
 
In addition to comparing COVID vs Influenza immune cell subtypes from the 
transcript expression data, fatal vs non-fatal data was also deconvoluted to 
provide further insight into the host response (Figure 3.16). Table 3.11 
provides a descriptive summary and the adjusted p-values are presented in 
Table 3.12. Interestingly, Illumina did not identify any significant differences 
between Fatal and Non-Fatal relative abundances, however, Nanopore data 
was able to identify significance for activated dendritic cells (p=0.008), 
Macrophages (M2) (p=0.020), Plasma Cells (p=0.029), gamma delta T-cells 
(p=0.010) and T-regs (p=0.042)
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Figure 3.15: CIBERSORTx was used to deconvolute transcript expression data from COVID (n=34) and Influenza (n=19) Patients 
and healthy controls (n=5) into immune cell subtypes and was plotted as boxplots to visualise the fractions of each immune subtype 
for each patient group. Matched samples were sequenced on nanopore and illumina sequencing platforms and are therefore plotted 
side by side to determine discrepencies between sequencing technogies.  
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Table 3.10: Descriptive summary of figure 15 
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Figure 3.16: CIBERSORTx was used to deconvolute transcript expression data from Fatal COVID (n=10) and Non-fatal COVID (n=24) Patients 
and healthy controls (n=5) into immune cell subtypes and was plotted as boxplots to visualise the fractions of each immune subtype for each 
patient group. Matched samples were sequenced on nanopore and illumina sequencing platforms and are therefore plotted side by side to 
determine discrepencies between sequencing technogies. 
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Table 3.11: Descriptive summary of figure 15 
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Table 3.12: To determine significance between the relative abundance of immune cell subtypes determined by CIBERSORTx for 
Influenza vs COVID and Fatal COVID vs Non-fatal COVID, an ANOVA was used with a Tukey Post-hoc. Adjusted p-values are 
presented in the table. Ns = not significant.  
 


























B-cells memory ns ns ns 0.030 ns ns ns ns ns ns ns ns 
Dendritic cells 
(activated) 
ns 0.007 0.002 ns ns ns <0.001 0.008 0.023 ns ns ns 
Macrophages (M0) ns ns ns 0.005 0.050 ns ns ns ns ns ns 0.046 
Macrophages (M2) ns ns ns ns ns ns ns 0.020 ns ns ns ns 
Mast cells (resting) ns 0.008 ns ns ns ns 0.010 ns 0.016 ns ns ns 
Monocytes ns ns ns ns ns ns 0.011 ns ns ns ns ns 
Neutrophils ns 0.007 0.002 ns 0.002 0.002 <0.001 ns 0.012 <0.001 ns 0.003 
NK cells (activated) ns ns 0.050 ns ns ns ns ns ns ns ns ns 
Plasma cells 0.006 0.042 ns ns ns ns ns 0.029 0.019 ns ns ns 
T-cells CD4 memory 
(activated) 
ns 0.050 ns ns ns ns 0.017 ns ns ns ns ns 
T-cells CD4 memory 
(resting) 
ns <0.001 <0.001 ns 0.006 0.020 <0.001 ns <0.001 0.005 ns 0.009 
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T-cells CD4 (naïve) ns <0.001 <0.001 ns ns ns <0.001 ns <0.001 ns ns ns 
T-cells CD8 ns <0.001 <0.001 ns <0.001 <0.001 <0.001 ns <0.001 <0.001 ns <0.001 
T-cells gamma delta ns ns ns ns ns ns 0.011 0.010 ns ns ns ns 
T-cells regulatory 
(Tregs) 






Emerging coronaviruses can cause severe disease in humans. Accessory 
proteins encoded within the viral genomes can facilitate immune evasion and 
particular host responses. Chapter 2 highlighted that severe and fatal COVID-
19 is contributed to by the host response, whereby the presence of virus and 
inflammation did not always co-exist in tissues (Dorward et al., 2020). The 
involvement of the host response in patient outcome is further supported by 
the impact of dexamethasone on the outcome of patients within intensive care 
units which is able to reduce inflammation through immunosuppression 
(Sterne et al., 2020, Horby et al., 2020). This chapter utilised samples from the 
COVID-19 and Influenza point of care trials to determine the blood 
transcriptome in patients who have just been admitted to hospital (Beard et al., 
2019, Brendish et al., 2020). All samples were sequenced using Illumina to 
acquire a substantial read depth for differential gene expression, however, a 
subset of samples was selected at random to sequence on the MinION to 
determine how the rapid, long read technology compared to the gold standard 
illumina sequencing. Whilst the comparison between COVID-19 and seasonal 
influenza might also not be direct because the study periods are roughly 1 year 
apart. It cannot be ascertained whether the 2018–19 seasonal influenza 
is representative of all seasonal influenzas, even though it was the most 
severe season in the past 5 years in France (Piroth et al., 2021). 
 
Both IAV and SARS-CoV-2 infections in humans can result in severe disease 
and the need for hospitalisation. The blood transcriptomes from Influenza or 
COVID-19 patients at point of care were compared to determine host response 
differences. There were no fatal cases within the Influenza cohort, however, 
there were 15 fatal cases in the COVID-19 dataset. Through differential gene 
expression analysis, a plethora of transcripts were identified that were unique 
to COVID-19 vs Flu, or Fatal COVID vs non-fatal COVID. Interestingly, through 
both illumina and nanopore sequencing, immunoglobulin transcripts were 
identified at an increased abundance when comparing COVID-19 patient’s 
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transcriptomes to Influenza patient transcriptomes. Likewise, when comparing 
fatal to non-fatal COVID-19. The significant over-representation of 
immunoglobulin transcripts associated with the heavy chain and light chain V 
genes has been reported previously (Robbiani et al., 2020). 
 
A previous study that utilised single cell sequencing of PBMC’s from 10 COVID 
patients identified an over-representation of the IGHV3 family, specifically, 
IGHV3-30, IGHV3-7, IGHV3-15, IGHV3-21 and IGHV3-23 (Wen et al., 2020). 
IGHV3-30 has been shown to facilitate the encoding of primary antibodies to 
neutralise human cytomegalovirus (Thomson et al., 2008, Thomson et al., 
2011). Additional studies into SARS-CoV-2 reveal that IGHV3-30 was 
overrepresented in convalescent patients and that IGHV3-30 facilitated kappa 
over lambda chains, it has also been hypothesised that IGHV3-30 is part of 
the initial response within the immunological repertoire under emergency 
situations (Xiaojie et al., 2020, Yuan et al., 2020). This has been further 
validated in other investigations where it has been concluded that S-reactive 
IgG positive B-cell responses are readily developed after infection where the 
same B-cell clones are detectable over time with a preference for the IGHV3-
30 gene segment (Kreer et al., 2020). Influenza viruses have also been 
recorded to utilise this gene for the generation of broadly neutralising 
antibodies, and with previous studies the importance of this gene seems to be 
important for the B-cell response to both respiratory viruses, although 
abundance is higher in COVID-19 patients (Fu et al., 2016). 
 
IGHV1-69D is an immunoglobulin heavy domain gene and is considered to be 
very polymorphic and has been found to be a preferentially used gene for the 
generation of neutralising antibodies for MERS-CoV (Tang et al., 2014), 
hepatitis C (Chan et al., 2001) and influenza viruses (Sui et al., 2009). Tang et 
al, (2014) propose that B-cell receptor precursors that utilise IGHV1-69 may 
be able to recognise the receptor binding domain of the MERS-CoV spike 
protein and a prolonged affinity maturation process is not necessary for an 
effective neutralising antibody response. Similar has been reported for SARS-
CoV against the spike receptor binding domain (Prabakaran et al., 2012). 
IGHV1-69 has also been identified as an upregulated gene when comparing 
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mild and severe Mycoplasma pneumoniae pneumonia in children (Wang et al., 
2017). Usage of IGHV1-69 was significantly increased in acute dengue virus 
infections in comparison to those with dengue virus but with no clinical warning 
signs (Godoy-Lozano et al., 2016). IGHV1-69 may be an interesting gene 
associated with inflammation as it has been recognised and implicated in 
severe viral and bacterial diseases. Further work would be required to 
characterise this gene and functionality in coronavirus disease.  
 
In addition to investigating the blood transcriptome of patients with Influenza 
or COVID-19 at point of care, sequencing methodologies were also compared 
and contrasted due to the longer turnaround time associated with illumina 
sequencing. A subset of samples was sequenced on Nanopore technologies 
and matched samples were considered throughout an analysis. Although 
Nanopore sequencing returned fewer sequencing reads in comparison to 
illumina sequencing, the reads acquired were approximately 750 base pairs 
long and were associated with a high mapping rate to the human 
transcriptome. Due to a much lower read depth, less transcripts were identified 
within the dataset, and thus less differentially expressed genes were 
associated within the Nanopore dataset. Filtered and normalised transcript 
counts were compared between matched illumina and nanopore datasets. 
There was a moderate correlation when comparing the log10 CPM values, 
however, when contrasts were formed against control samples to determine 
the log2 fold change of transcripts, a much stronger correlation was observed. 
Following independent analysis of both datasets, transcripts identified as 
increasing or decreasing in abundance were compared using Venn diagrams. 
Illumina datasets were richer with data, however, both sequencing 
technologies acquired unique transcripts that were changing in abundance 
between conditions. More importantly, when comparing COVID vs Influenza 
and Fatal and non-fatal transcripts, there was a strong agreement that 
immunoglobulins were associated with both COVID-19 disease and non-fatal 
cases. Thus, providing more confidence in the involvement of the adaptive 
immune response in COVID-19 disease. Data from illumina sequencing and 
nanopore sequencing also suggests that an early adaptive immune response 
may be associated with survival from disease.  
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CIBERSORTx was used to deconvolute expression data from nanopore and 
illumina data to identify immune subsets that may be different between groups. 
There was disagreement between illumina and nanopore datasets, this is likely 
to be because of the partial coverage of the transcriptome within the nanopore 
datasets. Illumina data could be considered as more reliable as more 
sequencing information is acquired. However, the other important caveats to 
consider are the sample sizes within the groups, as well as the age range of 
the healthy controls in comparison to the infection groups as it is known that 
the immune system can decline with age (Simon et al., 2015).  
 
In the influenza and COVID-19 and fatal and non-fatal COVID-19 
comparisons, both nanopore and illumina sequencing were in agreement for 
significant differences observed in neutrophils, T-cells CD4 memory resting 
cells, and T-cell CD8 cells. Neutrophils were in higher abundance in COVID 
and influenza in comparison to the healthy controls and higher in fatal COVID-
19. Previous studies have shown an elevation of neutrophils in blood and lungs 
in severe COVID-19 disease (Kuri-Cervantes et al., 2020, Li et al., 2020d, Liao 
et al., 2020, Schurink et al., 2020, Radermecker et al., 2020). Neutrophil-to-
lymphocyte ratios were identified as a clinical predictive marker for developing 
severe disease, which is reflected in the immune deconvolution of fatal and 
non-fatal COVID-19 patients (Liu et al., 2020a).  
 
CD4+ and CD8+ T-cells were identified as being significantly different to 
healthy controls but with no difference between groups. Although, when the 
whole cohort is considered in the analysis using illumina only as opposed to a 
subset, there are significant differences observed between COVID-19 and 
influenza patients as well as fatal and non-fatal COVID-19 (Legebeke et al., 
2021). Reinforcing the importance in sample size in investigating big data sets. 
The larger study, presented in Legebeke et al (2021), shows naïve CD4+ T-
cells in a higher relative abundance in comparison to CD8+ T-cells – which 
can also be seen here. This indicates a higher CD4+ T-cell response than a 
CD8+ response which has also been previously observed, and may control 
early SARS-CoV-2 infection (Grifoni et al., 2020, Sekine et al., 2020, 
Rydyznski Moderbacher et al., 2020). Although CD8+ T-cells were observed 
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more often in non-fatal COVID-19 patients, which has been associated with a 
positive outcome (Rydyznski Moderbacher et al., 2020, Peng et al., 2020, 
Legebeke et al., 2021).  
 
In this dataset, illumina sequencing did not identify any immune subtypes as 
significantly different between fatal and non-fatal COVID-19. Although, 
Macrophages (M0) and Memory B-cells were different between COVID-19 and 
influenza patients. Macrophages were higher in COVID in comparison to 
influenza patients, although there was no difference between groups in the 
nanopore data. As Nanopore and illumina datasets had little agreement when 
assessing immune subtypes, further validations are required to establish this 
as a downstream analysis for nanopore data. This may have been impacted 
by the smaller sample size that was used and a partially covered transcriptome 








Chapter 4: Transcriptomic analysis of a transgenic 
ACE-2 mouse model to determine the impact of 




Chapter 3 described the transcriptomic analysis on RNA obtained from the 
blood of human patients at point of care for both SARS-CoV-2 and IAV 
infections. To further investigate the host response to SARS-CoV-2, 
transcriptomic profiles from IAV and SARS-CoV-2 infections were compared 
using a transgenic mouse model (K18-hACE2 mice). This focused on both 
individual infections (allowing comparison to the human data) and a sequential 
infection of IAV followed by SARS-CoV-2. At the time of this study, the impact 
of sequential infection of IAV and SARS-CoV-2 was unknown and was 
important due to the impending 2020-2021 winter influenza virus season 
during the SARS-CoV-2 pandemic and the implications this could have on 
global public health, at least in the Northern Hemisphere. 
 
Cooperative or competitive pathogen-pathogen interactions can occur during 
dual infections especially when multiple respiratory viruses are in circulation at 
the same time (Nickbakhsh et al., 2019). During the 1918 Spanish Influenza A 
virus pandemic, secondary bacterial infections were considered to be the 
major contributing factor to mortality (Morens et al., 2008). Similarly, in Ebola 
virus disease, host responses and patient outcome has been shown to be 
influenced by the identification of a secondary infection such as malaria 
(Carroll et al., 2017). The second wave of SARS-CoV-2 was expected to 
coincide with the typical timings of Influenza A and Influenza B virus peaks, 
generally between the months of December and April, and there were limited 
findings on the impact of these two respiratory viruses as a coinfection (Gaunt 
et al., 2010). The initial hypothesis was that co-infection of IAV and SARS-
CoV-2 could lead to exacerbated clinical disease and outcome.  
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There is limited understanding of severe coronavirus infection in combination 
with other viruses or bacterial pathogens. For SARS-CoV, human 
metapneumovirus was circulating in Hong Kong at the same time, however, 
there was no evidence that coinfections influenced patient outcome (Lee et al., 
2007). IAV has been identified as a co-infection in patients with MERS-CoV, 
requiring co-management with anti-influenza virus therapeutics. Although, due 
to a small sample size, the impact of this coinfection was not characterised by 
this study (Alfaraj et al., 2017). Metatranscriptomic analysis conducted in Aljabr 
et al (2020) revealed dysbiosis in the respiratory microbiome in patients with 
MERS-CoV (Aljabr et al., 2020). Fatal cases were associated with an increase 
in an abundance of Proteobacteria including Actinobacteria (Aljabr et al., 
2020). Throughout the SARS-CoV-2 pandemic, there have been several 
reports of IAV and SARS-CoV-2 infection where severe outcomes have been 
observed (Ma et al., 2020) (Azekawa et al., 2020, Yue et al., 2020, Kondo et 
al., 2020, Hashemi et al., 2020, Hashemi et al., 2021). One study suggested 
the risk of death increased 6-fold when a coinfection was present. Although, 
the risk of testing positive with SARS-CoV-2 was 68% lower in those who 
tested positive for IAV infection, suggesting that these viruses excluded each 
other during infection in patients (Stowe et al., 2021).  
 
Post-mortem analysis can provide insight into severe coronavirus disease and 
the cause of fatality (Dorward et al., 2020). However, in this case many of the 
original parameters cannot be established, including time of infection and 
sequence of any co-infections. Likewise, post-mortem analysis can be 
severally impacted by the death pathway – including the activation of hypoxia 
at a cellular level and the degradation of tissue and nucleic acids – such as the 
RNA for analysis. Animal models provide an opportunity to study disease over 
a time course in a controlled manner. Previous studies with SARS-CoV in a 
mouse model were able to demonstrate that coinfection with a respiratory 
bacterium resulted in exacerbated pneumonia (Ami et al., 2008). Many animal 
models can be directly infected with the wildtype SARS-CoV-2, however, this 
study utilised K18-hACE2 transgenic mice to study pathogenesis where the 
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hACE2 expression is driven by the epithelial cell cytokeratin-18 (K18) 
promoter.  
 
Publications in preprint in support of this Chapter are: 
Jordan J. Clark, Rebekah Penrice-Randal, Parul Sharma, Anja Kipar, 
Xiaofeng Dong, Shaun H. Pennington, Amy E. Marriott, Stefano Colombo, 
Andrew Davidson, Maia Kavanagh Williamson, David A. Matthews, Lance 
Turtle, Tessa Prince, Grant L. Hughes, Edward I. Patterson, Ghada Shawli, 
Krishanthi Subramaniam, Jo Sharp, Lynn McLaughlin, En-Min Zhou, Joseph 
D. Turner, Giancarlo Biagini, Andrew Owen, Julian A. Hiscox, James P. 
Stewart. Sequential infection with influenza A virus followed by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe 
disease and encephalitis in a mouse model of COVID-19. bioRxiv 
2020.10.13.334532; doi: https://doi.org/10.1101/2020.10.13.334532. 
 
In this publication I conducted the long-read length sequencing and analysed 
the sequencing data. In the Clark et al. 2020 publication my work contributed 






4.2.1 Mice experiments 
This work was a collaboration with and led by the group of Prof. James Stewart 
at the University of Liverpool. Details of the mouse experiments are 
reproduced in full below. My specific involvement and the work described in 
this chapter centres around the analysis of the viral and host response in this 
animal model using transcriptomics to identify and quantify different RNA 
species. 
 
4.2.2 Ethics and clinical information 
Informed consent for sampling of hCoV-
2/human/Liverpool/REMRQ0001/2020 was obtained under the International 
Severe Acute Respiratory and emerging Infection Consortium (ISARIC) 
Clinical Characterisation Protocol CCP (https://isaric.net/ccp), reviewed and 
approved by the national research ethics service, Oxford (13/SC/0149). 
Samples from clinical specimens were processed at Containment Level 3 at 
the University of Liverpool by myself and a larger team. 
 
4.2.3 Biosafety 
All work was performed in accordance with risk assessments and standard 
operating procedures approved by the University of Liverpool Biohazards Sub-
Committee and by the UK Health and Safety Executive. Work with SARS-CoV-
2 was performed at Containment Level 3 by personnel equipped with respirator 
airstream units with filtered air supply. 
 
4.2.4 Cell culture and virus 
Influenza virus A/HKx31 (X31, H3N2) was propagated in the allantoic cavity of 
9-day-old embryonated chicken eggs at 35oC for 72 h. Titres were previously 
determined by an influenza plaque assay using MDCK cells.  
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A UK isolate of SARS-CoV-2 (hCoV-2/human/Liverpool/REMRQ0001/2020), 
which was cultured from a nasopharyngeal swab from a patient and passaged 
a further 4 times in Vero E6 cells (Patterson, 2020 #17). The fourth passage 
of virus was cultured with a MOI of 0.001 in Vero E6 cells with DMEM 
containing 4% FBS and 0.05 mg/mL gentamycin at 37°C with 5% CO2 and 
was harvested 48 h post inoculation. Virus stocks were stored at −80°C. The 
intracellular viral genome sequence and the titre of virus in the supernatant 
were determined.  Direct RNA sequencing was performed as describe 
previously (Davidson et al., 2020) and an inhouse script was used to check for 
deletions in the mapped reads. The Illumina reads were mapped to the 
reference sequence genome using HISAT and the consensus genome was 
called using an in-house script based on the dominant nucleotide at each 
location on the genome. The sequence has been submitted to Genbank, 
accession number MW041156.  
 
4.2.5 Mice 
Animal work was approved by the local University of Liverpool Animal Welfare 
and Ethical Review Body and performed under UK Home Office Project 
Licence PP4715265.  Mice carrying the human ACE2 gene under the control 
of the keratin 18 promoter (K18-hACE2; formally B6.Cg-Tg(K18-
ACE2)2Prlmn/J) were used in this study were purchased from Jackson 
Laboratories. Mice were maintained under SPF barrier conditions in 
individually ventilated cages.  
 
4.2.6 RNA extractions 
 
1ml of TRIzol reagent (Thermofisher) was added to mice lung tissue which 
were then homogenised using a Bead Ruptur 24 (Omni international) at 2 
meters per second for 30 seconds. Tissue homogenates were clarified by 
centrifugation at 12,000g for 5 minutes. The RNA extractions and DNase 
treatments were carried out as described in Chapter 2.  
 
 219 
4.2.7 Library preparation for long read sequencing 
 
Sequencing libraries were prepared as described in Chapter 3.  
 
4.2.8 Transcriptomics analysis and identification of differentially 
expressed genes 
Multiplexed sequencing reads were base called and demultiplexed by Guppy 
basecaller.  After assessment of read length using Nanoplot (De Coster et al., 
2018), minimap2 was used to index and map reads to the reference 
transcriptome (Mus_musculus.GRCm38.cdna.all) to generate alignment files 
using the –sr -N 100 -p 1.0 parameters (Li, 2018). Alignment files were sorted 
and indexed with samtools before counting reads using Salmon with the 
corresponding annotation file (Mus_musculus.GRCm38.101.gtf) from 
Ensembl using –noErrorModel -l U parameters (Li, 2018, Patro et al., 2017).  
 
The edgeR package was used to normalise sequencing libraries and identify 
differentially expressed genes, defined as at least a 2-fold difference from 
the mock infected group (n=5) and a false discovery rate (FDR) less than 
0.05 (Robinson et al., 2010). 
 
Principle component Analysis (PCA), volcano plots, heatmaps and Venn 
diagrams were produced in R studio using the following packages: edgeR, 
ggplot2 and pheatmap.   
 
 
4.2.9 Comparing differentially expressed genes identified in humans 
and mice 
 
To make datasets from mice and humans comparable, genes identified as 
differentially expressed in the mice dataset were converted to human gene 
names using BioMart in RStudio (Durinck et al., 2009). Venn diagrams were 
then produced in RStudio using the VennDiagram package (Chen and 




Due to the emergence of 2020-2021 influenza virus season during the 
projected peak of the SARS-CoV-2 pandemic in the UK, the impact of a 
sequential infection of IAV and SARS-CoV-2, was investigated in an animal 
model. This was achieved by using RNA from a transgenic mouse model that 
had been sequentially infected with IAV and SARS-CoV-2. Samples were 
taken longitudinally and sequenced using the long-read length cDNA-PCR 
sequencing protocol as described with the human blood samples based on the 
Oxford Nanopore platform.  
 
4.3.1 Distinct transcriptional signatures are associated with infection 
The transcriptional profile of lung samples can provide an insight on the host 
response to infection for a respiratory pathogen. Therefore, lung samples were 
taken at Day 6 and Day 10 post IAV infection from all four groups of mice. Total 
RNA was purified from cells and both host and viral mRNA (and genomic RNA 
in the case of SARS-CoV-2) were sequenced using the Oxford Nanopore 
oligo-dT cDNA synthesis approach to identify and quantify mRNA. A multiplex 
of 5-10 sequencing libraries were loaded onto a flow cell and sequenced on 
an Oxford Nanopore GridION for up to 72 hours. The read length was 
assessed using NanoPlot, which revealed that the average read length from 
this experiment was 259.2 (Figure 4.1), therefore, the data set was analysed 
using parameters for long and short read mapping (Table 4.1). Using the short-
read parameter with minimap2 to map to the mouse transcriptome improved 
the mapping rate of transcripts within the majority of samples.  
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Figure 4.1: RNA was extracted from post-mortem mice lung tissue and prepared for 
sequencing on the GridION. Following 72 hours of sequencing and basecalling of raw 
fast5 files, fastq lengths were assessed with Nanoplot to determine the mean read 
length and quality score. The mean read length obtained from this dataset was 259.2 












Table 4.1: The number of reads obtained per sample and the number and 
percentage of those that mapped to the host transcriptome. Mapping rate is 
















with -ax sr 
Uninfected 
(1) 
536504 170726 32% 147539 28% 
Uninfected 
(2) 
423992 130042 31% 114902 27% 
Uninfected 
(3) 
503418 149532 30% 135923 27% 
Uninfected 
(4) 
561403 119612 21% 118456 21% 
Uninfected 
(5) 
490923 148330 30% 135495 28% 
SARS-CoV-2 
Only Day 6 
(1) 
1065660 551193 52% 607426 57% 
SARS-CoV-2 
Only Day 6 
(2) 
1264683 483084 38% 594401 47% 
SARS-CoV-2 
Only Day 6 
(3) 
1620821 309330 19% 636983 39% 
SARS-CoV-2 
Only Day 6 
(4) 
1744801 773900 44% 917765 53% 
SARS-CoV-2 
Only Day 10 
(1) 
2451041 687274 28% 1183853 48% 
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SARS-CoV-2 
Only Day 10 
(2) 
1719123 763271 44% 887067 52% 
SARS-CoV-2 
Only Day 10 
(3) 
1988303 377495 19% 743625 37% 
SARS-CoV-2 
Only Day 10 
(4) 
1952677 345050 18% 812314 42% 
IAV only Day 
3 (1) 
1532669 524194 34% 705028 46% 
IAV only Day 
3 (2) 
1608979 674688 42% 769092 48% 
IAV only Day 
3 (3) 
1165274 567364 49% 640901 55% 
IAV only Day 
3 (4) 
1020801 536635 53% 547149 54% 
IAV only Day 
6 (1) 
2079511 148012 7% 752783 36% 
IAV only Day 
6 (2) 
1672738 653110 39% 776150 46% 
IAV only Day 
6 (3) 
2081581 375861 18% 824306 40% 
IAV only Day 
6 (4) 
2171045 349901 16% 703419 32% 
SARS-CoV-2 
& IAV Day 6 
(1) 
1595117 661289 41% 885290 56% 
SARS-CoV-2 
& IAV Day 6 
(2) 
1617092 252895 16% 587004 36% 
SARS-CoV-2 
& IAV Day 6 
(3) 
1635948 241966 15% 660923 40% 
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SARS-CoV-2 
& IAV Day 6 
(4) 
1369866 603698 44% 738358 54% 
SARS-CoV-2 
& IAV Day 10 
(1) 
1752491 106561 6% 567807 32% 
SARS-CoV-2 
& IAV Day 10 
(2) 
1442340 402428 28% 643284 45% 
SARS-CoV-2 
& IAV Day 10 
(3) 
1776963 168314 9% 625491 35% 
SARS-CoV-2 
& IAV Day 10 
(4) 
1603647 755179 47% 896439 56% 
 
 
Transcripts were aligned to the Mus musculus transcriptome then the 
alignment file was used to count the number of transcripts using Salmon (Patro 
et al., 2017). Transcript counts were normalised using the edgeR package 
before identifying differentially expressed transcripts using the transcription 
profile from mock infected mice as the control profile. A total of 970 
differentially expressed gene transcripts were observed in comparison to mock 
infected animals out of a total of 3495 gene transcripts identified when using 
the default mapping parameters. With the short-read parameter, a total of 1891 
differentially expressed genes were observed out of a total 6679 genes, 
therefore, analysis presented is from the latter. Principle component analysis 
(PCA) revealed overlapping transcriptional profiles between infection groups 
(Figure 4.2A). Overlapping signatures were likely to be indicative of the non-
specific anti-viral response. Contrast matrices were made between mice that 
were coinfected versus mice that were mock infected and mice that were singly 
infected (Table 4.2). The transcriptomic profile in mice 10 days post infection 
with IAV showed overlap with the healthy controls, consistent with resolution 
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of infection and regeneration seen in the pathology described in Clark et al 
(2020). The data indicated that coinfection at day 10 versus IAV day 10 had 
more differences with 36 gene transcripts at higher abundance, highlighted in 




Table 4.2: Number off differentially expressed genes with an FDR value less 
than 0.05 and a log2 fold change more than 2 and less than -2 compared to 
mock infected mice. Coinfection day 6 and day 10 were compared to day 6 
and 10 of individual IAV and SARS-CoV-2 infection. More differentially 
expressed genes are identified when using the short read mapping parameter, 
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Figure 4.2: RNA sequencing analysis from hACE2 mice lung homogenates 
from mice infected with either IAV only, SARS-CoV-2 only or IAV and SARS-
CoV-2 (n=4-5). A. Principal component analysis performed for 29 samples with 
log2 transformed counts per million (cpm). B. The top 75 differentially 
expressed gene transcripts across 4 groups are shown. C. Volcano plots 
comparing differentially expressed genes from each infection group vs mock 
infected. The horizontal dashed line is representative of a q-value <0.05, and 
the vertical dashed line is representative of a log2 fold-change of 2. Significant 
differentially expressed gene transcripts are marked as red. (A: IAV Day 6, B: 
IAV Day 10, C: SARS-CoV-2 Day 3, D: SARS-CoV-2 Day 7, E: Coinfection 
Day 6, F: Coinfection Day 10). 
 
Gene ontology analysis of gene transcripts that were significantly different in 
abundance at all time points revealed enrichment of gene clusters involved in 
the innate immune response, immune system regulation and cellular response 
to cytokine stimulus, interferon beta and interferon gamma (Figure 4.5).  
 
4.3.2 Interferon and cytokine responses are upregulated in response to 
infection, and maintained in coinfection 
Following gene ontology analysis, gene transcripts were grouped by biological 
process terms and presented as heatmaps to allow for direct comparison of 
their abundance across the experimental groups (Figure 4.3). SARS-CoV-2 
infection resulted in the increased abundance of gene transcripts involved in 
the interferon and cytokine signalling pathways. When mice were infected with 
both SARS-CoV-2 and IAV, certain gene transcripts within these pathways 
remained increased in abundance at later time points, in comparison to 
individual IAV infection at day 10 (Figure 4.3). These included Ifit1, Ifit3, Ifit3b, 
Isg15, Irf7 and Cxcl10. This suggested that IAV infected only animals were on 
a recovering trajectory whereas co-infected mice were demonstrating a 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.3: Following gene ontology cluster analysis, heatmaps were generated using pheatmap in 
RStudio. A. Negative effects on viral replication (GO:0045071), B. Cellular response to IFN-b 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.4: Transcripts were converted into counts per million (cpm) and normalised 
using the TMM method in Edge R. The top significant genes determined by FDR 
values were plotted as boxplots with ggplot2 to highlight the difference in abundance 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.3  dominant changes were observed in SARS-CoV-2 phenotype  
Figure 4.5: ClusterProfiler was used to compare gene cluster enrichments for Biological process, Molecular 
function and Cellular component GO terms associated with increased and decreased transcripts for each 
condition.  
Coinfection Day 3 Coinfection Day 7 IAV Day 6 IAV Day 10 SARS−CoV−2 Day 3 SARS−CoV−2 Day 10




parallel fiber to Purkinje cell synapse
excitatory synapse
cell surface
MHC class I peptide loading complex
external side of plasma membrane
extracellular membrane−bounded organelle
symbiont−containing vacuole






















Cellular Component GO Terms
Coinfection Day 3 Coinfection Day 7 IAV Day 6 SARS−CoV−2 Day 3 SARS−CoV−2 Day 10
Down Up Down Up Down Up Down Up Down Up






























Molecular Function GO Terms
Coinfection Day 3 Coinfection Day 7 IAV Day 6 IAV Day 10 SARS−CoV−2 Day 3 SARS−CoV−2 Day 10
Down Up Down Up Down Up Down Up Down Up Down Up
regulation of immune response
antigen processing and presentation
T cell mediated cytotoxicity
lymphocyte mediated immunity
cellular response to chemokine
response to chemokine
chemokine−mediated signaling pathway
positive regulation of T cell mediated cytotoxicity
leukocyte mediated cytotoxicity
antigen processing and presentation of endogenous peptide antigen via MHC class Ib
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathw ay, TAP−independent
positive regulation of leukocyte mediated cytotoxicity
viral genome replication
positive regulation of calcium ion transport
positive regulation of cell killing
regulation of defense response
G protein−coupled receptor signaling pathw ay
positive regulation of monocyte chemotaxis
positive regulation of mononuclear cell migration
sensory perception
response to cytokine
cellular response to cytokine stimulus
granulocyte migration
interspecies interaction between organisms
negative regulation of multi−organism process
negative regulation of viral process
positive regulation of leukocyte migration
regulation of cell killing
positive regulation of response to external stimulus
antigen processing and presentation of peptide antigen via MHC class I
cell killing
cytokine production
regulation of leukocyte mediated cytotoxicity
chemotaxis





positive regulation of immune response
positive regulation of immune system process
response to interferon−beta
cellular response to interferon−beta
immune effector process
response to other organism
















Biological Process GO Terms
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4.3.4 No dominant changes were observed in SARS-CoV-2 throughout 
infection 
SARS-CoV-2 virus from mice lungs were also sequenced with the artic 
protocol as described in Chapter 2 to determine whether any mutations arose 
throughout the time course of infection. Figure 4.6 illustrates that the only 
mutation that was novel between Day 3 and Day 7 infected mice out of the 
whole cohort was a Q22R mutation in orf1ab which was identified in one out 



























ORF1ab1 L 3606 F
ORF1ab1 N 2228 T
ORF1ab1 Q 22 R
ORF1ab2 A 2006 V
ORF1ab2 A 2513 V
S H 655 Y
















4.3.5 Comparison of human and mice DGE genes from nanopore 
experiments 
 
The number of reads obtained from the human blood RNA samples was 
greater than the mice lung RNA samples, therefore more differentially 
expressed genes were identified within the human datasets (Table 4.3) To 
compare mice DGE genes to human DGE genes from SARS-CoV-2 and IAV 
infection, mice gene names were converted to human gene names using 
BioMart in RStudio to allow for direct comparison in the MinION datasets.  
 
Table 4.3: Number of up and down regulated genes identified from MinION 
data that is compared for further investigation 











860 267 388 840 298 329 
Down 
regulated 
274 27 47 438 96 41 
 
For SARS-CoV-2, 17 up regulated genes were shared between human and 
mice at both timepoints. Where mice at day 3 shared more genes (21) than at 
day 7 (20) with the human genes. No down-regulated genes were shared 
between mice and humans in this analysis. For IAV infections in mice and 
humans, 37 upregulated genes were shared between mice at day 3 of infection 
and humans and 12 genes were identified in at day 7 with the human genes. 
Figure 4.6: Virus sequence obtained from mice lungs were interrogated for 
mutants in comparison to the NC_045512.2 reference. The only unique 




Whereas only one downregulated gene was shared between mice at day 3 
and 7 of infection and humans (Figure 4.7).  
 
Genes at the intercepts in Figure 4.7 were extracted and presented in Table 
4.4. More similarities were observed between human influenza patients and 







































Figure 4.7: Venn diagrams of up and down regulated genes shared between humans and 
mice at day 3 and day 7 of SARS-CoV-2 infection and day 6 and day 10 of IAV infection. 
Mice gene names were converted to human gene names to allow for comparison. A: SARS-
CoV-2 up, B: SARS-CoV-2 down, C: IAV up, D: IAV down.  
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Table 4.4: transcripts identified as up or down regulated in mice were 
converted to human gene names using BiomaRt and were compared to genes 
identified in the human data set. 
SARS-CoV-2 IAV 













C1QC C1QB C1QA PARP12 C1QA ENKUR FOS 
DDX60 C1QC C1QB PARP14 C1QC   
EIF2AK2 CALN1 C1QC PARP9 CALN1   
IFI44 IFI44 CMPK2 PGS1 EMSY   
IFIT2 IFIT2 DDX60 PRELP LILRA5   
IFIT3 IFIT3 DHX58 RNF213 LILRA6   
IFITM3 IFITM3 FKBP5 RSAD2 NUP98   
IGF2BP2 IGF2BP2 IFI44 RTP4 OAS1   
ISG15 ISG15 IFIT2 SLA OAS2   
MS4A4A MS4A4A IFIT3 TCN2 PDE6A   
MS4A4E MS4A4E IFITM3 TMEM106A TMEM106A   
MX1 MX1 IRF7 UBE2L6 UNC13C   
OAS1 OAS1 ISG15 UNC13C    
OAS2 OAS2 LGALS3BP USP18    
OAS3 PGS1 LILRA5 ZBP1    
PGS1 PRELP LILRA6     
PRELP SERPING1 MS4A4A     
RNF213 UNC13C MS4A4E     
RSAD2 USP18 MX1     
UNC13C ZBP1 OAS1     
USP18  OAS2     





To further investigate the host response described in Chapter 3, an ACE2 
transgenic mice model was used to compare the host response to IAV and 
SARS-CoV-2 infections, whilst determining the impact of sequential infection 
of both due to the threat of Influenza seasons and co-infections.  Although 
sequencing libraries from mice and human RNA samples were prepared the 
same way and with the same protocol, sequencing performance varied. The 
read length of transcripts from the blood transcriptome was approximately 750 
nucleotides long, whereas the mice transcripts were much shorter at 250 
nucleotides. This may be due to the fact the RNA from mice was obtained from 
tissue post-mortem and to extract the RNA, there was a tissue homogenisation 
step, which may have encouraged fragmentation. For future work for 
elucidating the transcriptome with long-read technology, further optimisations 
may be beneficial for extractions as the shorter reads seemed to have also 
impacted the mapping rate to the mice transcriptome. This was improved by 
adapting the alignment step in the bioinformatics analysis with the short reads 
parameter in minimap2.  
 
Regardless, the data obtained still demonstrated that sequential infection of 
IAV then SARS-CoV-2 seemed to prolong the inflammatory response which 
was supported by findings in pathology which are reported in Clark et al, 2020. 
In general, the top genes identified within this dataset follow similar trends. For 
example, in singular infections, the abundance of the gene decreases between 
the first time point and second time point of infection. However, the decrease 
is less in coinfected mice over time, especially in comparison to IAV. Ifit3, 
Gbp7, Ifi44, Ly6a, Oasl2 and Irf7 are a selection of genes that demonstrate 
this in Figure 4.4.  
 
Ly6c1 is transcript that appears to increase over time in coinfected mice and 
SARS-CoV-2 only mice where in IAV only mice it decreases over time. Ly6c1 
(lymphocyte antigen 6 complex, locus C1) is regulated by interferon gamma, 
showed to be sustained in SARS-CoV-2 and Coinfection over time. This 
transcript may play a role in the development and maturation of lymphocytes 
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(Seo et al., 2011). Previous studies have shown an association with Ly6C 
expression and short-lived effector T-cells where Ly6C expression was 
associated with effector CD4+ T-cell antiviral activity but inversely correlated 
with memory potential in Murine g-Herpesvirus 68 (Marshall et al., 2011, Hu et 
al., 2015, DeLong et al., 2018).  
 
APOBEC was identified as one of the most increased in abundance genes 
within the dataset. Chapter 2 discusses APOBEC in the context of a bias in 
C>U mutations observed in the SARS-CoV-2 genome throughout the 
pandemic. Therefore, SARS-CoV-2 genomes were sequenced with the ARTIC 
protocol mentioned in Chapter 2 to determine whether any dominant mutations 
were acquired in the presence of upregulated APOBEC. At the consensus 
level, there were no differences in the mutational spectra observed in the 
genomes in the mice studies. The only mutation that was novel between Day 
3 and Day 7 infected mice out of the whole cohort was a Q22R mutation in 
orf1ab which was identified in one out of the four coinfected mice. This 
mutation has been reported previously in a Lebanese isolate (Abou-Hamdan 
et al., 2021).  
 
This transcriptomics analysis contributed to a wider study (Clark et al., 2021). 
Weight loss data revealed that coinfected mice had an increased weight loss 
and more rapid mortality. Coinfection reduced the SARS-CoV-2 viral load 
determined by qRT-PCR at day 6 but not day 10 when comparing to singularly 
infected. This study identified that co-infection in the K18-hACE2 transgenic 
mice showed similar histological changes that were comparable with IAV 
infection at earlier time points, however, appeared to be slightly more 
extensive in coinfected mice. Histological interpretations supported 
observations made in qRT-PCR data where less SARS-CoV-2 antigen was 
identified at day 6 of coinfection. By day 10 of the infection time course, mice 
infected with only IAV showed that infection had nearly fully resolved with 
evidence of regenerative processes. SARS-CoV-2 only infected mice at day 7 
displayed multifocal areas with type II pneumocyte activation and syncytial cell 
formation, in addition to mononuclear infiltration and mild to moderate 
lymphocyte-dominated vasculitis and perivascular infiltration. Desquamative 
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pneumonia was also observed with intra-alveolar macrophages/type II 
pneumocytes, odema and fibrin deposition. It was also noted that 
macrophages and T-cells dominated the infiltrates whereas B-cells were found 
disseminated and in low numbers.  
 
In co-infected mice, the histological changes associated in SARS-CoV-2 only 
mice were more pronounced, however, the evidence regenerative processes 
observed in the IAV only mice were equally pronounced. Macrophages were 
the dominating infiltrating cells, although, the number of T-cells were 
comparatively low, and B-cells were rare. Interestingly, 2 out of the 4 co-
infected mice displayed mild to moderate meningoencephalitis associated with 
the midbrain and brainstem.  
 
Ultimately, this analysis demonstrated that sequential infection with IAV then 
SARS-CoV-2 resulted in more severe disease phenotypes when comparing to 
singularly infected mice. Previous studies have shown that sequential 
infections of different subsets of Influenza B Virus in a ferret model were able 
to provide protection when separated by 3 days (Laurie et al., 2018). The 
sequential infection of two distinct respiratory viruses, IAV and SARS-CoV-2 
did not provide resistance to the latter, however, viral shedding was reduced. 
This could be explained by the different time scales of weight loss between co-
infected mice and SARS-CoV-2 singularly infected mice. Mice infected with 
SARS-CoV-2 only exhibit weight loss at 4 days post infection where co-
infected mice are beginning to recover from IAV infection before succumbing 
to a delayed SARS-CoV-2 infection. Laurie et al (2018) demonstrate that viral 
shedding of the second virus was reduced, however, unlike in this study, the 
severity of disease was not influenced.  
 
A prior rhinovirus infection has been shown to interfere with IAV infections in 
vitro and in vivo (Nickbakhsh et al., 2019). The proposed mechanism for this 
interference is through the induction of interferon stimulated genes (ISGs) 
following an initial rhinovirus infection. Likewise, IAV infections result in the 
activation of the interferon response and thus the upregulation of ISGs which 
are responsible for the antiviral state which is able to limit infection (Forero et 
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al., 2017) (Killip et al., 2015). This is the mechanism that is suspected to inhibit 
the incoming SARS-CoV-2 infection at 3 days post IAV infection in this study 
and explains the lower viral load revealed through RT-qPCR. IAV viral load at 
day 6 was comparable between co-infected and singularly infected mice, 
supporting that the sequential of SARS-CoV-2 infection does not interfere with 
the prior IAV infection.  Further evidence for the lack of interference on the IAV 
infection, is that both co-infected and singularly infected mice were negative 
for IAV according to qPCR and immunohistology, suggesting that SARS-CoV-
2 infection does not prolong the initial IAV infection. Transcriptomic analysis 
supported that IAV day 10 mice had transcripts in the same abundance as the 
mock infected mice, such as Ifit3, Irf7, Isg15, Ligp1, Gbp6, and Gbp7.  
 
Despite evidence of regenerative processes in the coinfected mice at day 10, 
there were also several hallmarks of acute lung injury, including perivascular 
infiltration, vasculitis, and oedema. This is consistent with the viral load of 
SARS-CoV-2 observed at day 10 of co-infection and the sustained 
abundances of ISG transcription and other genes associated with cytokine and 
IFN-y signalling. Interestingly, Cfap126 is shown to be decreased in 
abundance at day 6 of coinfection and then increased at day 10 which is 
indicative of lung injury (Clark et al., 2021).  
 
During the pandemic, there have been signs of neurological implications from 
SARS-CoV-2 infections (Ellul et al., 2020). Previously, SARS-CoV has been 
shown to be able to enter the brain in K18-hACE2 mice models without notable 
inflammation unlike SARS-CoV-2 (Netland et al., 2008). The virus has been 
shown to spread throughout the brain at around 3 days post infection when 
introduced into the animal intranasally (McCray et al., 2007). This study is 
unable to determine viral spread to the brain at early stages of infection, 
however, the distribution of the virus antigen and inflammatory changes 
observed through immunohistology are consistent with ascending infection 
from the nasal cavity via the olfactory bulb (Netland et al., 2008). Co-infected 
mice presented with a more substantial spread of the virus within the brain with 
a more pronounced perivascular infiltration, with evidence of the breakdown of 
the blood-brain-barrier. The mechanism of the enhanced neurological SARS-
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CoV-2 infection resultant of a prior IAV infection is currently unknown. Brain 
infections have been documented in influenza infections (Hosseini et al., 2018, 
Chaves et al., 2014, Ekstrand, 2012), however, is associated with neurotropic 
and highly pathogenic strains and occurs due to the breakdown of the BBB 
(Wang et al., 2010). The integrity of the BBB is reduced by proinflammatory 
cytokines which can disrupt the tight junctions which are maintained by the 
microvascular endothelial cells (Miner and Diamond, 2016). Although the IAV 
X31 strain used in these experiments did not give rise to brain infection, it is 
suspected that the cytokine response in co-infected mice compromised the 
BBB integrity, thus allowing SARS-CoV-2 better access to the brain.  
 
As this thesis had the opportunity to study the host transcriptome in humans 
at point of care as well as in mice during dual and single infections of SARS-
CoV-2 and IAV. Section 5.1 provides a comparison between genes that were 
identified in both species. Although the transcriptomes are derived from 
different tissues, this may provide insight into essential genes involved in 
infection.  
 
Although different tissues may have different responses, as well as species, 
this comparison may give insight into key host factors involved in SARS-CoV-
2 infection. The identified transcripts from SARS-CoV-2 and IAV infected mice 
and humans seem comparable, where there are more similarities between IAV 
and humans at earlier timepoints, perhaps as the day 10 IAV mice were 
recovering from infection and patients are at point of care.  
 
Complement activation is indicated in both SARS-CoV-2 and IAV infections 
across humans and mice (C1QC and C1QB). Complement overactivation is 
thought to contribute to the exuberant host response (Ng and Powell, 2021). 
This pathway is thought to address both the hyperinflammation and the 
hypercoagulability observed in COVID-19 disease (Hill et al., 2013, Bryce et 
al., 2020, Ackermann et al., 2020, Varga et al., 2020). The complement 
pathway has also been implicated in SARS-CoV and MERS-CoV infections, 
where inhibition of these pathways has been proposed to reduce disease 
burden (Gralinski et al., 2018, Jiang et al., 2018). From this dataset, 
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SERPING1 was only present in the later time point in mice infected with SARS-
CoV-2. SERPING1 is also involved in the complement pathway and is heavily 
associated with coagulation and has previously been shown to interact with 
SARS-CoV-2 proteins (Holcomb et al., 2021). 
 
As expected, the majority of transcripts are effectors of the type I interferon 
antiviral response (Schoggins et al., 2011). DDX60 has been previously shown 
to promote RIG-I-like receptor mediated signalling (Miyashita et al., 2011). 
Expression of DDX60 increases after viral infection where the protein localises 
to the cytoplasm and following infection, DDX60 proteins bid to RIG-I proteins. 
DDX60 has been shown to be essential for RIG-I- or MDA5-dependent type I 
interferon and interferon inducible response during viral infection (Miyashita et 
al., 2011, Oshiumi et al., 2015). EIF2AK2 encodes for Protein Kinase R (PKR) 
and is an interferon stimulated gene (Gal-Ben-Ari et al., 2019). PKR detects 
cellular stress and is a pattern recognition receptor due to its ability to detect 
dsRNA (Elde et al., 2009).  
 
Unsurprisingly, IFIT genes were identified among both datasets. IFIT genes 
encode for proteins that are induced in response to IFN, viral infection or 
PAMP recognition (Sen and Sarkar, 2007). IFIT proteins have inhibitory effects 
on viral replication and can achieve this through a number of distinct 
mechanisms such as suppressing the initiation of translation, binding to 
uncapped viral RNA and by sequestering viral RNA or proteins in the 
cytoplasm (Diamond and Farzan, 2013). IFITM3 is a transmembrane protein 
which is expressed in basal conditions, however, is increased upon stimulation 
by IFNs (Diamond and Farzan, 2013). IFITM3 has been shown to inhibit IAV 
replication and when depleted, replication was enhanced (Brass et al., 2009). 
IFITM proteins interfere with viral replication steps that precede the fusion of 
viral and cellular membranes where IFITM proteins have been shown to 
restrict SARS-CoV entry and replication (Feeley et al., 2011, Huang et al., 
2011b). IFITM3 has been consistently identified in transcriptomic datasets for 
SARS-CoV-2 derived from humans and mammals as an early upregulated 
gene, consistent with these datasets (Hachim et al., 2020). Functional 
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assessment of IFITM genes have shown that they have restrictive capacity 
against SARS-CoV-2 (Shi et al., 2021). 
 
ISG15 has been shown to increase in abundance in the presence of IFN, 
although is present within cells at basal levels and conjugated to host proteins, 
including MDA5 (Liu et al., 2021a). This ISGlyation of MDA5 may be a priming 
mechanism where upon upregulation of ISG15 primes MDA5 to enter a ‘kick 
start’ mode (Liu et al., 2021a). ISG15 is involved in other pathways within the 
IFN response where in its unconjugated form reinforces USP18-mediated 
IFNAR-signal inhibition (Malakhova et al., 2006, Speer et al., 2016, Zhang et 
al., 2015). Interestingly, the SARS-CoV-2 PLpro domain of the Nsp3 protein 
blocks MDA5 signalling through direct de-ISGlyation (Klemm et al., 2020, Shin 
et al., 2020, Liu et al., 2021a). Other interferon stimulated genes such as MX1, 
RSAD2 (Viperin), OASs are increasing in abundance in response to infection. 
 
As this data derives from nanopore sequencing, the whole transcriptome from 
patients at point of care or mice was not captured. However, the transcripts 







Chapter 5: Conclusions and future directions 
 
The main aims of this thesis were to design a viral genome sequencing 
approach for MERS-CoV and SARS-CoV-2 to facilitate and support further 
genomic studies into coronavirus variation, evolution and tissue tropism in 
post-mortem samples.  In addition to viral genome sequencing, this thesis 
utilises transcriptomics and exploratory analysis to study the host response to 
SARS-CoV-2 in patients at point of care and hACE2 mice.  
 
Although MERS-CoV is only associated with sporadic cases throughout Saudi 
Arabia, the fatality rate is high at approximately 35%. Previous studies have 
highlighted that transmission events can occur from camels to humans, and 
vice versa. Lessons learnt from previous outbreaks caused by RNA viruses 
demonstrate the importance of genomic surveillance. Using nanopore 
technologies at the heart of the West Africa Ebola virus outbreak and Lassa 
virus in Nigeria allowed for the identification of transmission events, allowing 
for appropriate public health measures to be put in place (Carroll et al., 2015, 
Kafetzopoulou et al., 2018, Kafetzopoulou et al., 2019, Quick et al., 2016a). 
Chapter 2 of this thesis initially aimed to design an amplicon sequencing 
approach compatible with nanopore sequencing to support rapid genomic 
surveillance that could be utilised rapidly when cases emerged. Following 
validation on RNA from MERS-CoV infected cells, respiratory samples from 
patients with MERS-CoV were assessed using 30 amplicon and 15 amplicon 
approaches confirm compatibility with clinical samples. Genomes derived from 
these patients were then compared to previously published MERS-CoV 
sequences and the data was interrogated for deletions and minor variation. 
This project was unfortunately paused due to the emergence of SARS-CoV-2 
where resources were redirected to focus on SARS-CoV-2. Despite this 
change of direction, the approach designed for MERS-CoV was ultimately a 
success, and work on SARS-CoV-2 can now improve this methodology.  
 
The MERS-CoV sequencing approach was able to generate full consensus 
sequences from clinical samples which could be utilised for phylogenetics, 
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therefore fulfilling one of the aims of this thesis. Minor variation was also 
assessed from this data, although nanopore sequencing which is known for its 
inherently high error rate, the proportion of changes may still be of interest. For 
example, with longitudinal samples you could assess the impact of nucleotide 
and nucleoside analogues on the variation within viral genomes, however, 
there were no comparisons to be made in this case. Nanopore technologies 
are rapidly improving their products as well as their informatic pipelines. 
Development of bioinformatic tools and pipelines in the future may make this 
type of analysis more reliable. For MERS-CoV, too few samples were included 
to interpret the results. Deletions were observed in ORF4a, ORF5, N and 
ORF1A in MERS-CoV sequences. Deletions in this region may have 
implications on virus pathogenesis, however, would require further 
investigation to prove this. For example, ORF4A is able to inhibit early antiviral 
responses (IFN α/β) in the host (Yang et al., 2015), likewise ORF5 has been 
implicated in the reduction of the inflammatory response, therefore deletions 
within these genes may attenuate the disease if observed in the dominant 
population (Menachery et al., 2017).  
 
When the first 16 sequences were available through GISAID, primers were 
designed against the SARS-CoV-2 genome in late January 2020. This allowed 
for rapid investigation of SARS-CoV-2 genomes upon the arrival of the first 
patients to Royal Hospital in February 2020. Through this approach mutations 
and deletions were assessed in clinical samples. Through analysis of a subset 
of samples, it was identified that deletions were present in viral subpopulations 
within people. Deletions have been identified by others throughout the SARS-
CoV-2 pandemic where it is associated with a milder disease, suggesting that 
deletions may attenuate the virus (Lau et al., 2020, Young et al., 2020a). 
Although, deletions within the spike gene may facilitate immune escape (Abani 
et al., 2021, McCarthy et al., 2020). The deletions analysis from patients was 
observational, therefore no functional implications of these deletions can be 
deduced. Due to the progression of the pandemic, the primers designed and 
presented in this thesis could be updated to accommodate for the VOCs that 
have emerged.  
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Further into the pandemic, network ARTIC had designed their amplicon 
sequencing methodology which generated shorter amplicons and is now gold 
standard for genomic surveillance worldwide. Although longer amplicons may 
be more useful for determining recombination events, the generation of shorter 
amplicons were better at recovering viral genome sequencing data from post-
mortem tissue. Although currently literature on recombination events in the 
circulating SARS-CoV-2 is limited, one study identified 16 out of 279,000 
recombinant viruses in COG-UK data using consensus sequences (Jackson 
et al., 2021). Though these events may be rare and in low abundance in 
epidemiological data, it is important to consider as the pandemic progresses. 
 
The final part of Chapter 2 demonstrates the utilisation of viral genome 
sequencing as a tool to map organo-tropism of SARS-CoV-2. SARS-CoV-2 is 
able to enter multiple tissues in the body through the ACE2 receptor, yet only 
causes pathology in the respiratory tract (Dorward et al., 2020). Viral RNA is 
detectable in tissue in fatal COVID cases from over 30 days from first reports 
of symptoms, highlighting an element of viral persistence. Evidence from this 
study suggests that active replication and transcription is occurring within a 
later timeframe of disease. Work in this thesis contributed to a wider study that 
suggests that it is in fact immune-mediated damage that contributes to fatality. 
The viral genomes recovered through nanopore sequencing were assessed 
for SNPs, to determine whether variants were emerging in different tissues. 
This was not observed, however, future work should consider this surveillance 
due to lessons learnt from avian coronavirus IBV, where virus adaptations 
within the host occurs resulting in pathology in different tissues (Jiang et al., 
2020, Legnardi et al., 2020, Franzo et al., 2021). The sequencing approach 
used to sequence viral genomes from post-mortem tissue only recovered 
partial consensus sequences, therefore, illumina sequencing could be used to 
acquire more information as it is more sensitive.  
 
The Network ARTIC includes a primer complementary to the leader sequence, 
whereas the primer schemes designed for MERS-CoV and SARS-CoV-2 do 
not. To increase the versatility of the method described in this thesis, this 
primer could be added to facilitate the study of sgmRNAs. The detection of 
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sgmRNA implies that the viral replicase is actively undergoing the process of 
discontinuous transcription, to allow for the production of viral proteins and can 
be a useful tool. Studies conducted later on in the pandemic have seen 
differential usage of sgmRNA in different viral lineages of SARS-CoV-2 (Parker 
et al., 2021) 
 
The post-mortem study was the first indication of a hyper-inflammatory 
response and immunopathology in fatal COVID-19. To investigate the host 
response in more detail, blood samples were collected from COVID-19 and 
Influenza patients at point of care for the assessment of key host factors in 
early time points in disease. Through differential gene expression analysis, a 
plethora of transcripts were identified that were unique to COVID-19 vs Flu, or 
fatal vs non-fatal COVID. Immunoglobulin transcripts were identified at an 
increased abundance when comparing COVID-19 patient’s transcriptomes to 
Influenza patient transcriptomes and fatal to non-fatal COVID-19.  
 
In the influenza and COVID-19 and fatal and non-fatal COVID-19 immune 
subset comparisons, significant differences were observed in neutrophils. 
Neutrophils were in higher abundance in COVID and influenza in comparison 
to the healthy controls and higher in fatal COVID-19. This is consistent with 
previous studies showing an elevation of neutrophils in blood and lungs in 
severe COVID-19 disease (Kuri-Cervantes et al., 2020, Li et al., 2020d, Liao 
et al., 2020, Schurink et al., 2020, Radermecker et al., 2020). Neutrophil-to-
lymphocyte ratios were identified as a clinical predictive marker for developing 
severe disease, which is reflected in the immune deconvolution of fatal and 
non-fatal COVID-19 patients (Liu et al., 2020a). The post-mortem and mice 
study also observed immune cell infiltration in vascular and lung tissue (Clark 
et al., 2021, Dorward et al., 2020). 
 
RNA extracted from blood was sequenced using Illumina and Nanopore 
sequencing platforms. Illumina sequencing acquired a global view of the 
transcriptome within patients, whereas Nanopore sequencing was used to 
gain a rapid insight into disease. Ultimately, there was a moderate positive 
correlation between datasets when considering the normalised expression of 
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transcripts, and a strong correlation when comparing the LogFC derived from 
each dataset. Only illumina sequencing was able provide a global 
transcriptome, and nanopore data was less rich, therefore when comparing 
the two technologies genes were removed from the illumina dataset to match 
the nanopore dataset. Regardless, comparison of both technologies 
demonstrate that differential expression of immunoglobulin transcripts are 
involved in COVID-19 disease, and that a delayed adaptive immune response 
may play a role in fatality. For downstream analysis such as immune 
deconvolution, there was disagreement between datasets, indicating further 
considerations may be needed for the nanopore data, or more sequencing 
information is required. Collaboration on this data is still ongoing where 
machine learning analysis to identify transcripts that are predictive of outcome 
is being conducted, similar to previous work conducted on blood samples from 
patients with fatal and non-fatal ebola virus disease (Bosworth et al., 2021, Liu 
et al., 2017). The outputs of this analysis will be used to design a multiplex 
qPCR that could be used as prognostic test for COVID-19 which could inform 
clinicians on how to triage patients based upon biomarkers. One particular use 
of such prognostics could be used to inform clinicians on which patients can 
be taken off intensive care unit or discharged. This may be useful during times 
where hospitals are overwhelmed due to high infection rates and facilitate the 
prioritisation of those who are severely unwell from coronavirus infections.  
 
Furthering the transcriptomic analysis from patients at point of care, differential 
gene expression was conducted to understand the host response to viral 
infection with Influenza A and SARS-CoV-2 from mice lung tissue as individual 
infections but also as a dual infection in mice. Previous studies show that when 
mice are infected with rhinovirus 2 days before influenza virus disease severity 
is reduced and rapid clearance of IAV is observed (Gonzalez et al., 2018). The 
inflammatory response to the rhinovirus infection provided an early and 
controlled response to the sequential IAV infection, resulting in an attenuated 
response to IAV (Gonzalez et al., 2018). When mice were infected with RV 
and IAV together a higher mortality was observed in comparison to sequential 
infection, however, not as many for a singular IAV infection. When mice were 
infected with IAV 2 days before rhinovirus, IAV disease was exacerbated. 
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Suggesting that disease severity during co-infection could be time dependent. 
Pathological findings in mice conducted by collaborators supported what was 
observed in fatal COVID-19 tissue samples with immune cell infiltration in 
vascular and pulmonary tissue, reinforcing the suitability of the model (Clark 
et al., 2021, Dorward et al., 2020). Animal models continue to be a useful tool 
to investigate SARS-CoV-2 throughout the pandemic. 
 
Sequencing read lengths from nanopore data for humans were on average 
750 nucleotides, whereas the mice data were 250 nucleotides despite using 
the same sequencing methodology. The RNA extraction methodology for 
tissue samples requires a homogenisation step which may facilitate the 
degradation of RNA and thus lead to shorter read lengths. Extraction 
methodologies for tissue compatible for long-read sequencing may need to be 
further investigated. As the read lengths were shorter than anticipated for the 
mice data, the mapping parameters for minimap2 were adjusted to 
accommodate, which lead to an overall improved mapping rate. Regardless of 
the technical challenges, the identified transcripts and the indication of the 
sustained interferon response was consistent with the pathological findings in 
the study, however, to improve the resolution of the data, illumina sequencing 
may be more appropriate for this tissue type. 
 
The human dataset showed that immunoglobulin domains were in differing 
abundances for COVID-19 and Influenza patients and fatal and non-fatal 
COVID-19. The transcripts increasing and decreasing in abundance from the 
human and mice nanopore sequencing data were compared to identify 
transcripts that were shared across species and tissue types. As expected, 
genes associated with the innate immune response were identified, typically 
associated with interferon signalling pathways. The genes highlighted are 
likely to be a fraction of the similarities shared between mice and humans. 
Comparing transcriptomic profiles from different species in comparison to 
patients is insightful if the disease and the host response is similar, as this 
reinforces the animal model, but also if the disease is asymptomatic in a model 
organism and not humans, this can give insight into host response driven 
pathogenesis. Future and ongoing work is to draw these comparisons from 
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NHPs and ferret models to human transcriptomic responses to further 
understand the mechanism of disease.  
 
To conclude, the results described within this thesis provide insights into the 
novel coronavirus SARS-CoV-2 and COVID-19 disease in humans. 
Interestingly, this thesis supports the involvement of immunopathology as 
mechanism of severe COVID-19, predominantly informed by the post-mortem 
organotropism study and transcriptomics studies. Additionally, the outputs of 
this thesis provide a foundation for further investigation and development of 
Nanopore sequencing methodologies for viral genome sequencing of 
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